WO2024097247A1 - Uses of farnesoid x receptor agonists - Google Patents
Uses of farnesoid x receptor agonists Download PDFInfo
- Publication number
- WO2024097247A1 WO2024097247A1 PCT/US2023/036520 US2023036520W WO2024097247A1 WO 2024097247 A1 WO2024097247 A1 WO 2024097247A1 US 2023036520 W US2023036520 W US 2023036520W WO 2024097247 A1 WO2024097247 A1 WO 2024097247A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- patient
- compound
- score
- pharmaceutically acceptable
- amino acid
- Prior art date
Links
- 229940121360 farnesoid X receptor (fxr) agonists Drugs 0.000 title abstract description 120
- 238000000034 method Methods 0.000 claims abstract description 316
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 105
- 210000004185 liver Anatomy 0.000 claims abstract description 56
- 229940125904 compound 1 Drugs 0.000 claims description 236
- 150000003839 salts Chemical class 0.000 claims description 174
- 229940024606 amino acid Drugs 0.000 claims description 171
- 235000001014 amino acid Nutrition 0.000 claims description 171
- 150000001413 amino acids Chemical class 0.000 claims description 171
- 208000002353 alcoholic hepatitis Diseases 0.000 claims description 131
- 206010019728 Hepatitis alcoholic Diseases 0.000 claims description 130
- 238000011282 treatment Methods 0.000 claims description 117
- 208000019423 liver disease Diseases 0.000 claims description 115
- 230000001154 acute effect Effects 0.000 claims description 89
- 208000002467 Acute-On-Chronic Liver Failure Diseases 0.000 claims description 87
- 230000004083 survival effect Effects 0.000 claims description 48
- 239000003246 corticosteroid Substances 0.000 claims description 38
- 108010003415 Aspartate Aminotransferases Proteins 0.000 claims description 31
- 102000004625 Aspartate Aminotransferases Human genes 0.000 claims description 31
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 31
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 claims description 30
- 108010082126 Alanine transaminase Proteins 0.000 claims description 30
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 claims description 28
- 206010016654 Fibrosis Diseases 0.000 claims description 27
- 230000007423 decrease Effects 0.000 claims description 27
- 201000010099 disease Diseases 0.000 claims description 27
- 230000036541 health Effects 0.000 claims description 26
- 230000009467 reduction Effects 0.000 claims description 26
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 25
- 230000001225 therapeutic effect Effects 0.000 claims description 19
- 230000007882 cirrhosis Effects 0.000 claims description 18
- 210000002966 serum Anatomy 0.000 claims description 18
- 206010023126 Jaundice Diseases 0.000 claims description 16
- 206010057573 Chronic hepatic failure Diseases 0.000 claims description 13
- 208000010334 End Stage Liver Disease Diseases 0.000 claims description 13
- 208000011444 chronic liver failure Diseases 0.000 claims description 13
- 231100000240 steatosis hepatitis Toxicity 0.000 claims description 13
- 239000003795 chemical substances by application Substances 0.000 claims description 12
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims description 12
- 230000007863 steatosis Effects 0.000 claims description 12
- 238000002054 transplantation Methods 0.000 claims description 12
- 206010040047 Sepsis Diseases 0.000 claims description 11
- 230000002496 gastric effect Effects 0.000 claims description 11
- 208000015181 infectious disease Diseases 0.000 claims description 11
- 230000000968 intestinal effect Effects 0.000 claims description 11
- BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 claims description 10
- 229960001476 pentoxifylline Drugs 0.000 claims description 10
- 208000022309 Alcoholic Liver disease Diseases 0.000 claims description 9
- 208000004930 Fatty Liver Diseases 0.000 claims description 9
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 9
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 9
- 229960005205 prednisolone Drugs 0.000 claims description 9
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims description 9
- 208000024891 symptom Diseases 0.000 claims description 9
- 239000003613 bile acid Substances 0.000 claims description 8
- 230000000740 bleeding effect Effects 0.000 claims description 8
- 230000002550 fecal effect Effects 0.000 claims description 8
- 239000006041 probiotic Substances 0.000 claims description 8
- 230000000529 probiotic effect Effects 0.000 claims description 8
- 235000018291 probiotics Nutrition 0.000 claims description 8
- 239000013589 supplement Substances 0.000 claims description 8
- 208000019206 urinary tract infection Diseases 0.000 claims description 8
- 208000027244 Dysbiosis Diseases 0.000 claims description 7
- 239000003963 antioxidant agent Substances 0.000 claims description 7
- 239000000090 biomarker Substances 0.000 claims description 7
- 229940109239 creatinine Drugs 0.000 claims description 7
- 230000007140 dysbiosis Effects 0.000 claims description 7
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 7
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 7
- 230000002458 infectious effect Effects 0.000 claims description 7
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 6
- 208000005176 Hepatitis C Diseases 0.000 claims description 6
- 239000003242 anti bacterial agent Substances 0.000 claims description 6
- 208000002672 hepatitis B Diseases 0.000 claims description 6
- 208000010710 hepatitis C virus infection Diseases 0.000 claims description 6
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 claims description 5
- 102000004190 Enzymes Human genes 0.000 claims description 5
- 108090000790 Enzymes Proteins 0.000 claims description 5
- 102100031734 Fibroblast growth factor 19 Human genes 0.000 claims description 5
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims description 5
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 claims description 5
- 229960004308 acetylcysteine Drugs 0.000 claims description 5
- 230000003078 antioxidant effect Effects 0.000 claims description 5
- 229940098164 augmentin Drugs 0.000 claims description 5
- 230000003115 biocidal effect Effects 0.000 claims description 5
- 229960004584 methylprednisolone Drugs 0.000 claims description 5
- 208000009304 Acute Kidney Injury Diseases 0.000 claims description 4
- 206010007882 Cellulitis Diseases 0.000 claims description 4
- 206010035664 Pneumonia Diseases 0.000 claims description 4
- 208000033626 Renal failure acute Diseases 0.000 claims description 4
- 201000011040 acute kidney failure Diseases 0.000 claims description 4
- 239000002831 pharmacologic agent Substances 0.000 claims description 4
- RYKKQQUKJJGFMN-HVDRVSQOSA-N 4,5-bis(hydroxymethyl)-2-methylpyridin-3-ol;(2s)-5-oxopyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCC(=O)N1.CC1=NC=C(CO)C(CO)=C1O RYKKQQUKJJGFMN-HVDRVSQOSA-N 0.000 claims description 3
- 101710099705 Anti-lipopolysaccharide factor Proteins 0.000 claims description 3
- 241000283690 Bos taurus Species 0.000 claims description 3
- 208000000419 Chronic Hepatitis B Diseases 0.000 claims description 3
- 208000006154 Chronic hepatitis C Diseases 0.000 claims description 3
- 206010019280 Heart failures Diseases 0.000 claims description 3
- 208000027761 Hepatic autoimmune disease Diseases 0.000 claims description 3
- 206010019851 Hepatotoxicity Diseases 0.000 claims description 3
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 3
- 208000019693 Lung disease Diseases 0.000 claims description 3
- 208000012902 Nervous system disease Diseases 0.000 claims description 3
- 206010033645 Pancreatitis Diseases 0.000 claims description 3
- 206010033647 Pancreatitis acute Diseases 0.000 claims description 3
- 201000009454 Portal vein thrombosis Diseases 0.000 claims description 3
- 206010000891 acute myocardial infarction Diseases 0.000 claims description 3
- 201000003229 acute pancreatitis Diseases 0.000 claims description 3
- 239000000427 antigen Substances 0.000 claims description 3
- 102000036639 antigens Human genes 0.000 claims description 3
- 108091007433 antigens Proteins 0.000 claims description 3
- 206010003119 arrhythmia Diseases 0.000 claims description 3
- 210000004369 blood Anatomy 0.000 claims description 3
- 239000008280 blood Substances 0.000 claims description 3
- 230000036765 blood level Effects 0.000 claims description 3
- 229960001838 canakinumab Drugs 0.000 claims description 3
- 210000003022 colostrum Anatomy 0.000 claims description 3
- 235000021277 colostrum Nutrition 0.000 claims description 3
- 231100000304 hepatotoxicity Toxicity 0.000 claims description 3
- 230000007686 hepatotoxicity Effects 0.000 claims description 3
- HUOOMAOYXQFIDQ-UHFFFAOYSA-N isoginkgetin Chemical compound C1=CC(OC)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C(C=3C(=CC=C(C=3)C=3OC4=CC(O)=CC(O)=C4C(=O)C=3)OC)=C2O1 HUOOMAOYXQFIDQ-UHFFFAOYSA-N 0.000 claims description 3
- 238000012544 monitoring process Methods 0.000 claims description 3
- 229960005489 paracetamol Drugs 0.000 claims description 3
- 238000012959 renal replacement therapy Methods 0.000 claims description 3
- 230000035939 shock Effects 0.000 claims description 3
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 claims description 3
- 239000002451 tumor necrosis factor inhibitor Substances 0.000 claims description 3
- 230000009385 viral infection Effects 0.000 claims description 3
- 230000001580 bacterial effect Effects 0.000 claims description 2
- 206010034674 peritonitis Diseases 0.000 claims description 2
- 230000002269 spontaneous effect Effects 0.000 claims description 2
- 101000846394 Homo sapiens Fibroblast growth factor 19 Proteins 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 31
- 208000006454 hepatitis Diseases 0.000 abstract description 19
- 231100000283 hepatitis Toxicity 0.000 abstract description 18
- 208000030090 Acute Disease Diseases 0.000 abstract description 2
- 208000037765 diseases and disorders Diseases 0.000 abstract description 2
- 230000001737 promoting effect Effects 0.000 abstract description 2
- 238000011084 recovery Methods 0.000 abstract description 2
- 235000002639 sodium chloride Nutrition 0.000 description 157
- 230000002354 daily effect Effects 0.000 description 46
- 239000000203 mixture Substances 0.000 description 44
- 230000001965 increasing effect Effects 0.000 description 26
- 241001465754 Metazoa Species 0.000 description 21
- 238000004448 titration Methods 0.000 description 20
- 235000005911 diet Nutrition 0.000 description 19
- 230000037213 diet Effects 0.000 description 19
- 230000000694 effects Effects 0.000 description 18
- 238000004458 analytical method Methods 0.000 description 17
- 230000006870 function Effects 0.000 description 16
- 238000002560 therapeutic procedure Methods 0.000 description 16
- 230000008859 change Effects 0.000 description 15
- 239000003814 drug Substances 0.000 description 14
- 238000011156 evaluation Methods 0.000 description 14
- 230000006872 improvement Effects 0.000 description 14
- 238000012360 testing method Methods 0.000 description 13
- 238000009472 formulation Methods 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 229960001334 corticosteroids Drugs 0.000 description 11
- 210000003494 hepatocyte Anatomy 0.000 description 11
- 238000012216 screening Methods 0.000 description 11
- 239000011734 sodium Substances 0.000 description 11
- 239000003981 vehicle Substances 0.000 description 11
- 230000003247 decreasing effect Effects 0.000 description 10
- 239000002158 endotoxin Substances 0.000 description 10
- 229940068196 placebo Drugs 0.000 description 10
- 239000000902 placebo Substances 0.000 description 10
- 150000003431 steroids Chemical class 0.000 description 10
- 230000009885 systemic effect Effects 0.000 description 10
- 230000008901 benefit Effects 0.000 description 9
- 230000001684 chronic effect Effects 0.000 description 9
- 229940125782 compound 2 Drugs 0.000 description 9
- 230000006378 damage Effects 0.000 description 9
- 230000004761 fibrosis Effects 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 239000002775 capsule Substances 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- ZXERDUOLZKYMJM-ZWECCWDJSA-N obeticholic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)CCC(O)=O)CC[C@H]21 ZXERDUOLZKYMJM-ZWECCWDJSA-N 0.000 description 8
- 229960001601 obeticholic acid Drugs 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 7
- 102000052508 Lipopolysaccharide-binding protein Human genes 0.000 description 7
- 108010053632 Lipopolysaccharide-binding protein Proteins 0.000 description 7
- 206010062070 Peritonitis bacterial Diseases 0.000 description 7
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 7
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 7
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 7
- 230000034994 death Effects 0.000 description 7
- 231100000517 death Toxicity 0.000 description 7
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 6
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- 208000032843 Hemorrhage Diseases 0.000 description 6
- 235000013334 alcoholic beverage Nutrition 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 239000002207 metabolite Substances 0.000 description 6
- 210000000440 neutrophil Anatomy 0.000 description 6
- 229910052708 sodium Inorganic materials 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 229940124597 therapeutic agent Drugs 0.000 description 6
- -1 3-hydroxyl Chemical class 0.000 description 5
- 108010074051 C-Reactive Protein Proteins 0.000 description 5
- 108020004206 Gamma-glutamyltransferase Proteins 0.000 description 5
- 108010010234 HDL Lipoproteins Proteins 0.000 description 5
- 102000015779 HDL Lipoproteins Human genes 0.000 description 5
- 108090001005 Interleukin-6 Proteins 0.000 description 5
- 102000004889 Interleukin-6 Human genes 0.000 description 5
- 102100033421 Keratin, type I cytoskeletal 18 Human genes 0.000 description 5
- 108010066327 Keratin-18 Proteins 0.000 description 5
- 108010007622 LDL Lipoproteins Proteins 0.000 description 5
- 102000007330 LDL Lipoproteins Human genes 0.000 description 5
- 206010067125 Liver injury Diseases 0.000 description 5
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 5
- 230000002411 adverse Effects 0.000 description 5
- 235000020940 control diet Nutrition 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 102000006640 gamma-Glutamyltransferase Human genes 0.000 description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 description 5
- 230000002440 hepatic effect Effects 0.000 description 5
- 230000001976 improved effect Effects 0.000 description 5
- 229940100601 interleukin-6 Drugs 0.000 description 5
- 230000037356 lipid metabolism Effects 0.000 description 5
- 238000012317 liver biopsy Methods 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 235000016709 nutrition Nutrition 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000000699 topical effect Effects 0.000 description 5
- 108020004465 16S ribosomal RNA Proteins 0.000 description 4
- IOIZWEJGGCZDOL-RQDYSCIWSA-N 7alpha-hydroxycholest-4-en-3-one Chemical group C([C@H]1O)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 IOIZWEJGGCZDOL-RQDYSCIWSA-N 0.000 description 4
- 208000007848 Alcoholism Diseases 0.000 description 4
- 101710153349 Fibroblast growth factor 19 Proteins 0.000 description 4
- 206010019799 Hepatitis viral Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 description 4
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 description 4
- 229940024142 alpha 1-antitrypsin Drugs 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 239000002270 dispersing agent Substances 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 231100000753 hepatic injury Toxicity 0.000 description 4
- 210000003405 ileum Anatomy 0.000 description 4
- 230000008595 infiltration Effects 0.000 description 4
- 238000001764 infiltration Methods 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 229920006008 lipopolysaccharide Polymers 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 4
- 150000003626 triacylglycerols Chemical class 0.000 description 4
- 201000001862 viral hepatitis Diseases 0.000 description 4
- 102000057234 Acyl transferases Human genes 0.000 description 3
- 108700016155 Acyl transferases Proteins 0.000 description 3
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 description 3
- 101710189683 Alkaline protease 1 Proteins 0.000 description 3
- 101710154562 Alkaline proteinase Proteins 0.000 description 3
- 102100021253 Antileukoproteinase Human genes 0.000 description 3
- 101710170876 Antileukoproteinase Proteins 0.000 description 3
- 206010070545 Bacterial translocation Diseases 0.000 description 3
- 101710112538 C-C motif chemokine 27 Proteins 0.000 description 3
- 241001678559 COVID-19 virus Species 0.000 description 3
- 208000008964 Chemical and Drug Induced Liver Injury Diseases 0.000 description 3
- 206010008635 Cholestasis Diseases 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 238000008789 Direct Bilirubin Methods 0.000 description 3
- 206010072268 Drug-induced liver injury Diseases 0.000 description 3
- 206010071602 Genetic polymorphism Diseases 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 206010019663 Hepatic failure Diseases 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 102000004895 Lipoproteins Human genes 0.000 description 3
- 108090001030 Lipoproteins Proteins 0.000 description 3
- 208000001145 Metabolic Syndrome Diseases 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- 206010053159 Organ failure Diseases 0.000 description 3
- 108050009491 Patatin-like phospholipase domains Proteins 0.000 description 3
- 102000002057 Patatin-like phospholipase domains Human genes 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 101710140337 Transmembrane 6 superfamily member 2 Proteins 0.000 description 3
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 3
- 230000001476 alcoholic effect Effects 0.000 description 3
- 208000026594 alcoholic fatty liver disease Diseases 0.000 description 3
- 230000007375 bacterial translocation Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 238000002565 electrocardiography Methods 0.000 description 3
- 230000007717 exclusion Effects 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 239000013029 homogenous suspension Substances 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 230000003870 intestinal permeability Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 208000007903 liver failure Diseases 0.000 description 3
- 231100000835 liver failure Toxicity 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 230000036542 oxidative stress Effects 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 230000035935 pregnancy Effects 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 230000000750 progressive effect Effects 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- 230000003319 supportive effect Effects 0.000 description 3
- 230000008718 systemic inflammatory response Effects 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 102100038495 Bile acid receptor Human genes 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 108010012236 Chemokines Proteins 0.000 description 2
- 102000019034 Chemokines Human genes 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 102100026745 Fatty acid-binding protein, liver Human genes 0.000 description 2
- 101710188974 Fatty acid-binding protein, liver Proteins 0.000 description 2
- 101710189565 Fatty acid-binding protein, liver-type Proteins 0.000 description 2
- 238000000729 Fisher's exact test Methods 0.000 description 2
- 206010019708 Hepatic steatosis Diseases 0.000 description 2
- 102100034459 Hepatitis A virus cellular receptor 1 Human genes 0.000 description 2
- 101710185991 Hepatitis A virus cellular receptor 1 homolog Proteins 0.000 description 2
- 206010019842 Hepatomegaly Diseases 0.000 description 2
- 101000603876 Homo sapiens Bile acid receptor Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000003810 Interleukin-18 Human genes 0.000 description 2
- 108090000171 Interleukin-18 Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 102000013519 Lipocalin-2 Human genes 0.000 description 2
- 108010051335 Lipocalin-2 Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 238000011887 Necropsy Methods 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 108010077895 Sarcosine Proteins 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 description 2
- 102000008233 Toll-Like Receptor 4 Human genes 0.000 description 2
- 108010060804 Toll-Like Receptor 4 Proteins 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 201000007930 alcohol dependence Diseases 0.000 description 2
- 208000025746 alcohol use disease Diseases 0.000 description 2
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000002424 anti-apoptotic effect Effects 0.000 description 2
- 230000003510 anti-fibrotic effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 229940125717 barbiturate Drugs 0.000 description 2
- 229940049706 benzodiazepine Drugs 0.000 description 2
- 150000001557 benzodiazepines Chemical class 0.000 description 2
- 235000019445 benzyl alcohol Nutrition 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- RUDATBOHQWOJDD-BSWAIDMHSA-N chenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-BSWAIDMHSA-N 0.000 description 2
- 238000003759 clinical diagnosis Methods 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 229940099112 cornstarch Drugs 0.000 description 2
- 238000009223 counseling Methods 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000000779 depleting effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 229960004242 dronabinol Drugs 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 238000009093 first-line therapy Methods 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- 229960002449 glycine Drugs 0.000 description 2
- 230000003118 histopathologic effect Effects 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 231100000546 inhibition of ovulation Toxicity 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 230000015788 innate immune response Effects 0.000 description 2
- 210000001865 kupffer cell Anatomy 0.000 description 2
- 238000009533 lab test Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 235000020888 liquid diet Nutrition 0.000 description 2
- 210000005228 liver tissue Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 229940127240 opiate Drugs 0.000 description 2
- 238000002638 palliative care Methods 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 239000011049 pearl Substances 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000001376 precipitating effect Effects 0.000 description 2
- 230000002028 premature Effects 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 229940043230 sarcosine Drugs 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000002626 targeted therapy Methods 0.000 description 2
- 229960003080 taurine Drugs 0.000 description 2
- 150000003751 zinc Chemical class 0.000 description 2
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- IGRCWJPBLWGNPX-UHFFFAOYSA-N 3-(2-chlorophenyl)-n-(4-chlorophenyl)-n,5-dimethyl-1,2-oxazole-4-carboxamide Chemical compound C=1C=C(Cl)C=CC=1N(C)C(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl IGRCWJPBLWGNPX-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102100032752 C-reactive protein Human genes 0.000 description 1
- 208000025721 COVID-19 Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 108010001202 Cytochrome P-450 CYP2E1 Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 102100025353 G-protein coupled bile acid receptor 1 Human genes 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 101000857733 Homo sapiens G-protein coupled bile acid receptor 1 Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 101100390675 Mus musculus Fgf15 gene Proteins 0.000 description 1
- 102000003940 Occludin Human genes 0.000 description 1
- 108090000304 Occludin Proteins 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102100026456 POU domain, class 3, transcription factor 3 Human genes 0.000 description 1
- 101710133393 POU domain, class 3, transcription factor 3 Proteins 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010061481 Renal injury Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- YIQKLZYTHXTDDT-UHFFFAOYSA-H Sirius red F3B Chemical compound C1=CC(=CC=C1N=NC2=CC(=C(C=C2)N=NC3=C(C=C4C=C(C=CC4=C3[O-])NC(=O)NC5=CC6=CC(=C(C(=C6C=C5)[O-])N=NC7=C(C=C(C=C7)N=NC8=CC=C(C=C8)S(=O)(=O)[O-])S(=O)(=O)[O-])S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)[O-])S(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+] YIQKLZYTHXTDDT-UHFFFAOYSA-H 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 229940124532 absorption promoter Drugs 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 231100000354 acute hepatitis Toxicity 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 238000011374 additional therapy Methods 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 206010001584 alcohol abuse Diseases 0.000 description 1
- 208000029650 alcohol withdrawal Diseases 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 210000000270 basal cell Anatomy 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 229940047120 colony stimulating factors Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000008387 emulsifying waxe Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 230000004149 ethanol metabolism Effects 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000003090 exacerbative effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 208000020694 gallbladder disease Diseases 0.000 description 1
- 208000030304 gastrointestinal bleeding Diseases 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 229930182480 glucuronide Natural products 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 208000027700 hepatic dysfunction Diseases 0.000 description 1
- 208000007386 hepatic encephalopathy Diseases 0.000 description 1
- 210000004024 hepatic stellate cell Anatomy 0.000 description 1
- 230000000423 heterosexual effect Effects 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 210000004283 incisor Anatomy 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000003960 inflammatory cascade Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003871 intestinal function Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 208000037806 kidney injury Diseases 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 206010024378 leukocytosis Diseases 0.000 description 1
- 230000008604 lipoprotein metabolism Effects 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000010197 meta-analysis Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229940042472 mineral oil Drugs 0.000 description 1
- 230000004065 mitochondrial dysfunction Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000003448 neutrophilic effect Effects 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical class C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 102000007863 pattern recognition receptors Human genes 0.000 description 1
- 108010089193 pattern recognition receptors Proteins 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 229940100618 rectal suppository Drugs 0.000 description 1
- 239000006215 rectal suppository Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000000934 spermatocidal agent Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 230000019635 sulfation Effects 0.000 description 1
- 238000005670 sulfation reaction Methods 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- MHXBHWLGRWOABW-UHFFFAOYSA-N tetradecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC MHXBHWLGRWOABW-UHFFFAOYSA-N 0.000 description 1
- 210000001578 tight junction Anatomy 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 description 1
- 229960001661 ursodiol Drugs 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- 229940091251 zinc supplement Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J11/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 3
Definitions
- the present invention relates to compounds and methods of use thereof for treating, ameliorating, or promoting recovery from diseases and disorders, such as acute diseases of the liver.
- Alcoholic hepatitis (also known as alcohol-associated hepatitis or acute alcohol-associated hepatitis) is an acute form of alcohol-induced liver injury that occurs with the consumption of a large quantity of alcohol over a prolonged period. Alcoholic hepatitis can range in severity from asymptomatic derangement of biochemistries to liver failure and death. Severe alcoholic hepatitis is a severe form of an acute alcoholic liver disease caused by excessive alcohol consumption which may be characterized by rapid onset of jaundice, malaise, tender hepatomegaly, and features of systemic inflammatory response (Shah N.J., Royer A, John S. Alcoholic Hepatitis. Stat Pearls.
- Severe alcoholic hepatitis is a life-threatening medical condition with an average 30-day mortality as high as 17% to 50%, and an average 1-year mortality of about 56% (Mathurin P., et al. Gastroenterology 1996 Jun;l 10(6): 1847-53; Thursz, M.R., et al. N Engl J Med. 2015 Apr 23;372(17): 1619-28; hereby incorporated by reference).
- Treatment options for patients with sAH are limited to systemic corticosteroids (unless there are contraindications such as sepsis, infection, gastrointestinal bleeding or acute kidney injury) along with supportive care, nutrition, and alcohol abstinence.
- Corticosteroids do not impart long-term benefit in patients with sAH and their use is limited due to the risk of infection and GI bleeding. Further, liver transplantation for alcohol-related liver disease is currently at an all-time high (Noureddin, N., et al. Transplant Direct 2020 Oct 8 ;6( 1 l):e612), and the number of patients in the US awaiting and undergoing liver transplantation for acute alcohol-associated hepatitis has increased substantially during the COVID- 19 pandemic (Bitterman, T., et al. JAMA Netw. Open. 2021;4(7):e2118713).
- ACLF acute decompensated liver disease
- ACLF acute-on-chronic liver failure
- Alcoholic hepatitis and chronic viral hepatitis are the most common underlying liver diseases. Up to 40%-50% of the cases of ACLF have no identifiable trigger; in the remaining patients, sepsis, active alcoholism, and relapse of chronic viral hepatitis are the most common reported precipitating factors. An excessive systemic inflammatory response seems to play a crucial role in the development of ACLF.
- the present invention provides a method of treating an acute liver disease comprising administering to a patient in need thereof an effective amount of Compound 1:
- Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof.
- the present invention provides a method of treating an acute liver disease comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein the acute liver disease is alcoholic hepatitis (AH).
- AH alcoholic hepatitis
- the present invention provides a method of treating an acute liver disease comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein the acute liver disease is severe alcoholic hepatitis (sAH).
- sAH severe alcoholic hepatitis
- the present invention provides a method of treating an acute liver disease comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein the acute liver disease is acute-on-chronic liver failure (ACLF).
- ACLF acute-on-chronic liver failure
- the present invention provides a method of treating an acute liver disease (e.g., AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein the patient exhibits a Maddrey discriminant function (MDF) score of >32 prior to treatment with Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof.
- an acute liver disease e.g., AH, sAH or ACLF
- MDF Maddrey discriminant function
- the present invention provides a method of treating an acute liver disease (e.g., AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein the patient exhibits a model for end stage liver disease (MELD or MELD-Na) score of >18, or >20, or >21 prior to treatment with Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof.
- an acute liver disease e.g., AH, sAH or ACLF
- MELD or MELD-Na model for end stage liver disease
- the present invention provides a method of treating an acute liver disease (e.g.. AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein the patient exhibits a MDF score of 32 to 60.
- an acute liver disease e.g.. AH, sAH or ACLF
- the present invention provides a method of treating an acute liver disease (e.g., AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein the patient exhibits a MELD score of 18, or 20 or 21 to 25 or 30 or MELD-Na score of 18, or 20, or 21 to 25 or 30.
- an acute liver disease e.g., AH, sAH or ACLF
- the present invention provides a method of treating an acute liver disease (e.g., AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein the patient exhibits a MELD score of 21 to 30 prior to treatment with Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof.
- an acute liver disease e.g., AH, sAH or ACLF
- the present invention provides a method of treating an acute liver disease (e.g., AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein the patient exhibits a Maddrey discriminant function (MDF) score of >32, and a MELD score of 21 to 30 (inclusive) prior to treatment with Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof.
- MDF Maddrey discriminant function
- the present invention provides a method of treating an acute liver disease (e.g., AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein the patient exhibits an AST of > (greater than or equal to) 50 U/L (or IU/L) prior to treatment with Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof.
- an acute liver disease e.g., AH, sAH or ACLF
- the present invention provides a method of treating an acute liver disease (e.g., AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein the patient exhibits an AST I ALT ratio of >1.5 prior to treatment with Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof.
- an acute liver disease e.g., AH, sAH or ACLF
- the present invention provides a method of treating an acute liver disease (e.g., AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein the patient exhibits prior to treatment with Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof one or more of an AST of >50 U/L; an AST / ALT ratio of >1.5; a Maddrey discriminant function (MDF) score of >32; and/or a model for end-stage liver disease (MELD or MELD-Na) score of >18 or >20 or >21, for example from 21-30.
- an acute liver disease e.g., AH, sAH or ACLF
- the present invention provides a method of treating an acute liver disease (e.g., AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein the method reduces the MELD or MELD-Na score of the patient by at least 3 and/or reduces the MDF score of the patient by at least 3 by day 28 of treatment.
- an acute liver disease e.g., AH, sAH or ACLF
- the present invention provides a method of treating an acute liver disease (e.g., AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof is administered daily at a dose of about 1.0 mg to about 300 mg.
- an acute liver disease e.g., AH, sAH or ACLF
- the present invention provides a method of treating an acute liver disease (e.g., AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof is administered daily at a dose of about 2.5 mg to about 300 mg.
- an acute liver disease e.g., AH, sAH or ACLF
- the present invention provides a method of treating an acute liver disease (e.g., AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein Compound 1 is administered daily at a dose of from about 5 mg to about 120 mg.
- an acute liver disease e.g., AH, sAH or ACLF
- the present invention provides a method of treating an acute liver disease (e.g., AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein Compound 1 is administered daily at a dose of from about 5 mg to about 100 mg.
- an acute liver disease e.g., AH, sAH or ACLF
- the present invention provides a method of treating an acute liver disease (e.g., AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein Compound 1 is administered daily at a dose of from about 5 mg to about 50 mg.
- an acute liver disease e.g., AH, sAH or ACLF
- the present invention provides a method of treating an acute liver disease (e.g., AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein Compound 1 is administered daily at a dose of from about 5 mg to about 25 mg.
- an acute liver disease e.g., AH, sAH or ACLF
- the present invention provides a method of treating an acute liver disease (e.g., AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein Compound 1 is administered daily at a dose of from about 5 mg to about 10 mg.
- an acute liver disease e.g., AH, sAH or ACLF
- the present invention provides a method of treating an acute liver disease (e.g., AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof is administered daily at a dose of about 5 mg to about 150 mg.
- an acute liver disease e.g., AH, sAH or ACLF
- the present invention provides a method of treating an acute liver disease (e.g., AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof is administered daily at a dose of about 5 mg to about 120 mg.
- an acute liver disease e.g., AH, sAH or ACLF
- the present invention provides a method of treating an acute liver disease (e.g., AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof is administered daily at a dose of about 10 mg to about 100 mg.
- an acute liver disease e.g., AH, sAH or ACLF
- the present invention provides a method of treating an acute liver disease (e.g., AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof is administered daily at a dose of about 50 mg to about 250 mg.
- an acute liver disease e.g., AH, sAH or ACLF
- the present invention provides a method of treating an acute liver disease (e.g., AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein Compound 1 is administered daily at a dose of about 2.5 mg, about 5 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 35 mg, about 45 mg, about 50 mg, about 60 mg, about 75 mg, about 85 mg, about 100 mg, about 115 mg, about 120 mg, about 125 mg, about 140 mg, about 150 mg, about 165 mg, about 175 mg, about 190 mg, or about 200 mg.
- an acute liver disease e.g., AH, sAH or ACLF
- the present invention provides a method of treating an acute liver disease (e.g., AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof is administered in single or multiple doses sufficient to achieve a total daily dose of about 1.0 mg to about 300 mg; 1.0 mg to about 300 mg; or about 2.5 mg to about 300 mg; or about 5 mg to about 100 mg; or about 5 mg to about 50 mg; or about 5 mg to about 25 mg; or about 5 mg to about 10 mg; or about 5 mg to about 150 mg; or about 5 mg to about 120 mg; or about 10 mg to about 100 mg; or about 50 mg to about 200 mg; or about 2.5 mg, about 5 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 35 mg, about 45 mg, about 50 mg, about 60 mg, about 75 mg, about 85 mg, about 100 mg,
- an acute liver disease
- the present invention provides a method of treating an acute liver disease (e.g., AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, further comprising monitoring blood levels of a biomarkcr in the patient after administration of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein the biomarker is selected from C4, FGF-19, and endogenous bile acids.
- an acute liver disease e.g., AH, sAH or ACLF
- the present invention provides a method of treating an acute liver disease selected from sAH and ACLF, comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein the patient has a chronic liver disease in addition to sAH or ACLF.
- the present invention provides a method of treating an acute liver disease (e.g., AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein the patient has alcohol-related (or alcohol-associated) liver disease (ALD), previously known as alcoholic liver disease.
- an acute liver disease e.g., AH, sAH or ACLF
- ALD alcohol-related liver disease
- the present invention provides a method of treating an acute liver disease (e.g., AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein the patient exhibits one or more of the following: (1) ongoing alcohol consumption of more than 40 g of alcohol per day if the patient is a woman and more than 60 g of alcohol per day if the patient is a man for 6 months or more, with less than 60 days of abstinence before the onset of jaundice; (2) the presence of elevated liver enzymes (aspartate aminotransferase [AST] and alanine aminotransferase [ALT] concentrations >50 IU/L but ⁇ 400 IU/L and an AST/ALT ratio of >1:5); and (3) worsening jaundice, with bilirubin concentrations greater than 3 mg/dL.
- an acute liver disease e.g., AH, sAH or ACLF
- the present invention provides a method of treating an acute liver disease (e.g., AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein the patient exhibits alcohol-associated cirrhosis, liver fibrosis, steatosis, steatohepatitis, alcoholic hepatitis, or intestinal dysbiosis.
- an acute liver disease e.g., AH, sAH or ACLF
- the present invention provides a method of treating an acute liver disease (e.g., AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein the patient has previously been diagnosed with sAH and has suffered at least one relapse of sAH.
- an acute liver disease e.g., AH, sAH or ACLF
- the present invention provides a method of treating an acute liver disease (e.g., AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein the method improves 30-day survival of the patient versus an otherwise similar patient who was not administered Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof.
- an acute liver disease e.g., AH, sAH or ACLF
- the present invention provides a method of treating an acute liver disease (e.g., AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein the method improves 60-day survival of the patient versus an otherwise similar patient who was not administered Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof.
- an acute liver disease e.g., AH, sAH or ACLF
- the present invention provides a method of treating an acute liver disease (e.g., AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein the method improves 90-day survival of the patient versus an otherwise similar patient who was not administered Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof.
- an acute liver disease e.g., AH, sAH or ACLF
- the present invention provides a method of treating an acute liver disease (e.g., AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein the method improves 90-day transplant-free survival of the patient versus an otherwise similar patient who was not administered Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof.
- an acute liver disease e.g., AH, sAH or ACLF
- the present invention provides a method of treating an acute liver disease (e.g., AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein the method improves 28-day survival of the patient versus an otherwise similar patient who was not administered Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof.
- an acute liver disease e.g., AH, sAH or ACLF
- the present invention provides a method of treating an acute liver disease (e.g., AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein the method improves the 6-month survival of the patient versus an otherwise similar patient who was not administered Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof.
- an acute liver disease e.g., AH, sAH or ACLF
- the present invention provides a method of treating an acute liver disease (e.g., AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein the method improves the 6-month transplant-free survival of the patient versus an otherwise similar patient who was not administered Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof.
- an acute liver disease e.g., AH, sAH or ACLF
- the present invention provides a method of treating an acute liver disease (e.g., AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein the method improves the patient's MELD and/or Lille scores at day 28 and/or day 90 after administration of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, versus an otherwise similar patient who was not administered Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof.
- an acute liver disease e.g., AH, sAH or ACLF
- the present invention provides a method of treating an acute liver disease (e.g.. AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein the method improves the patient's occurrence of hospital re-admission for alcohol-associated hepatitis versus an otherwise similar patient who was not administered Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof.
- an acute liver disease e.g. AH, sAH or ACLF
- the present invention provides a method of treating an acute liver disease (e.g., AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein the method improves one or more of: the patient's length of stay in the hospital, the number of days the patient spends in the ICU, the number of major medical procedures performed on the patient, and/or the number of emergency room visits by the patient, versus an otherwise similar patient who was not administered Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof.
- an acute liver disease e.g., AH, sAH or ACLF
- the present invention provides a method of treating an acute liver disease (e.g., AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein the method improves one or more pharmacokinetic and pharmacodynamic biomarkers, including: change from Baseline in one or more serum liver biochemistries selected from ALP, AST, ALT, GGT, and total and direct bilirubin; change from Baseline in IL-6, hs-CRP, CK-18, and TNF-a at Day 28; change from Baseline in Lipoproteins (LDL, HDL, VLDL), total cholesterol, and/or triglycerides at Day 28; and change from Baseline in lipid metabolism (LBP), 16S rDNA and/or stool sample for alpha- 1 -antitrypsin and microbiome/metabolome analysis; versus an otherwise similar patient who was not administered Compound 1 or
- an acute liver disease e
- the present invention provides a method of treating an acute liver disease (e.g., AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein the method improves survival by about 10% to about 40% (relative to the standard of care (SOC)).
- an acute liver disease e.g., AH, sAH or ACLF
- SOC standard of care
- the present invention provides a method of treating an acute liver disease (e.g., AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein the method improves survival by about 10% to about 30%.
- an acute liver disease e.g., AH, sAH or ACLF
- the present invention provides a method of treating an acute liver disease (e.g., AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein the method improves survival by about 10% to about 20%.
- the present invention provides a method of treating an acute liver disease (e.g., AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein the method provides a reduction in health care utilization.
- an acute liver disease e.g., AH, sAH or ACLF
- the present invention provides a method of treating an acute liver disease (e.g., AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein the method provides a reduction in liver-related events in patients with sAH.
- the present invention provides a method of treating an acute liver disease (e.g., AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein the method provides a decrease in the patient’s health care utilization by at least 10% for 60 days.
- an acute liver disease e.g., AH, sAH or ACLF
- the present invention provides a method of treating an acute liver disease (e.g., AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein the method reduces one or more of hospital re-admission within 30-days after discharge, number of hospitalizations, length of stay, emergency room visits, intensive care unit (ICU) days, infectious complications selected from sepsis, pneumonia, urinary tract infection (UTI), cellulitis, spontaneous and bacterial peritonitis (SBP), and major medical procedures.
- an acute liver disease e.g., AH, sAH or ACLF
- ICU intensive care unit
- infectious complications selected from sepsis, pneumonia, urinary tract infection (UTI), cellulitis, spontaneous and bacterial peritonitis (SBP), and major medical procedures.
- the present invention provides a method of treating an acute liver disease (e.g.. AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, further comprises co-administering to the patient an effective amount of anti-inflammatory agent, an antibiotic, a probiotic, a fecal transplant, Zn- supplement or a combination of any of those agents.
- an acute liver disease e.g. AH, sAH or ACLF
- the present invention provides a method of treating an acute liver disease (e.g., AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, further comprises co-administcring to the patient an effective amount of pentoxifylline, Augmentin, bovine colostrum, corticosteroid (e.g., prednisolone or methylprednisolone), an ELAD agent, canakinumab, a TNF inhibitor, IL-22, N- acetylcysteine, metadoxine, IgG anti-LPS, a probiotic, a fecal transplant, Zn- supplement, or a combination of any of those agents.
- an acute liver disease e.g., AH, sAH or ACLF
- the present invention provides a method of treating an acute liver disease (e.g., AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein the patient does not exhibit one or more of: AST or ALT >400 U/L, MDF >60 prior to treatment, MELD score >30 or MELD-Na >25 prior to treatment, other causes of liver disease selected from chronic hepatitis B (hepatitis B surface antigen [HBsAg] positive), chronic hepatitis C (HCV RNA positive), acetaminophen hepatotoxicity, biliary obstruction, and autoimmune liver disease; concomitant of previous history of hepatocellular carcinoma (HCC), a history of liver transplantation, untreated sepsis, known positivity for human immunodeficiency virus infection, uncontrolled gastrointestinal (GI) bleeding or controlled GI bleeding within 7 days of beginning treatment that was associated
- an acute liver disease
- the present invention provides a method of treating an acute liver disease (e.g., AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein the method provides at least a 15% reduction in mortality at 90 days compared to standard of care (SOC).
- an acute liver disease e.g., AH, sAH or ACLF
- SOC standard of care
- the present invention provides a method of treating an acute liver disease (e.g., AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein the method provides a reduction in hospitalization (length of stay) by at least 15% and/or a reduction in progression to transplant by at least 15%.
- an acute liver disease e.g., AH, sAH or ACLF
- the present invention provides a method of treating an acute liver disease (e.g., AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof is administered to the patient for about 30 to about 90 days.
- an acute liver disease e.g., AH, sAH or ACLF
- the present invention provides a method of treating an acute liver disease (e.g., AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof is administered orally.
- an acute liver disease e.g., AH, sAH or ACLF
- the present invention provides a method of determining candidacy of a patient for therapeutic treatment for sAH, comprising determining the patient's MELD-Na score, wherein the patient's MELD-Na score is > 18, for example from 21-30.
- the method further comprises determining the patient's MDF score, for example wherein the patient's MDF score is from 32 to 60 inclusive.
- the present invention provides a method for treating sAH comprising selecting a patient having a MELD-Na score > 18, for example from 21-30; and administering a therapeutic treatment for sAH, for example wherein the patient also has a MDF score > 32, for example from 32 to 60 inclusive.
- the therapeutic treatment comprises administering a pharmacologic agent to the patient, and/or a liver transplant
- FIG. 1 and FIG. 2 clinical chemistry results and liver and ileum histology from mouse alcoholic liver disease (ALD) study (Compound 1 is designated as Comp 1 and Compound 2 is designated as Comp 2).
- FIG. 3 Study design for a Phase 2a, Randomized, Double-Blind, Placebo Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of Compound 1 (Comp 1) in Subjects with Severe Alcohol-Associated Hepatitis (sAH).
- sAH Severe Alcohol-Associated Hepatitis
- the present invention provides a method of treating an acute liver disease comprising administering to a patient in need thereof an effective amount of an FXR agonist.
- the present invention provides a method of treating alcoholic hepatitis (AH), comprising administering to a patient in need thereof an effective amount of an FXR agonist.
- the present invention provides a method of treating an acute liver disease selected from severe alcoholic hepatitis (sAH) and acute-on-chronic liver failure (ACLF), comprising administering to a patient in need thereof an effective amount of an FXR agonist.
- sAH severe alcoholic hepatitis
- ACLF acute-on-chronic liver failure
- the present invention provides a method of treating severe alcoholic hepatitis (sAH) comprising administering to a patient in need thereof an effective amount of an FXR agonist.
- sAH severe alcoholic hepatitis
- the present invention provides a method of treating sAH which represent a significant advance over systemic corticosteroid therapy, the standard of care in the treatment of sAH.
- the present invention further provides a method of treating ACLF comprising administering to a patient in need thereof an effective amount of an FXR agonist.
- the FXR agonist is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N
- the FXR agonist is a tauro- or gly co-conjugate of Compound 1, or a pharmaceutically acceptable salt thereof.
- Compound 1 may be prepared using methods known in the art, for example, as described in U.S. Patent Nos. 10,815,267, and 11,319,337, each of which is hereby incorporated by reference in its entirety. These patents also describe various FXR agonists which may be used in accordance with the present invention.
- the present invention provides an FXR agonist for use in treating an acute liver disease.
- the present invention provides an FXR agonist for use in treating alcoholic hepatitis (AH).
- the present invention provides an FXR agonist for use in treating an acute liver disease selected from severe alcoholic hepatitis (sAH) and acute-on-chronic liver failure (ACLF).
- sAH severe alcoholic hepatitis
- ACLF acute-on-chronic liver failure
- the present invention provides Compound 1, or a pharmaceutically acceptable salt or amino acid conjugate thereof, for use in treating an acute liver disease.
- the acute liver disease is alcoholic hepatitis (AH).
- the acute liver disease is severe alcoholic hepatitis (sAH).
- the acute liver disease is moderate alcoholic hepatitis.
- the acute liver disease is mild alcoholic hepatitis.
- the acute liver disease is acute-on-chronic liver failure (ACLF).
- the present invention provides Compound 1, or a pharmaceutically acceptable salt or amino acid conjugate thereof, for use in treating alcoholic hepatitis (AH).
- AH alcoholic hepatitis
- the present invention provides Compound 1, or a pharmaceutically acceptable salt or amino acid conjugate thereof, for use in treating an acute liver disease selected from severe alcoholic hepatitis (sAH) and acute-on-chronic liver failure (ACLF).
- sAH severe alcoholic hepatitis
- ACLF acute-on-chronic liver failure
- the patient has a chronic liver disease in addition to sAH or ACLF.
- the chronic liver disease is a cholestatic liver disease.
- the chronic liver disease is a non-cholestatic liver disease.
- the patient exhibits a chronic liver condition in addition to the acute liver disease, such as AH or sAH or ACLF.
- the acute liver disease or condition is present in addition to the chronic liver disease or condition which can be selected from, but not limited to, cirrhosis (alcohol-related cirrhosis), liver fibrosis, alcohol-related steatohepatitis (ASH), steatosis, or cholestatic liver disease.
- the acute liver disease or condition is present in addition to the chronic liver disease or condition which can be selected from, but not limited to, cirrhosis, liver fibrosis, alcohol-related steatohepatitis, or steatosis.
- the patient exhibits cirrhosis. In some embodiments, the patient exhibits liver fibrosis. In some embodiments, the patient exhibits steatosis. In some embodiments, the patient exhibits ASH. In some embodiments, the patient exhibits alcoholic hepatitis.
- the patient has ALD selected from early ALD (stage 0- 2) or advanced ALD (bridging fibrosis, stage 3; or cirrhosis, stage 4).
- the patient does not exhibit cirrhosis. In some embodiments, the patient exhibits a Maddrey discriminant function (MDF) score of >32 prior to treatment with the FXR agonist.
- MDF Maddrey discriminant function
- the patient exhibits a model for end-stage liver disease (MELD or MELD-Na) score of >18 prior to treatment with the FXR agonist.
- MELD end-stage liver disease
- the patient exhibits both an MDF score of >32 and a MELD or MELD-Na score of >18 prior to treatment with the FXR agonist. [0082] In some embodiments, the patient exhibits an MDF score of 32 to 60.
- the patient exhibits a MELD score of 18 to 25 or 30 or
- the patient exhibits a MELD score of 21 to 30, or MELD-Na score of 21 to 30.
- the patient exhibits an MDF score of 20 to 31 optionally in combination with a MELD score of 18 to 25 or 30 or MELD-Na score of 18 to 25 or 30. [0086] In some embodiments, the patient exhibits an MDF score of >32 optionally in combination with a MELD score of 10 to 20 (or MELD-Na ⁇ 21); or a MELD score of 10 to 17 (or MELD-Na ⁇ 18).
- the patient exhibits an MDF score of >32 in combination with a MELD score of 21-30 (or MELD-Na 21-30).
- the patient exhibits an MDF score of 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54. 55, 56, 57, 58, 59, or 60.
- the patient exhibits a MELD or MELD-Na score of 6, 7, 8, 9, or 10. In some embodiments, the patient exhibits a MELD or MELD-Na score of 11, 12, 13, 14, 15, 16, or 17. In some embodiments, the patient exhibits a MELD or MELD- Na score of 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30.
- the patient exhibits an AST of >50 U/L prior to treatment. [0091] In some embodiments, the patient exhibits an AST / ALT ratio of >1.5 prior to treatment.
- the patient exhibits one or more of an AST of >50 U/L; an AST / ALT ratio of >1.5; a Maddrey discriminant function (MDF) score of >32; and/or a model for end-stage liver disease (MELD or MELD-Na) score of >18, 20 or 21, for example from 21-30.
- an AST of >50 U/L
- an AST / ALT ratio of >1.5
- MDF Maddrey discriminant function
- MELD or MELD-Na model for end-stage liver disease
- the method comprises administering to the patient in need thereof the FXR agonist in the amount of about 1 mg to about 500 mg. In some embodiments, the method comprises administering to the patient in need thereof the FXR agonist in the amount of about 1 mg to about 300 mg. In some embodiments, the method comprises administering to the patient in need thereof the FXR agonist in the amount of about 1 mg to about 200 mg. In some embodiments, the method comprises administering to the patient in need thereof the FXR agonist in the amount of about 1 mg to about 150 mg. In some embodiments, the method comprises administering to the patient in need thereof the FXR agonist in the amount of about 1 mg to about 100 mg.
- the method comprises administering to the patient in need thereof the FXR agonist in the amount of about 1 mg to about 50 mg. In some embodiments, the method comprises administering to the patient in need thereof the FXR agonist in the amount of about 1 mg to about 25 mg. In some embodiments, the method comprises administering to the patient in need thereof the FXR agonist in the amount of about 1 mg to about 10 mg. In some embodiments, the method comprises administering to the patient in need thereof the FXR agonist in the amount of about 2.5 mg to about 500 mg. In some embodiments, the method comprises administering to the patient in need thereof the FXR agonist in the amount of about 2.5 mg to about 300 mg.
- the method comprises administering to the patient in need thereof the FXR agonist in the amount of about 2.5 mg to about 200 mg. In some embodiments, the method comprises administering to the patient in need thereof the FXR agonist in the amount of about 2.5 mg to about 150 mg. In some embodiments, the method comprises administering to the patient in need thereof the FXR agonist in the amount of about 2.5 mg to about 100 mg. In some embodiments, the method comprises administering to the patient in need thereof the FXR agonist in the amount of about 2.5 mg to about 50 mg. In some embodiments, the method comprises administering to the patient in need thereof the FXR agonist in the amount of about 2.5 to about 25 mg. In some embodiments, the method comprises administering to the patient in need thereof the FXR agonist in the amount of about 2.5 to about 10 mg.
- the method comprises administering to the patient in need thereof the FXR agonist in the amount of about 2.5 mg, about 5 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 50 mg, about 60 mg, about 75 mg, about 85 mg, about 100 mg, about 120 mg or about 150 mg.
- the method comprises administering Compound 1 in the amount of about 2.5 mg, about 5 mg, about 10 mg, about 25 mg, about 50 mg, about 100 mg or about 120 mg.
- the method comprises administering Compound 1 in the amount of about 2.5 mg, about 5 mg, about 10 mg, about 25 mg, or about 50 mg.
- the method comprises administering to the patient in need thereof the FXR agonist in the amount of about 5 mg to about 100 mg or 5 mg to about 120 mg. In some embodiments, the method comprises administering to the patient in need thereof the FXR agonist in the amount of about 5 mg to about 50 mg. In some embodiments, the method comprises administering to the patient in need thereof the FXR agonist in the amount of about 5 to about 25 mg. In some embodiments, the method comprises administering to the patient in need thereof the FXR agonist in the amount of about 5 to about 10 mg. In some embodiments, the method comprises administering to the patient in need thereof the FXR agonist in the amount of about 5 mg.
- the method comprises administering to the patient in need thereof the FXR agonist in the amount of about 10 mg. In some embodiments, the method comprises administering to the patient in need thereof the FXR agonist in the amount of about 25 mg. In some embodiments, the method comprises administering to the patient in need thereof the FXR agonist in the amount of about 50 mg. In some embodiments, the method comprises administering to the patient in need thereof the FXR agonist in the amount of about 100 mg.
- the method provides improved 90-day transplant-free survival of the patient versus an otherwise similar patient who was not administered Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof.
- the method provides a reduction in Lille score at 7 days over standard of care (SOC). In some embodiments, the method reduces Lille score by 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, or 0.9 or greater. In some embodiments, the method reduces Lille score at 7 days by 0.1, 0.2, 0.3, or 0.4. In some embodiments, the method provides a Craft score of 0.4, 0.3, 0.2, 0.1, or less than 0.1.
- the method provides a clinical outcome of 7-day Lille score of ⁇ 0.45. In some embodiments, the method provides a clinical outcome of 7-day Lille score of ⁇ 0.45 and 28-day MELD or MELD-Na score of a decrease to ⁇ 21, or to ⁇ 20, or to ⁇ 18, or a decrease of at least 10-25% (or by least 2 or 3) in combination with one, two, three, four, five, or more endpoints described below:
- the method provides an improvement in one or more of: liver biochemistry and hepatic synthetic function, inflammation, lipoprotein metabolism, famesoid X receptor (FXR) activation markers, and bacterial translocation (e.g., lipopolysaccharide binding protein [LBP], 16S rDNA, alpha- 1-antitrypsin).
- liver biochemistry and hepatic synthetic function inflammation, lipoprotein metabolism, famesoid X receptor (FXR) activation markers
- FXR famesoid X receptor
- bacterial translocation e.g., lipopolysaccharide binding protein [LBP], 16S rDNA, alpha- 1-antitrypsin.
- the dose of the patient is increased to a maximum of 50 mg per day. In some embodiments, the dose of the patient is increased to a maximum of 100 mg per day. In some embodiments, the dose of the patient is increased to a maximum of 125, 150, 175, 200, 225, 250, 275, or 300 per day.
- the method reduces the MELD or MELD-Na score of the patient by at least 2, by at least 3, by at least 4, by at least 5, or by at least 6 by day 28 of treatment. In some embodiments, the method reduces the MELD or MELD-Na score of the patient by at least 2 by day 28, or day 90, of treatment. In some embodiments, the method reduces the MELD or MELD-Na score of the patient by at least 3 by day 28, or day 90. of treatment. In some embodiments, the method reduces the MELD or MELD-Na score of the patient by at least 4 by day 28, or day 90, of treatment.
- the method reduces the MELD or MELD-Na score of the patient by at least 5 by day 28, or day 90, of treatment. In some embodiments, the method reduces the MELD or MELD- Na score of the patient by at least 6 by day 28, or day 90, of treatment. In some embodiments, the method reduces the MELD or MELD-Na score of the patient by 2 by day 28, or day 90, of treatment. In some embodiments, the method reduces the MELD or MELD-Na score of the patient by 3 by day 28, or day 90, of treatment. In some embodiments, the method reduces the MELD or MELD-Na score of the patient by 4 by day 28, or day 90, of treatment.
- the method reduces the MELD or MELD-Na score of the patient by 5 by day 28, or day 90, of treatment. In some embodiments, the method reduces the MELD or MELD-Na score of the patient by 6 by day 28, or day 90, of treatment.
- the method reduces the MELD or MELD-Na score by 10-25%. In some embodiments, the method reduces the MELD or MELD-Na score by about 10%, about 15%, about 20%, or about 25%. In some embodiments, the method reduces the MELD or MELD-Na score by about 30%, 35%, 40%, or 50%. In some embodiments, the method reduces the MELD or MELD-Na score by at least 10-25%. In some embodiments, the method reduces the MELD or MELD-Na score by at least 10%, at least 15%, at least 20%, or at least 25% or at least 30%, or at least 35%, or at least 40%.
- the method reduces the MDF score of the patient by at least 2, by at least 3, by at least 4, by at least 5, or by at least 6 by day 28, or day 90, of treatment. In some embodiments, the method reduces the MDF score of the patient by 5, 6, 7, 8, 9, or 10. In some embodiments, the method reduces the MDF score of the patient by 5 or more. In some embodiments, the method reduces the MDF score by 10-25%. In some embodiments, the method reduces the MDF score by about 10%, about 15%, about 20%, or about 25%. In some embodiments, the method reduces the MDF score by about 30%, 35%, 40%, or 50%. In some embodiments, the method reduces the MDF score by at least 10-25%. In some embodiments, the method reduces the MDF score by at least 10%, at least 15%, at least 20%, or at least 25%.
- the method reduces the MELD or MELD-Na score of the patient by at least 2-6 and/or reduces the MDF score of the patient by at least 2-6 by day 28, or day 90, of treatment. In some embodiments, the method reduces the MELD or MELD-Na score of the patient by at least 2 and/or reduces the MDF score of the patient by at least 2 by day 28, or day 90, of treatment. In some embodiments, the method reduces the MELD or MELD-Na score of the patient by at least 3 and/or reduces the MDF score of the patient by at least 3 by day 28, or day 90, of treatment.
- the method reduces the MELD or MELD-Na score of the patient by at least 4 and/or reduces the MDF score of the patient by at least 4 by day 28, or day 90, of treatment. In some embodiments, the method reduces the MELD or MELD-Na score of the patient by at least 5 and/or reduces the MDF score of the patient by at least 5 by day 28, or day 90, of treatment. In some embodiments, the method reduces the MELD or MELD-Na score of the patient by at least 6 and/or reduces the MDF score of the patient by at least 6 by day 28, or day 90, of treatment.
- the method reduces the MELD or MELD-Na score of the patient by at least 5 by day 28, or day 90, of treatment. In some embodiments, the method reduces the MDF score of the patient by at least 5 by day 28, or day 90, of treatment. In some embodiments, the method reduces the MELD or MELD-Na score of the patient by at least 5 and reduces the MDF score of the patient by at least 5 by day 28, or day 90, of treatment. In some embodiments, the method provides a reduction in MELD or MELD-Na score at 28, or 90 days. In some embodiments, the method provides a reduction in MDF score at 28 days or 90 days.
- the method further comprises monitoring the blood levels of a biomarker in the patient after administration of the FXR agonist of the present disclosure.
- the biomarker is selected from C4, FGF-19, and endogenous bile acids.
- the patient has alcohol-related (or alcohol-associated) liver disease (ALD), also known as alcoholic liver disease.
- ALD alcohol-related liver disease
- the patient exhibits jaundice.
- the patient exhibits one or more of the following: (1) ongoing alcohol consumption of more than 40 g of alcohol per day in women and more than 60 g of alcohol per day in men for 6 months or more, with less than 60 days of abstinence before the onset of jaundice; (2) the presence of elevated liver enzymes (aspartate aminotransferase [AST] and/or alanine aminotransferase [ALT] concentrations >50 IU/L but ⁇ 400 IU/L and an AST/ALT ratio of >1:5); and (3) worsening jaundice, with bilirubin concentrations greater than 3 mg/dL.
- AST aspartate aminotransferase
- ALT alanine aminotransferase
- the patient is diagnosed with sAH after a liver biopsy in addition to one, two, three, or all of the preceding signs.
- the patient exhibits ongoing alcohol consumption of more than 40 g of alcohol per day in women and more than 60 g of alcohol per day in men for 6 months or more, with less than 60 days of abstinence before the onset of jaundice.
- the patient exhibits the presence of elevated liver enzymes (aspartate aminotransferase [AST] and/or alanine aminotransferase [ALT] concentrations >50 IU/L but ⁇ 400 IU/L and an AST/ALT ratio of >1:5).
- the patient exhibits worsening jaundice, with bilirubin concentrations greater than 3 mg/dL.
- the patient exhibits the absence of any other causes of liver disease.
- the patient is considered ineligible for a liver transplant per generally-accepted criteria known in the art.
- the patient has alcoholic use disorder (AUD).
- AUD can be defined based on consumption of alcohol, e.g., as consuming 3 or more alcoholic drinks per day (men) or 2 or more alcoholic drinks per day (women).
- the patient has been treated previously for sAH with a corticosteroid. In some embodiments, the patient did not respond to the corticosteroid. In some embodiments, the patient exhibited a Geb score of more than 0.45 after 7 days or more of treatment with the corticosteroid.
- the patient is currently hospitalized, i.e., hospitalized prior to beginning treatment with the FXR agonist.
- the patient is currently hospitalized and exhibits an MDF score of at least 32 and a MELD score of 18, or 20, or 21 to 30 or MELD-Na score of 18, or 20, or 21 to 25 or 30.
- the patient has suffered at least one relapse of sAH, i.e., has been diagnosed and/or treated at least once before for sAH.
- the patient exhibits one or more of the following in addition to sAH: obesity, metabolic syndrome, hepatitis C infection, or a genetic polymorphism such as patatin-like phospholipase domain protein 3, membrane bound O- acyltransferase, and transmembrane 6 superfamily member 2 genes.
- the patient exhibits intestinal dysbiosis.
- the method improves one or measures of sAH, such as intestinal dysbiosis. [00117] In some embodiments, the method improves 30-day survival of the patient having sAH or ACLF versus an otherwise similar patient having sAH or ACLF who was not administered the FXR agonist. In some embodiments, the method improves 60-day survival of the patient versus an otherwise similar patient who was not administered the FXR agonist. In some embodiments, the method improves 90-day survival of the patient versus an otherwise similar patient who was not administered the FXR agonist. In some embodiments, the method improves the 120-day, 180-day, or 1-year survival of the patient versus an otherwise similar patient who was not administered the FXR agonist.
- the method improves 30-day mortality of the patient versus an otherwise similar patient who was not administered the FXR agonist. In some embodiments, the method improves 60-day mortality of the patient versus an otherwise similar patient who was not administered the FXR agonist. In some embodiments, the method improves 90-day mortality of the patient versus an otherwise similar patient who was not administered the FXR agonist. In some embodiments, the method improves the 120-day, 180-day, or 1-year mortality of the patient versus an otherwise similar patient who was not administered the FXR agonist.
- the improvement in survival or mortality of the patient includes an increase in survival, or a decrease in mortality, of about 10% to about 70%. Such improvements may be measured over, for example, 30 days, 60 days, 90 days, 120 days, 180 days, 1 year, or greater than 1 year. In some embodiments, the improvement in survival or mortality of the patient includes an increase in survival, or a decrease in mortality, of about 10% to about 60%, about 10% to about 50%, about 10% to about 40%, about 10% to about 30%, or about 10% to about 20%.
- the method provides at least a 15% reduction in mortality at 90 days compared to standard of care (SOC). In some embodiments, the method provides a 15-20% reduction in mortality at 30 days compared to SOC. In some embodiments, the method provides a 10% reduction in mortality at 6 months. In some embodiments, the method provides a 5-10% absolute reduction in mortality at 1 year.
- SOC standard of care
- the method provides a reduction in risk of mortality for the patient. In some embodiments, the method provides a reduction in risk of mortality and health care utilization for liver-related events in patients with sAH. In some embodiments, such reductions are compared with the current standard of care, e.g., treatment with a corticosteroid such as prednisolone.
- the FXR agonist such as Compound 1 or a pharmaceutically acceptable salt thereof or an amino acid conjugate thereof, is indicated for first-line therapy.
- the method provides a decrease in the patient’s health care utilization by at least 10% for 30 days, 60 days, 90 days, 120 days, 180 days, or for 1 year, or for greater than 1 year.
- the term “heath care utilization” includes one or more of hospital re-admission within 30-days after discharge, number of hospitalizations, length of stay, emergency room visits, intensive care unit (ICU) days, and infectious complications (e.g., sepsis, pneumonia, urinary tract infection [UTI], cellulitis, spontaneous bacterial peritonitis [SBP]), and major medical procedures such as liver transplant.
- the method provides a decrease in the patient’s health care utilization by at least 20% for 30 days, 60 days, 90 days, 120 days, 180 days, or for 1 year, or for greater than 1 year. In some embodiments, the method provides a decrease in the patient’s health care utilization by at least 30% for 30 days, 60 days, 90 days, 120 days, 180 days, or for 1 year, or for greater than 1 year. In some embodiments, the method provides a decrease in the patient’s health care utilization by about 10% to about 40% for 30 days, 60 days, 90 days, 120 days, 180 days, or for 1 year, or for greater than 1 year.
- the method improves 90-day survival of the patient and decreases the patient’s re -hospitalizations by at least 10%, or at least 20%, or between 10% and 30%.
- the method provides an improvement in liver-related events (such as decompensation), or hospitalization/re-hospitalization.
- the method provides a reduction in hospitalization by at least 15%.
- the method provides a reduction in progression to transplant by at least 15%.
- Compound 1 is a semi-synthetic bile acid derived from CDCA, the natural ligand for the FXR.
- FXR agonist Compound 1 could represent a significant advance over systemic corticosteroid therapy, the standard of care in the treatment of patients with sAH. Compound 1 likely also decreases intestinal permeability and could provide a considerable advance over corticosteroids with respect to bacterial translocation and infectious complications seen in patients with sAH.
- the targeted mechanism of action of FXR agonists such as Compound 1 represents a novel therapeutic option over the nonspecific action of corticosteroids, the current standard of care for sAH.
- the present invention provides methods of treating alcoholic hepatitis or severe alcoholic hepatitis or ACLF, comprising administering to a patient in need thereof an effective amount of an FXR agonist described herein.
- FXR agonists described herein meet a long-felt need in the art for efficacious therapies for acute liver diseases such as severe alcoholic hepatitis (sAH) and acute-on- chronic liver failure (ACLF).
- sAH severe alcoholic hepatitis
- ACLF acute-on- chronic liver failure
- Dysfunction of the gut-liver axis, including increased intestinal permeability, is an important driver of alcohol-induced liver damage (Sehrawat, T.S., et al. The knowns and unknowns of treatment for alcoholic hepatitis. Lancet Gastroenterol Hepatol. 2020;5(5)494-506).
- Severe alcoholic hepatitis is an acute liver disease distinct from other alcoholic liver diseases, many of which are chronic in nature. Furthermore, sAH has distinctive histopathologic and pathophysiologic features and may be present in a patient along with underlying, chronic liver diseases such as alcoholic liver disease (ALD) (Shah N.J., Royer A, John S. Alcoholic Hepatitis. Stat Pearls. 2021 Jan; 1-8; hereby incorporated by reference).
- ALD alcoholic liver disease
- LPS lipopolysaccharide
- PAMPs pathogen-associated molecular patterns
- Increased endotoxin levels in alcoholic hepatitis are caused by alcohol-induced qualitative and quantitative changes in the gut microbiota and increases in intestinal permeability.
- LPS activates Kupffer cells and hepatic stellate cells via toll-like receptor 4 (TLR4) and produce reactive oxygen species (ROS), proinflammatory cytokines and chemokines that together with alcohol contribute to hepatocyte damage.
- ROS reactive oxygen species
- Other factors contributing to hepatocyte damage include alcohol- induced activation of various immune cells (i.e., neutrophils, T cells, and other leukocytes); in addition, alcohol’s direct effect on adipose tissue results in the production of damage- associated molecular- patterns (DAMPs).
- DAMPs damage- associated molecular- patterns
- liver biopsy is not required. However, liver biopsy may be needed to confirm the diagnosis of AH.
- Findings that confirm the diagnosis of AH on liver biopsy include hepatocyte ballooning, neutrophil infiltrate and Mallory-Denk bodies, on a background of variable degrees of steatosis and fibrosis (Singal, A.K., et al. Journal of Hepatology 2019, vol.70, 305-313).
- the method of the present disclosure improves one or more histologic measures of sAH, such as macrovesicular steatosis with at least one of the following: neutrophil infiltration, hepatocyte injury (ballooning), and Mallory-Denk bodies.
- the method of the present disclosure improves macrovesicular steatosis.
- the method of the present disclosure improves neutrophil infiltration.
- the method of the present disclosure improves hepatocyte injury (ballooning).
- the method of the present disclosure improves Mallory-Denk bodies.
- Alcohol-induced liver injury can range from steatosis to alcohol-induced steatohepatitis with fibrosis to cirrhosis and hepatocellular carcinoma.
- ALD alcohol-related liver disease
- Alcoholic hepatitis (or alcohol-associated hepatitis), also referred to as symptomatic alcoholic steatohepatitis, is a clinical syndrome of acute hepatitis due to heavy alcohol consumption with distinct histopathologic findings including steatohepatitis, neutrophilic infiltration, and fibrosis (Crabb, D.W., el al., “Standard definitions and common data elements for clinical trials in patients with alcoholic hepatitis: Recommendation from the NIAAA Alcoholic Hepatitis Consortia,” Gastroenterology 2016 Apr;150(4):785-90; hereby incorporated by reference).
- AH AH-related diseases
- abnormalities that could contribute to liver injury include production of oxidative stress as a by-product of the metabolism of ethanol and the “leakage” of endotoxin through the intestinal wall and into the portal circulation. Endotoxin binds to receptors on Kupffer cells and activates an inflammatory response. The inflammatory response in the liver leads to hepatocyte dysfunction and death.
- TNF tumor necrosis factor
- Direct hepatocyte injury is due to the cytotoxic effect of ethanol and its metabolites (e.g., acetaldehyde).
- the ethanol-induced injury incites an inflammatory response and is associated with high morbidity and mortality, especially in patients with severe disease.
- Ethanol metabolism also changes the redox state of hepatocytes and interferes with carbohydrate and lipid metabolism, thus contributing to hepatic steatosis.
- Alcohol increases the susceptibility of hepatocytes to free radical damage by activating the CYP2E1 enzyme inducing mitochondrial dysfunction, depleting antioxidant stores, and recruiting inflammatory cells.
- DAMPs and PAMPs bind to pattern recognition receptors and potently stimulate the innate immune response.
- Alcoholic hepatitis (or alcohol-associated hepatitis) is thus a distinct disease (Sehrawat, T.S., et al. “The knowns and unknowns of treatment for alcoholic hepatitis,” Lancet Gastroenterol Hepatol.
- Patients with sAH are defined by MDF >32 and/or MELD.
- the short-term mortality for patients with sAH has been reported to be as high as 46% in prior interventional studies (Akriviadis, E., et al. “Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo- controlled trial,” Gastroenterology 2000 Dec; 119(6): 1637-48; hereby incorporated by reference).
- a more recent study reported a longer term 1-year mortality (or liver transplantation) rate of 56% to 57% in patients with sAH (Thursz, M.R., et al.
- Patients with acute alcoholic hepatitis will have an elevated total bilirubin and transaminases typically at least 2-6 times the upper limit or normal. Severe alcoholic hepatitis may be marked by bilirubin levels over 10-15 mg/dL; levels of aspartate aminotransferase (AST) are usually between 100 and 200 U/L (or IU/L) and are almost always less than 400 U/L (or IU/L); alanine aminotransferase (ALT) is usually approximately 25-50% the value of AST, somewhere in the range of 50-150 U/L (or IU/L); and other typical findings include fever, leukocytosis (white blood cell >10,000/pL), ascites, and tender hepatomegaly (Morgan, T.
- AST aspartate aminotransferase
- ALT alanine aminotransferase
- the Lille Model is a medical modeling tool for predicting mortality in patients with alcoholic hepatitis who are not responding to steroid therapy.
- the model risk stratifies patients who have been receiving steroid treatment for seven days to predict who will improve and who should be considered for alternative treatment options including early referral for transplant (Mathurin, P., et al., Early change in bilirubin levels is an important prognostic factor in severe alcoholic hepatitis treated with prednisolone. Hepatology, 2003, 38 (6): 1363-9).
- the model is based on: Age; Albumin; Bilirubin (initial); Bilirubin (day 7); Creatinine; and Prothrombin time (PT).
- the Lille model can be used to predict mortality at 6 months. Lower scores indicated more improvement (in response to corticosteroids). Typically, scores >0.45 predict a 6-month survival of 25%. Scores ⁇ 0.45 predict a 6-month survival of 85%.
- Lille scores at day 7 can range from less than 0.1 and greater than 0.9.
- Mut score at day 7 for Responder is ⁇ 0.45 and Lille score at day 7 for non-Responder is >0.45.
- Several scores such as Maddrey’s discriminant function (MDF), MELD or MELD-Na, ABIC, and GAHS are used for a 28-day mortality prognosis.
- MDF is defined as 4.6 x (patient - control PT) + serum bilirubin, with severe disease being a score of 32 or higher.
- An MDF score less than 32 means mild to moderate alcoholic hepatitis.
- An MDF score equal to or greater than 32 means one is likely to have severe alcoholic hepatitis and is a candidate for corticosteroid therapy or pentoxifylline treatment under current standard of care.
- MDF less than 32 (mild to moderate AH) does not benefit from steroid therapy. There is some mortality associated with mild to moderate AH, so it is beneficial to have a therapy for this group (given that steroids are not indicated because they do not impart mortality benefit).
- Model for End-Stage Liver Disease (MELD) score is a prognostic scoring system, based on laboratory parameters, used to predict 3-month mortality due to liver disease.
- the MELD score ranges from 6 to 40 and is based on results from several lab tests.
- MELD scores for mild AH ranges from 6 to 10.
- MELD scores for moderate AH ranges from 11 to 20.
- MELD for sAH ranges from 21 to 30.
- MELD is defined as 9.57 log e (S creatinine) + 3.78 log c (serum bilirubin) + 11.2 log c (INR) + 6.43.
- a severe disease is MELD score of 21 or higher. Singal, A.K., et al., “Diagnosis and Treatment of Alcohol- Associated Liver Disease,” JAMA. 2021;326(2): 165-176, hereby incorporated by reference.
- MELD 3.0 A new version of MELD (MELD 3.0) was recently developed, which added female gender and albumin in the score, demonstrating a slightly more accurate mortality prediction than MELD-Na in cirrhotic patients. See Kim W.R., et al. MELD 3.0: The Model for End-stage Liver Disease Updated for the Modern Era. Gastroenterology 2021 (available on line at https://doi.Org/10.1053/j.gastro.2021.08.050), incorporated herein by reference. Each of the embodiments described herein that list MELD or MELD-Na ranges and/or values are intended to also include the corresponding MELD 3.0 ranges and/or values.
- MDF Maddrey discriminant function
- the MELD-Na score is a modification of the MELD score that adjusts for serum sodium.
- the MELD-Na score is currently an accepted criterion for determining candidacy for liver transplants.
- the study described herein includes patients that have MELD-Na scores of 18-25 (inclusive) and a MDF of >32.
- MELD-Na score includes serum Na; this score improves slightly the predictive accuracy of the MELD score in predicting mortality (Kim, W.R., et al. N Engl J Med 2008; 359:1018-1026).
- the MELD-Na is a validated scoring system used to assess the severity of chronic liver disease.
- the MELD-Na score is useful in assessing subjects with significant decompensation and is now used by the Organ Procurement and Transplantation Network (OPTN) in the US and the Eurotransplant (ET) regions of the EU to manage the organ allocation for liver transplantation.
- OPTN Organ Procurement and Transplantation Network
- ET Eurotransplant
- the patient is of at least 18 years of age. In some embodiments, the patient is of at least 30 years of age. In some embodiments, the patient is of at least 35 years of age. In some embodiments, the patient is of at least 40 years of age. In some embodiments, the patient is of at least 60 years of age. In some embodiments, the patient is 18 to 65 years of age. In some embodiments, the patient is of at least 42, 45, 48, 50, 52, 55, 58, 62, 65, 68, 70, 72, 75, 78, or 80 years of age. In some embodiments, the patient is 40-60 years of age. In some embodiments, the patient is 60-85 year s of age. In some embodiments, the patient is 40-50 year's of age. In some embodiments, the patient is 70-80 years of age. [00148] In some embodiments, the patient is male. In some embodiments, the patient is female.
- the patient is stratified according to disease severity.
- Short-term mortality can be predicted using the Maddrey discriminant function (MDF), Model for End-Stage Liver Disease (MELD or MELD-Na) score, Age-Bilirubin-Intemational Normalized Ratio -Creatinine score, and Glasgow Alcoholic Hepatitis Scores.
- MDF Maddrey discriminant function
- MELD or MELD-Na Model for End-Stage Liver Disease
- MELD or MELD-Na Age-Bilirubin-Intemational Normalized Ratio -Creatinine score
- Glasgow Alcoholic Hepatitis Scores Glasgow Alcoholic Hepatitis Scores.
- Patients with severe AH (sAH) defined by a Maddrey discriminant function of 32 or greater have a 1-month morality rate as high as 20%-50%, so in prior clinical studies, the 30-day survival was the endpoint for most trials.
- the maximum MDF score is typically less than 60, as patients with MDF score
- a MELD or MELD-Na score of >20 or >21 is used as a criterion for selecting a patient.
- a MELD or MELD-Na score of >18 is used as a criterion for selecting a patient.
- a MELD score of 21 or greater predicts a 90-day mortality of 20% .
- the maximum MELD score is typically less than 30, as patients with MELD score of more than 30 likely need liver transplant. Failure of improvement in serum bilirubin (the Lille score) predicts patients with severe AH who are unlikely to benefit from continued corticosteroid therapy.
- the patient has mild alcoholic hepatitis. In some embodiments, the patient has moderate alcoholic hepatitis. In some embodiments, the patient has a Maddrey’s discriminant function score of about 32, and/or a MELD or MELD-Na score of 18, 19, 20, 21, 22, 23, 24, or 25.
- the patient has a Maddrey’s discriminant function score of > 32, and/or a MELD or MELD-Na score of 21-30.
- the patient has underlying alcohol-related liver disease (ALD) associated with sAH.
- ALD alcohol-related liver disease
- the patient exhibits jaundice.
- the patient exhibits one or more of the following: (1) ongoing alcohol consumption of more than 40 g of alcohol per day in women and more than 60 g of alcohol per day in men for 6 months or more, with less than 60 days of abstinence before the onset of jaundice; (2) the presence of elevated liver enzymes (aspartate aminotransferase [AST] and alanine aminotransferase [ALT] concentrations >50 IU/L but ⁇ 400 IU/L and an AST/ALT ratio of >1:5); and (3) worsening jaundice, with bilirubin concentrations greater than 3 mg/dL.
- the patient is diagnosed with sAH after a liver biopsy in addition to one, two, three, or all of the preceding signs of the disease.
- the patient is considered ineligible for a liver transplant per generally accepted criteria known in the art.
- the patient has alcoholic use disorder (AUD), defined as consuming 3 or more alcoholic drinks per day (men) or 2 or more alcoholic drinks per day (women).
- AUD alcoholic use disorder
- the patient has been treated previously for sAH with a corticosteroid. In some embodiments, the patient did not respond to the corticosteroid. In some embodiments, the patient exhibited a Geb score of more than 0.45 after 7 days or more of treatment with the corticosteroid.
- the patient has an MDF score of 32 or higher, and/or a MELD or MELD-Na score of 18, or 20, or 21 or higher, for example 21-30.
- the patient has asymptomatic sAH, or “walking AH.” In some embodiments, the patient has asymptomatic sAH that includes cirrhosis.
- the patient in addition to sAH, is diagnosed using Child- Turcotte-Pugh criteria. In some embodiments, the patient has a Child-Turcotte-Pugh score of 7 or greater, e.g., 7-15, 8-15. 9-15, 10-15, or 8-12.
- the patient exhibits alcohol-associated cirrhosis.
- the patient exhibits alcohol-associated liver fibrosis.
- the patient exhibits alcohol-associated steatosis.
- the patient exhibits alcohol-associated steatohepatitis.
- the patient exhibits alcoholic hepatitis.
- the patient has ALD in addition to sAH, wherein the ALD is selected from early ALD (stage 0-2) or advanced ALD (bridging fibrosis, stage 3; or cirrhosis, stage 4).
- ALD is selected from early ALD (stage 0-2) or advanced ALD (bridging fibrosis, stage 3; or cirrhosis, stage 4).
- the patient does not exhibit cirrhosis.
- the patient is currently hospitalized, i.e., hospitalized prior to beginning treatment with the FXR agonist.
- the patient is currently hospitalized and exhibits an MDF score of at least 32 and a MELD score of 18, or 20, or 21 to 25 or 30, or 21-30, or MELD-Na score of 18, 20 or 21 to 25 or 30.
- the patient has suffered at least one relapse of sAH.
- the patient exhibits one or more of the following in addition to sAH: obesity, metabolic syndrome, hepatitis C infection, or a genetic polymorphism such as patatin-like phospholipase domain protein 3, membrane bound O- acyltransferase, and transmembrane 6 superfamily member 2 genes.
- the patient exhibits intestinal dysbiosis.
- the method improves one or measures of sAH, such as intestinal dysbiosis.
- the present disclosure provides a method of determining candidacy of a patient for therapeutic treatment for sAH, comprising determining the patient's MELD-Na score, wherein the patient's MELD-Na score is > 18.
- the method further comprises determining the patient's MDF score, for example wherein the patient's MDF score is from 32 to 60 inclusive.
- the present disclosure provides a method of determining candidacy of a patient for therapeutic treatment for sAH, comprising determining the patient's MELD score, wherein the patient's MELD score is > 21, for example from 21 to 30.
- the method further comprises determining the patient's MDF score, for example wherein the patient's MDF score is > 32, for example from 32 to 60 inclusive.
- the present disclosure provides a method for treating sAH comprising selecting a patient having a MELD-Na score > 18; and administering a therapeutic treatment for sAH, for example wherein the patient also has a MDF score from 32 to 60 inclusive.
- the therapeutic treatment comprises administering a pharmacologic agent to the patient, and/or a liver transplant.
- the present disclosure provides a method for treating sAH comprising selecting a patient having a MELD score > 21, for example from 21 to 30; and administering a therapeutic treatment for sAH, for example wherein the patient also has a MDF score > 32, for example from 32 to 60 inclusive.
- the therapeutic treatment comprises administering a pharmacologic agent to the patient, and/or a liver transplant.
- the method provides improvements in one or more measures of patient health outcomes.
- references to “a patient” or “the patient” may refer to an individual patient or to a group of patients.
- a decrease in the patient’s health care utilization may refer to an individual patient or to a group of patients.
- the method improves 30-day survival of the patient versus an otherwise similar patient who was not administered the FXR agonist. In some embodiments, the method improves 60-day survival of the patient versus an otherwise similar patient who was not administered the FXR agonist. In some embodiments, the method improves 90-day survival of the patient versus an otherwise similar patient who was not administered the FXR agonist. In some embodiments, the method improves the 120-day, 180-day, or 1-ycar survival of the patient versus an otherwise similar patient who was not administered the FXR agonist.
- the method improves 30-day mortality of the patient versus an otherwise similar patient who was not administered the FXR agonist. In some embodiments, the method improves 60-day mortality of the patient versus an otherwise similar patient who was not administered the FXR agonist. In some embodiments, the method improves 90-day mortality of the patient versus an otherwise similar' patient who was not administered the FXR agonist. In some embodiments, the method improves the 120-day, 180-day, or 1-year mortality of the patient versus an otherwise similar patient who was not administered the FXR agonist.
- the improvement in survival or mortality of the patient includes an increase in survival, or a decrease in mortality, of about 10% to about 70%. Such improvements may be measured over, for example, 30 days, 60 days, 90 days, 120 days, 180 days, 1 year, or greater than 1 year. In some embodiments, the improvement in survival or mortality of the patient includes an increase in survival, or a decrease in mortality, of about 10% to about 60%, about 10% to about 50%, about 10% to about 40%, about 10% to about 30%, or about 10% to about 20%.
- the improvement in survival or mortality of the patient includes an increase in survival, or a decrease in mortality, of about 20% to about 70%, about 20% to 60%, about 20% to about 50%, about 20% to about 40%, about 20% to about 30%, about 30% to about 70%, about 30% to about 60%, about 30% to about 50%, about 30% to about 40%, about 40% to about 70%, about 40% to about 60%, about 40% to about 50%, about 50% to about 70%, about 50% to about 60%, or about 60% to about 70%.
- the improvement in survival or mortality of the patient includes an increase in survival, or a decrease in mortality, of about 10%, 15%, 20%. 25%, 30%, 35%, 40%. 45%, 50%, 55%, 60%. 65%, 70%, 75%, 80%, 85%, 90%, or 95%.
- the method provides a reduction in risk of mortality for the patient. In some embodiments, the method provides a reduction in risk of mortality and health care utilization for liver-related events in patients with sAH. In some embodiments, such reductions are compared with the current standard of care, e.g., treatment with a corticosteroid such as prednisolone.
- the FXR agonist such as Compound 1 or a pharmaceutically acceptable salt thereof or an amino acid conjugate thereof, is indicated for first-line therapy.
- the method provides a decrease in the patient’s health care utilization by at least 10% for 30 days, 60 days, 90 days, 120 days, 180 days, or for 1 year, or for greater than 1 year.
- the term “heath care utilization” includes one or more of hospital re-admission within 30-days after discharge, number of hospitalizations, length of stay, emergency room visits, intensive care unit (ICU) days, and infectious complications (e.g., sepsis, pneumonia, urinary tract infection [UTI], cellulitis, spontaneous bacterial peritonitis [SBP]), and major medical procedures such as liver transplant.
- the method provides a decrease in the patient’s health care utilization by at least 20% for 30 days, 60 days, 90 days, 120 days, 180 days, or for 1 year, or for greater than 1 year. In some embodiments, the method provides a decrease in the patient’s health care utilization by at least 30% for 30 days, 60 days, 90 days, 120 days, 180 days, or for 1 year, or for greater than 1 year. In some embodiments, the method provides a decrease in the patient’s health care utilization by about 10% to about 40% for 30 days, 60 days, 90 days, 120 days, 180 days, or for 1 year, or for greater than 1 year.
- the method provides a decrease in the patient’s health care utilization by about 10% to about 40% for 30 days, 60 days, 90 days. 120 days, 180 days, or for 1 year, or for greater than 1 year. In some embodiments, the method provides a decrease in the patient’s health care utilization by about 20% to about 30% for 30 days, 60 days, 90 days, 120 days, 180 days, or for 1 year, or for greater than 1 year. In some embodiments, the method provides a decrease in the patient’s health care utilization by about 10% to about 20% for 30 days, 60 days, 90 days, 120 days, 180 days, or for 1 year, or for greater than 1 year.
- the method decreases the patient’s re-hospitalizations by at least 10%. In some embodiments, the method decreases the patient’s re-hospitalizations by 10-80%.
- the method improves 90-day survival of the patient and decreases the patient’s re -hospitalizations by at least 10%.
- the method further comprises administering the FXR agonist in combination with another therapeutic agent.
- the method further comprises co-administcring to the patient an effective amount of anti-inflammatory agent, an antibiotic, a probiotic, a fecal transplant. Zinc- supplement or a combination of any of those agents.
- another therapeutic agent can be an antiinflammatory agent, an antibiotic (e.g., Augmentin), an antioxidant, a probiotic, a fecal transplant, Zn-supplement or a combination of any of those agents.
- the method comprises administering the FXR agonist and an anti-inflammatory agent.
- the anti-inflammatory agent is a corticosteroid.
- the corticosteroid may be selected from prednisolone (e.g., about 40 mg/d) or methylprednisolone (e.g., about 32 mg/d).
- the additional therapeutic agent for co-administration is pentoxifylline.
- the FXR agonist is administered in combination with corticosteroid or pentoxifylline.
- the method further comprises co-administering to the patient an effective amount of pentoxifylline, Augmentin, bovine colostrum, corticosteroid (e.g., prednisolone or methylprednisolone), an ELAD agent, canakinumab, a TNF inhibitor, IL-22, N- acetylcysteine, metadoxine, IgG anti-LPS, a probiotic, a fecal transplant, Zn-supplement, or a combination of any of those agents.
- corticosteroid e.g., prednisolone or methylprednisolone
- canakinumab e.g., a TNF inhibitor, IL-22, N- acetylcysteine, metadoxine, IgG anti-LPS, a probiotic, a fecal transplant, Zn-supplement, or a combination of any of those agents.
- the further treatment comprises alcohol cessation and/or counseling.
- Acute-on-chronic liver failure is a syndrome characterized by acute decompensation of chronic liver disease associated with organ failures and high short-term mortality.
- Alcohol and chronic viral hepatitis are the most common underlying liver diseases. Up to 40%-50% of the cases of ACLF have no identifiable trigger; in the remaining patients, sepsis, active alcoholism and relapse of chronic viral hepatitis are the most common reported precipitating factors.
- An excessive systemic inflammatory response seems to play a crucial role in the development of ACLF.
- Using a liver-adapted sequential organ assessment failure score it is possible to triage and prognosticate the outcome of patients with ACLF.
- the course of ACLF is dynamic and changes over the course of hospital admission.
- the patient is of at least 18 years of age. In some embodiments, the patient is of at least 30 years of age. In some embodiments, the patient is of at least 35 years of age. In some embodiments, the patient is of at least 40 years of age. In some embodiments, the patient is of at least 60 years of age. In some embodiments, the patient is 18-65 years of age. In some embodiments, the patient is of at least 42, 45, 48, 50, 52, 55, 58, 62, 65, 68, 70, 72, 75, 78, or 80 years of age. In some embodiments, the patient is 40-65 years of age. In some embodiments, the patient is 65-85 years of age. In some embodiments, the patient is 40-50 years of age. In some embodiments, the patient is 70-80 years of age.
- the patient is male. In some embodiments, the patient is female.
- the patient has alcoholic use disorder (AUD), defined as consuming 3 or more alcoholic drinks per day (men) or 2 or more alcoholic drinks per day (women).
- AUD alcoholic use disorder
- the patient has ALD-related ACLF.
- the patient has ALD selected from early ALD (stage 0- 2) or advanced ALD (bridging fibrosis, stage 3; or cirrhosis, stage 4).
- the patient has a Maddrey’s discriminant function (MSF) score of 32 or higher, and/or a MELD or MELD-Na score of 18, 20, or 21 or higher, for example from 21-30.
- MSF discriminant function
- the patient has been diagnosed with ACLF using the Sequential [Sepsis-related] Organ Failure Assessment, APACHE (Acute Physiology and Chronic Health Evaluation), or acute-on-chronic liver failure score.
- the patient exhibits cirrhosis.
- the patient exhibits liver fibrosis.
- the patient exhibits steatosis.
- the patient exhibits alcoholic hepatitis.
- the patient does not exhibit cirrhosis.
- the patient exhibits intestinal dysbiosis.
- the patient exhibits one or more of the following in addition to ACLF: obesity, metabolic syndrome, hepatitis C infection, or a genetic polymorphism such as patatin-like phospholipase domain protein 3, membrane bound O- acyltransferase, and transmembrane 6 superfamily member 2 genes.
- ACLF is precipitated by sAH
- same therapeutics as for sAH are used for treatment.
- Antioxidants, such as N-acetylcysteine, are used in ACLF.
- the method of the present disclosure includes a coadministered treatment.
- the method comprises administering the FXR agonist in combination with another therapeutic agent.
- another therapeutic agent can be an anti-inflammatory agent, an antibiotic (e.g.. Augmentin), an antioxidant, a probiotic, a fecal transplant, Zn-supplement or a combination of any of those agents.
- the method comprises administering the FXR agonist and an anti-inflammatory agent.
- the anti-inflammatory agent is a corticosteroid.
- the corticosteroid may be selected from prednisolone (e.g., about 40 mg/d) or methylprednisolone (e.g., about 32 mg/d).
- the additional therapeutic agent for co-administration is pentoxifylline.
- the FXR agonist is administered in combination with corticosteroid or pentoxifylline.
- the FXR agonist is administered in combination with N-acetylcysteine.
- the further treatment comprises alcohol cessation and/or counseling.
- the invention provides a composition comprising a disclosed compound and a pharmaceutically acceptable carrier, adjuvant, or vehicle.
- a composition of this invention is formulated for administration to a patient in need of such composition.
- a composition of this invention is formulated for oral administration to a patient.
- subject or “patient,” as used herein, means a human.
- compositions of this invention refers to a non-toxic carrier, adjuvant, or vehicle that docs not destroy the pharmacological activity of the compound with which it is formulated.
- Pharmaceutically acceptable carriers, adjuvants or vehicles that may be used in the compositions of this invention include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances (e.g., hydroxypropyl methylcellulose), polyethylene glycol, sodium carboxymethylcellulose
- a “pharmaceutically acceptable derivative” means any non-toxic salt, ester, salt of an ester or other derivative of a compound of this invention that, upon administration to a recipient, is capable of providing, either directly or indirectly, a compound of this invention or an active metabolite or amino acid conjugate thereof.
- amino acid conjugate refers to a conjugate of a compound of the invention with any suitable amino acid.
- Taurine NHjCFb SChH
- glycine glycine
- sarcosine -N/CHsjCFhCChH
- Suitable amino acid conjugates of the compounds have the added advantage of enhanced integrity in bile or intestinal fluids.
- Suitable amino acids are not limited to taurine, glycine, and sarcosine.
- the term “metabolite” refers to glucuronidated and sulfated derivatives of the compounds described herein, wherein one or more glucuronic acid or sulfate moieties are linked to the compound of the invention.
- Glucuronic acid moieties may be linked to the compounds through glycosidic bonds with the hydroxyl groups of the compounds (e.g., 3-hydroxyl, 7-hydroxyl, 11-hydroxyl).
- Sulfated derivatives of the compounds may be formed through sulfation of the hydroxyl groups (e.g., 3-hydroxyl, 7- hydroxyl, 11-hydroxyl).
- metabolites include, but are not limited to, 3-0- glucuronide, 7-O-glucuronide, 11-O-glucuronide, 3-O-7-O-diglucuronide, 3-0-11-0- triglucuronide, 7-0-11-O-triglucuronide, and 3-O-7-O-ll-O-triglucuronide, of the compounds described herein, and 3-sulfate, 7-sulfate, 11-sulfate, 3,7-bisulfate, 3,11- bisulfatc, 7, 11 -bisulf ate, and 3,7,11-trisulfatc, of the compounds described herein.
- pharmaceutically acceptable salt refers to a conventional nontoxic salt of a compound of the invention wherein the parent compound is modified by forming acid or base salts thereof.
- Suitable pharmaceutically acceptable salts according to the present disclosure can be readily determined and prepared by one skilled in the art and will include, for example, basic salts such as aluminum, calcium, lithium, magnesium, potassium, sodium, and zinc salts of Compound 1 or organic salts, such as quaternary ammonium salts of Compound 1.
- the amount of a disclosed compound (i.e., active agent) that should be present in a composition for use a disclosed method or a disclosed pharmaceutical composition will generally be a therapeutically effective amount.
- a “therapeutically effective amount” or dose (or “effective amount”) refers to that amount of the active agent sufficient to result in a desired therapeutic result.
- the effective amount refers to a titrated dosage administered during a titration period. In other embodiments, the effective amount refers to an adjusted or re-adjusted dosage administered after a titration period.
- a “starting dose” as used herein refers to an initial dose provided to a patient to provide a clinical effect while minimizing onset or occurrence of an adverse effect.
- a starting dose can, in certain instances, be less than an amount typically administered to a patient.
- a starting dose is provided in an amount that is titrated or gradually increased over the course of a titration period or during the course of treatment with the FXR agonist described herein.
- a starting dose can, in certain instances, be more than an amount typically administered to a patient.
- a starting dose is provided in an amount that is titrated or gradually increased or reduced over the course of a titration period or during the course of treatment with the FXR agonist described herein to achieve the desired therapeutic result.
- a “titration period” refers to a length of time for which a starting dose is administered to a patient. A titration period continues for a specified length of time, where the patient is often monitored for liver function and/or liver biochemistry as described herein.
- An “adjusted dose” as used herein refers to a dose of the FXR agonist of the present disclosure or a composition thereof administered after the termination of a titration period.
- An adjusted dose can be increased or decreased compared to a starting dose but, as provided herein, patient tolerance and other factors described herein determine the dosage amount of an adjusted dose.
- a “re-adjusted dose” as used herein refers to any changed dosage amount or dose frequency of an adjusted dose in a patient.
- the amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof as provided above can refer to a starting dose administered during a titration period.
- a starting daily dose of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof administered to a patient described herein can be 2.5 mg. In certain embodiments, a starting daily dose of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof administered to a patient described herein can be 5 mg. In certain embodiments, a starting daily dose of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof administered to a patient described herein can be 7.5 mg. In certain embodiments, a starting daily dose of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof administered to a patient described herein can be 10 mg.
- a starting daily dose of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof administered to a patient described herein can be 12.5 mg. In certain embodiments, a starting daily dose of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof administered to a patient described herein can be 15 mg. In certain embodiments, a starting daily dose of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof administered to a patient described herein can be 20 mg. In certain embodiments, a starting daily dose of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof administered to a patient described herein can be 25 mg.
- a starting daily dose of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof administered to a patient described herein can be 50 mg. In certain embodiments, a starting daily dose of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof administered to a patient described herein can be 100 mg. In certain embodiments, a starting daily dose of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof administered to a patient described herein can be 120 mg.
- the adjusted dose of the patient can be increased to 5 mg, 10 mg, 25 mg, 50 mg, 100 mg or 120 mg. In some embodiments, an adjusted daily dose of the patient can be increased to 5 mg. In some embodiments, an adjusted daily dose of the patient can be increased to 10 mg. In some embodiments, an adjusted daily dose of the patient can be increased to 25 mg. In some embodiments, an adjusted daily dose of the patient can be increased to 50 mg. In some embodiments, an adjusted daily dose of the patient can be increased to 100 mg. In some embodiments, an adjusted daily dose of the patient can be increased to 120 mg.
- the adjusted dose of the patient can be increased to 125 mg, 150 mg, 175 mg, 200 mg, 225 mg, 250 mg, 275 mg, 300 mg, 325 mg, 350 mg, 375 mg, 400 mg, 425 mg, 450 mg, 475 mg, or 500 mg.
- a starting daily dose of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof administered to a patient described herein can be 120 mg, 100 mg, 50 mg, 25, mg, 20 mg, 15 mg, 12.5 mg, 10 mg, 7.5 mg, or 5 mg.
- an adjusted daily dose of the patient can be decreased to 100 mg. In some embodiments, an adjusted daily dose of the patient can be decreased to 50 mg. In some embodiments, an adjusted daily dose of the patient can be decreased to 25 mg. In some embodiments, the adjusted dose of the patient is decreased to 20 mg. In some embodiments, an adjusted daily dose of the patient can be decreased to 10 mg. In some embodiments, an adjusted daily dose of the patient can be decreased to 5 mg. In some embodiments, an adjusted daily dose of the patient can be decreased to 2.5 mg. In some embodiments, the adjusted dose of the patient is decreased to 15 mg, 12.5 mg, 10 mg, 7.5 mg, 5 mg, or 2.5 mg.
- the amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof can refer to an adjusted dose administered after a titration period as described herein.
- an adjusted dose of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof administered to a patient described herein can be 2.5 mg.
- an adjusted dose of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof administered to a patient described herein can be 5 mg.
- an adjusted dose of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof administered to a patient described herein can be 7.5 mg.
- an adjusted dose of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof administered to a patient described herein can be 10 mg. In certain embodiments, an adjusted dose of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof administered to a patient described herein can be 12.5 mg. In certain embodiments, an adjusted dose of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof administered to a patient described herein can be 15 mg. In certain embodiments, an adjusted dose of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof administered to a patient described herein can be 20 mg. In still another embodiment, an adjusted dose of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof administered to a patient described herein can be 25 mg.
- an adjusted dose of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof administered to a patient described herein can be 50 mg. In yet another embodiment, an adjusted dose of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof administered to a patient described herein can be 100 mg. In yet another embodiment, an adjusted dose of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof administered to a patient described herein can be 120 mg. In yet another embodiment, an adjusted dose of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof administered to a patient described herein can be 150 mg. In yet another embodiment, an adjusted dose of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof administered to a patient described herein can be 200 mg.
- an adjusted dose of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof administered to a patient described herein can be 250 mg. In yet another embodiment, an adjusted dose of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof administered to a patient described herein can be 300 mg.
- the amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof as provided above can refer to a re-adjusted dose administered after a titration period as described herein.
- a re-adjusted dose of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof administered to a patient described herein can be 2.5 mg.
- a readjusted dose of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof administered to a patient described herein can be 5 mg.
- a re-adjusted dose of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof administered to a patient described herein can be 7.5 mg.
- a re-adjusted dose of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof administered to a patient described herein can be 10 mg. In still another embodiment, a re-adjusted dose of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof administered to a patient described herein can be 25 mg. In yet another embodiment, a re-adjusted dose of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof administered to a patient described herein can be 50 mg. In yet another embodiment, a re-adjusted dose of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof administered to a patient described herein can be 100 mg.
- a re-adjusted dose of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof administered to a patient described herein can be 120 mg. In yet another embodiment, a re-adjusted dose of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof administered to a patient described herein can be 150 mg. In yet another embodiment, a re-adjusted dose of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof administered to a patient described herein can be 200 mg. In yet another embodiment, a re-adjusted dose of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof administered to a patient described herein can be 250 mg. In yet another embodiment, a re-adjusted dose of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof administered to a patient described herein can be 300 mg.
- a titration period can be a period of time of about 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 15 days, 16 days, 17 days, 18 days, 19 days, 20 days, 21 days, 22 days, 23 days, 24 days, 25 days, 26 days, 27 days, 28 days, 29, days, 30 days, or 31 day.
- a titration period includes a time of about 1 week, 2 weeks, 3 weeks, 4 weeks, or 5 weeks.
- the titration period includes a time of about 1 month, 2 months, 3 months, 4 months, 5 months, or 6 months.
- the titration period can be longer than 6 months.
- the titration period includes a time of about 3 days, 5 days, 7 days, 10 days, 14 days, 21 days or 28 days.
- a titration period can be about 1 week.
- a titration period can be about 2 weeks.
- a titration period can be about 3 days.
- a titration period can be about 5 days.
- a titration period can be about 5 days.
- compositions of the present invention may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir.
- parenteral as used herein includes subcutaneous, intravenous, intramuscular-, intra-articular, intra-synovial, intracistemal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques.
- the compositions are administered orally, intraperitoneally or intravenously.
- Sterile injectable forms of the compositions of this invention may be aqueous or oleaginous suspension.
- suspensions may be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents.
- the sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, for example as a solution in 1,3 -butanediol.
- acceptable vehicles and solvents that may be employed are water, Ringer’s solution and isotonic sodium chloride solution.
- sterile, fixed oils are conventionally employed as a solvent or suspending medium.
- any bland fixed oil may be employed including synthetic mono- or di-glycerides.
- Fatty acids such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions.
- These oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant, such as carboxymethyl cellulose or similar dispersing agents that are commonly used in the formulation of pharmaceutically acceptable dosage forms including emulsions and suspensions.
- Other commonly used surfactants such as Tweens, Spans and other emulsifying agents or bioavailability enhancers which are commonly used in the manufacture of pharmaceutically acceptable solid, liquid, or other dosage forms may also be used for the purposes of formulation.
- compositions of this invention may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, aqueous suspensions or solutions.
- carriers commonly used include lactose and corn starch.
- Lubricating agents such as magnesium stearate, are also typically added.
- useful diluents include lactose and dried cornstarch.
- aqueous suspensions are required for oral use, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening, flavoring or coloring agents may also be added.
- compositions of this invention may be administered in the form of suppositories for rectal administration.
- suppositories for rectal administration.
- suppositories can be prepared by mixing the agent with a suitable non-irritating excipient that is solid at room temperature but liquid at rectal temperature and therefore will melt in the rectum to release the drug.
- suitable non-irritating excipient include cocoa butter, beeswax and polyethylene glycols.
- compositions of this invention may also be administered topically, especially when the target of treatment includes areas or organs readily accessible by topical application, including diseases of the eye, the skin, or the lower intestinal tract. Suitable topical formulations are readily prepared for each of these areas or organs.
- Topical application for the lower intestinal tract can be affected in a rectal suppository formulation (see above) or in a suitable enema formulation. Topical and transdermal patches may also be used.
- compositions may be formulated in a suitable ointment containing the active component suspended or dissolved in one or more carriers.
- Carriers for topical administration of compounds of this invention include, but arc not limited to, mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compound, emulsifying wax and water.
- provided pharmaceutically acceptable compositions can be formulated in a suitable lotion or cream containing the active components suspended or dissolved in one or more pharmaceutically acceptable carriers.
- Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.
- compositions of this invention may also be administered by nasal aerosol or inhalation.
- Such compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other conventional solubilizing or dispersing agents.
- compositions of this disclosure are formulated for oral administration. Such formulations may be administered with or without food. In some embodiments, pharmaceutically acceptable compositions of this disclosure are administered without food. In other embodiments, pharmaceutically acceptable compositions of this invention are administered with food.
- compositions of this disclosure are formulated for intravenous (IV) administration.
- compositions should be formulated so that a dosage of between 0.01 - 100 mg/kg body weigh t/day of the compound can be administered to a patient receiving these compositions.
- a specific dosage and treatment regimen for any particular patient will depend upon a variety of factors, including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, rate of excretion, drug combination, and the judgment of the treating physician and the severity of the particular disease being treated.
- the amount of a compound of the present invention in the composition will also depend upon the particular compound in the composition.
- treating includes any effect, e.g.. lessening, reducing, modulating, or eliminating, that results in the improvement of the condition, disease, disorder, etc.
- Treating” or “treatment” of a disease state includes inhibiting the existing disease state, i.e., arresting the development of the disease state or its clinical symptoms, or relieving the disease state, i. e. , causing temporary or permanent regression of the disease state or its clinical symptoms.
- Preventing a disease state includes causing the clinical symptoms of the disease state not to develop in a subject that may be exposed to or predisposed to the disease state but does not yet experience or display symptoms of the disease state.
- inhibitors refers to any detectable positive effect on the progression of a disease or condition. Such a positive effect may include the delay in progression of at least one symptom or sign of the disease or condition, alleviation or reversal of the symptom(s) or sign(s) and slowing of the further worsening of the symptom(s) or sign(s).
- Disclosed methods of treatment encompass administration of the FXR agonist of the present disclosure, or a composition thereof as needed to obtain the desired therapeutic effect.
- the compound or composition can be administered as long as necessary to maintain the desired therapeutic effect.
- the FXR agonist of the present disclosure is administered for a period (duration of treatment) between about one week and about 12 months. In some embodiments, the FXR agonist is administered for a period between about one week and about six months. In some embodiments, the FXR agonist is administered for a period between about one week and about three months. In some embodiments, the FXR agonist is administered for a period between about one week and about ten weeks. In some embodiments, the FXR agonist is administered for a period between about one week and about six weeks. In some embodiments, the FXR agonist is administered for a period between about one week and about four weeks.
- the FXR agonist is administered for a period between about one week and about three weeks. In some embodiments, the FXR agonist is administered for a period between about one week and about two weeks. In some embodiments, the FXR agonist is administered for a period of about one week.
- the FXR agonist is administered to the patient for about
- the FXR agonist is administered to the patient for about
- the FXR agonist is administered to the patient for about
- the FXR agonist is administered to the patient for about
- the FXR agonist is administered to the patient for about 30 to about 180 days. In some embodiments, the FXR agonist is administered to the patient for about 60 to about 120 days. In some embodiments, the FXR agonist is administered to the patient for about 90 to about 120 days. In some embodiments, the FXR agonist is administered to the patient for about 90 to about 180 days.
- the FXR agonist is administered to the patient from about 3 days to about 365 days. In some embodiments, the FXR agonist is administered to the patient for about 3 days, about 5 days, about 7 days, about 10 days, about 14 days, about 21 days, about 28 days, about 30 days, about 35 days, about 40 days, about 50 days, about 60 days, about 70 days, about 80 days, about 90 days, about 100 days, about 110 days, about 120 days, about 130 days, about 140 days, about 150 days, about 160 days, about 170 days or about 180 days.
- the FXR agonist is administered for about one month, about two months, about three months, about four months, about five months, about six months, about seven months, about eight months, about nine months, about ten months, about eleven months, about twelve months or as needed to bring about the desired therapeutic effect.
- the FXR agonist such as Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof is administered daily at a dose of about 1 mg to about 300 mg.
- the FXR agonist such as Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof is administered daily at a dose of about 1.0 mg, about 1.5 mg, about 2.0 mg, about 2.5 mg, about 5 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 40 mg, about 50 mg, about 60 mg, about 75 mg, about 85 mg, about 100 mg, about 120 mg, about 125 mg, about 140 mg, about 150 mg, about 165 mg, about 175 mg, about 200 mg, about 225 mg, about 250 mg, or about 300 mg.
- Compound 1 is administered daily at a dose of about 2.5 mg, about 5 mg, about 10 mg, about 25 mg, about 30 mg, about 35 mg, about 50 mg, about 75 mg, or about 100 mg.
- the FXR agonist such as Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof is administered in single or multiple doses sufficient to achieve a total daily dose of about 1 mg to about 150 mg.
- the FXR agonist such as Compound 1 or a pharmaceutically acceptable salt thereof or amino acid conjugate thereof is administered three times a day, twice a day, once a day, once every two days, once every three days, once every four days, once every five days, twice per week, once a week, or once every two weeks.
- the FXR agonist such as Compound 1 or a pharmaceutically acceptable salt thereof or amino acid conjugate thereof is administered at a dose of about 1 am to about 500 mg. In some embodiments, the FXR agonist such as Compound 1 or a pharmaceutically acceptable salt thereof or amino acid conjugate thereof is administered at a dose of about 2.5 mg to about 300 mg. In some embodiments, the FXR agonist such as Compound 1 or a pharmaceutically acceptable salt thereof or amino acid conjugate thereof is administered at a dose of about 2.5 mg to about 120 mg, or about 2.5 mg to about 100 mg. In some embodiments, the FXR agonist of the present disclosure is administered at a dose of about 0.1 mg to about 25 mg.
- the FXR agonist of the present disclosure is administered at a dose of about 2.5 mg to about 50 mg. In some embodiments, the FXR agonist of the present disclosure is administered at a dose of about 2.5 mg to about 10 mg. In some embodiments, the FXR agonist of the present disclosure is administered at a dose of about 2.5 mg to about 5 mg. In some embodiments, the FXR agonist of the present disclosure is administered at a dose of about 0.5 mg to about 5 mg. In some embodiments, the FXR agonist of the present disclosure is administered at a dose of about 0.5 mg to about 2.5 mg.
- the FXR agonist such as Compound 1 or a pharmaceutically acceptable salt thereof or amino acid conjugate thereof is administered at a dose of about 2.5 mg to about 120 mg, 2.5 mg to about 100 mg, about 5.0 mg to about 100 mg, about 10 mg to about 100 mg, or about 50 mg to about 100 mg.
- the FXR agonist of the present disclosure is administered at a dose of about 2.5 mg to about 50 mg, about 10 mg to about 50 mg, or about 25 mg to about 50 mg.
- the FXR agonist such as Compound 1 or a pharmaceutically acceptable salt thereof or amino acid conjugate thereof is administered at a dose of about 2.5 mg to about 120 mg, about 2.5 mg to about 100 mg, about 10 mg to about 100 mg, about 25 mg to about 100 mg, or about 50 mg to about 100 mg.
- the FXR agonist such as Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof is administered in single or multiple doses sufficient to achieve a total daily dose of about 2.5 mg, about 5 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 50 mg, about 70 mg, about 80 mg, about 90 mg, about 100 mg, about 110 mg, about 120 mg, about 130 mg, or about 150 mg.
- the FXR agonist of the present disclosure is administered in single or multiple doses sufficient to achieve a total daily dose about 2.5 mg, about 5 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 50 mg, about 100 mg, about 120 mg, about 150 mg, about 200 mg, about 250 mg, or about 300 mg.
- the FXR agonist of the present disclosure is administered to the patient in a fasted state. In some embodiments, the FXR agonist is administered to the patient in a fed state.
- EXEMPLIFICATION Example 1 Treatment Effects of Three Test Articles on the Development of Alcoholic Steatohepatitis in C57BL/6J Female Mice
- OCA obeticholic acid
- Compound 2 also known as TC-100, is a semi- synthetic bile acid derived from CDCA, the natural ligand for the FXR.
- Compound 1 is the first reported example of an 1 ip-OH bile acid and the only known FXR specific bile acid derivative that has no activity on the bile acid G-protein coupled receptor, TGR5.
- the l ip-OH imparts not only FXR agonist specificity but also makes Compound 1 highly water soluble (16-fold higher than obeticholic acid or OCA), with a high critical micellular concentration like ursodeoxycholic acid, giving Compound 1 a very low liability for detergency and thus low toxicity.
- the compound showed a very low hepatic residence time being promptly secreted in the bile mostly as such and, therefore, localized along the entire intestinal tract.
- Dose formulations was divided into aliquots where required to allow them to be dispensed on each dosing occasion.
- Test articles for Groups 3-5 was prepared weekly, stored at 2-8°C until ready for use and stirred at room temperature for 30 mins prior to dosing. Dose formulations was sonicated as necessary and stirred during dosing.
- Test articles for Groups 6-7 was prepared every 3 days, stored at controlled room temperature until ready for use and stirred at room temperature for 30 mins prior to dosing. Dose formulations was stirred during dosing. The dosing solutions were homogenous suspensions. Any observations regarding phase separation, color, turbidity were noted.
- Control Diet To make 1 L of the Control Diet, weigh 225.55 gram of dry mix (F1259SP- control diet) into a lidded container. Add 350 mL of RO grade water and shake vigorously for 30 seconds. Make sure that a homogenous suspension is obtained. Add 510 mL of RO water to bring up to IL. A blender may be used to obtain a homogenous suspension. Control diet is administered to all groups on Day -28. The prepared diet may be stored at 4°C and is dispensed within 3 days. The prepared diet should not be kept longer than 48 hours at room temperature to prevent diet deterioration. Additionally, the pre-weighed dry powder can be stored at 4°C for up to one week. Prior to dispensing, the diet is stirred at room temperature for at least 30 minutes.
- a blender may be used to obtain a homogenous suspension.
- the prepared diet may be stored at 4°C and is used within 48 hours. Additionally, the pre-weighed dry powder can be stored at 4°C up to one week. Prior to dispensing, the diet was stirred at room temperature for at least 30 minutes.
- Method A subcutaneously implanted electronic identification chip or other approved identification method such as indelible ink where required.
- Fresh diet was prepared every other day from Day -28 to Day 14 and was served in the afternoon.
- Dose Route and timing Oral Gavage (Group 2-7) Once Daily (Day 1-14). The first day of dosing was designated as Day 1 The dose formulations were stirred continuously during dosing. The doses were given using a syringe with attached gavage cannula.
- liver samples from main study were analyzed in duplicates for the estimation of liver lipids including triglycerides and cholesterol. Liver samples were kept on dry ice until transferred to sample management and stored in a freezer set to maintain - 80°C until analysis.
- liver and small intestine collected from all animals in Groups 1-7 were fixed in 10% neutral buffered formalin for 24-48 hours and transferred to 70% EtOH, stored under ambient conditions and transferred to the histopathology lab at Testing Facility.
- Compound 2 improved survival better than OCA.
- Compound 1 (Comp 1 in FIGs. 1 and 2) increased serum ALP but decreased bilirubin. The reduction in serum endotoxin is significant.
- the Compound 2 10 mpk group was close to statistical significance.
- fibrosis as analyzed by Pico Sirius Red, the animal model did not have fibrosis at baseline or in the vehicle group. A minimal increase in fibrosis was seen in OCA 30 mpk.
- Compound 2 30 mpk and Compound 230 mpk For exploratory endpoints for ileum, all H&E sections IHC stains for tight junctions were normal and the same between groups.
- FIGs. 1 and 2 for clinical chemistry results and liver and ileum histology from this study. Without wishing to be bound by theory, it is believed that these results suggest improved gut function with all compounds, and greatly improved survival for the 10 mg/kg and 30 mg/kg Compound 2 (Comp 2 in FIGs. 1 and 2) groups that was superior to the results with the other two compounds.
- Example 2 A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of Compound 1 in Subjects with Severe Alcohol-Associated Hepatitis
- Compound 1 is a modified bile acid with high potency and selectivity for the farnesoid X receptor (FXR). Due to its FXR-mediated effects, Compound 1 is a novel therapy for alcohol-associated hepatitis.
- FXR farnesoid X receptor
- Compound 1 is administered daily in capsule form at escalating doses starting at 5 mg. and increasing stepwise.
- GSC Global Safety Committee
- sAH defined by a Maddrey discriminant function [MDF] >32 and ⁇ 60 and a model for end-stage liver disease-sodium [MELD-Na] score of 18 to 25 [inclusive]
- MDF Maddrey discriminant function
- MELD-Na model for end-stage liver disease-sodium
- Each dose cohort is comprised of 2 groups containing a total of 10 subjects, with 8 subjects randomized to study treatment (Treatment Group) and 2 subjects to placebo (Control Group).
- the primary objective of the study is to evaluate the effect of Compound 1 treatment on sAH disease progression, as assessed by the Lille score on Day 7. Secondary objectives include evaluation of the effect of Compound 1 treatment on the MELD-Na score at Day 28, mortality at 56 and 84 days (short-term and intermediate-term mortality) or liver transplantation, and any infectious complications, as well as evaluation of the PK of Compound 1 and its metabolites glyco-Compound 1 and tauro-Compound 1 and evaluation of the safety and tolerability of Compound 1 in the proposed patient population. Safety and tolerability are assessed by recording adverse events, laboratory assessments, ECGs, vital signs, and physical examinations.
- Exploratory objectives/measures include (1) occurrence of hospital re-admission for alcohol-associated hepatitis (hospitalization as defined by a stay of >24 hours) during the study period;, (2) hospitalization reason, length of stay, ICU days, major medical procedures, and emergency room visits; (3) change from Baseline in serum liver biochemistries (ALP, AST, ALT, GGT, and total and direct bilirubin); (4) measurement of health-related quality of life (EQ-5D-5L), (5) change from Baseline in IL-6, hs-CRP, CK-18, and TNF-a at Day 28; (6) change from Baseline in Lipoproteins (LDL, HDL, VLDL), total cholesterol, and triglycerides at Day 28; and (8) change from Baseline in lipid metabolism (LBP), 16S rDNA and stool sample for alpha- 1 -antitrypsin and microbiome/metabolome analysis.
- LBP lipid metabolism
- the Control Group in the study provides useful information on efficacy and safety outcomes in this patient population with severe alcohol- associated hepatitis treated with standard of care.
- the placebo-treated subjects within cohorts are meant to blind the study drug administration while the data across dose cohorts will be used for the overall analysis.
- the study is designed to assess increasing doses of Compound 1 in a stepwise fashion (FIG. 3). The decision to progress to the next higher dose cohort is made after a clinical review of safety and tolerability.
- the study design includes five Compound 1 dose cohorts. Each dose cohort is comprised of 2 groups containing a total of 10 subjects, with 8 subjects randomized to study treatment (Treatment Group) and 2 subjects to placebo (Control Group). Safety and tolerability is evaluated by examining the incidence of unexpected treatment emergent serious adverse events (SAEs), investigational product discontinuations, and the incidence of potential drug induced liver injury (DILI) at each dose. Additional considerations are given to overall treatment-emergent adverse events (TEAEs), clinical laboratory tests, ECGs, and vital signs.
- SAEs serious adverse events
- DILI drug induced liver injury
- FXR Farnesoid X receptor
- Female subjects must be postmenopausal, surgically sterile, or, if premenopausal (and not surgically sterile), be prepared to use >1 highly effective method of contraception during the study and for 90 days after the last dose of investigational product as follows: Surgical sterilization (bilateral tubal occlusion, etc.); Placement of an intrauterine device (IUD) or intrauterine system (e.g., intrauterine hormone-releasing system [IUS]); Combined (estrogen and progesterone containing) hormonal contraceptive associated with inhibition of ovulation: Oral; Intravaginal; Transdcrmal; Progcstcronc-only hormonal contraception associated with inhibition of ovulation: Oral; Injectable; Implantable; Sexual abstinence, if in line with the preferred and usual lifestyle of the subject (where abstinence is defined as refraining from heterosexual intercourse during the entire period of risk associated with study treatments).
- IUD intrauterine device
- IUS intrauterine hormone-
- liver disease including chronic hepatitis B (hepatitis B surface antigen [HBsAg] positive), chronic hepatitis C (HCV) RNA positive, acetaminophen hepatotoxicity, biliary obstruction, and autoimmune liver disease
- HCC hepatocellular carcinoma
- Untreated sepsis e.g., has not initiated appropriate medical treatment for infection and/or septic shock
- Kidney injury defined as a serum creatinine >133 pmol/L (>1.5 mg/dL) confirmed by repeat testing within 48 hours or the requirement for renal replacement therapy
- Acute pancreatitis or acute gallbladder disease e.g., cholecystitis
- Severe associated disease e.g., cardiac failure, acute myocardial infarction, severe cardiac arrhythmias, severe pulmonary disease, neurologic disease
- Malignancy within the 2 years prior to Screening with the exception of specific cancers that have been cured by surgical resection (e.g., basal cell skin cancer). Subjects under evaluation for possible malignancy are not eligible
- Positive Urine Drug Screen (amphetamines, barbiturates, benzodiazepines, cocaine and opiates) except tetrahydrocannabinol (THC) or in the setting of documented prescription medications (e.g., opiates, benzodiazepines, amphetamines, barbiturates, including medications prescribed as part of in-patient management. Subjects being treated for alcohol withdrawal may be exempt, verify with Medical Monitor)
- SARS-CoV-2 positive SARS Coronavirus 2
- the investigational product, Compound 1 is supplied in multiple capsule strengths ranging from 5 mg to 120 mg. Multiple Compound 1 capsules may be taken to achieve the appropriate Compound 1 dose levels (e.g., 10 mg, 25 mg, 50 mg, 100 mg or 120 mg). Matching placebo capsule(s) will also be provided for blinding purposes. This study is conducted in a double-blind (subjects and site staff) manner, randomized in a 4:1 fashion for each dose cohort.
- systemic corticosteroids are initiated during the screening period, the subject will not be considered eligible for randomization. If systemic corticosteroids are initiated within the first 7 days post-randomization, the subject will be discontinued and replaced in that study cohort.
- the use of systemic corticosteroids post-randomization can be considered on a case-by-case basis if clinically warranted (e.g., Lane score >0.56 with rising total bilirubin at Day 7 or MELD-Na score increases >3 points, not due to acute kidney injury).
- sAH defined by a Maddrey discriminant function [MDF] >32 and a model for end-stage liver disease [MELD] score of 21-30 [inclusive]
- Dose cohorts (2, 3, 4 or 5 cohorts) are planned with doses ranging from 5 mg to 120 mg Compound 1 (or Comp 1).
- Each dose cohort is comprised of 2 groups containing a total of 10 subjects, with 8 subjects randomized to study treatment (Treatment Group) and 2 subjects to placebo (Control Group).
- the study is generally carried out in accordance with the objectives, procedures, inclusion and exclusion criteria, efficacy analyses, criterial for evaluation, dosing amounts and regimens described above in Example 2, modified as follows:
- the primary objective of the study is to evaluate the effect of Compound 1 treatment on 90-day transplant-free survival of patients with sAH. Secondary objectives include evaluation of the effect of Compound 1 treatment on mortality at 28 days (short-term mortality), the MELD and Lille scores at Days 28 and 90, and evaluation of the safety and tolerability of Compound 1 in the proposed patient population at Days 28 and 90, and at 6 months. Safety and tolerability are assessed by recording adverse events, laboratory assessments, ECGs, vital signs, and physical examinations.
- Exploratory objectives/measures include (1) mortality at 6-months; 2) healthcare utilization including: occurrence of hospital re-admission for alcohol- associated hepatitis (hospitalization as defined by a stay of >24 hours) during the study period; hospitalization reason, length of stay, ICU days, major medical procedures, and emergency room visits; (3) evaluation of pharmacokinetic and pharmacodynamic biomarkers, including: change from Baseline in serum liver biochemistries (ALP, AST, ALT, GGT, and total and direct bilirubin); change from Baseline in IL-6, hs-CRP.
- CK-18, and TNF-a at Day 28 change from Baseline in Lipoproteins (LDL, HDL, VLDL), total cholesterol, and triglycerides at Day 28; and change from Baseline in lipid metabolism (LBP), 16S rDNA and stool sample for alpha- 1 -antitrypsin and microbiome/metabolome analysis; and (4) measurement of health-related quality of life (EQ-5D-5L).
- LBP Lipoproteins
- VLDL total cholesterol
- triglycerides change from Baseline in lipid metabolism (LBP), 16S rDNA and stool sample for alpha- 1 -antitrypsin and microbiome/metabolome analysis
- EQ-5D-5L measurement of health-related quality of life
Landscapes
- Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention relates to FXR agonist compounds and methods of use thereof for treating, ameliorating, or promoting recovery from diseases and disorders, such as acute diseases of the liver, for example, severe alcohol-associated hepatitis.
Description
USES OF FARNESOID X RECEPTOR AGONISTS
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority benefit of U.S. Provisional Applications Nos. 63/381,754 filed October 31, 2022, and 63/497,602 filed April 21, 2023, the disclosures of each of which are incorporated herein by reference in their entireties.
TECHNICAL FIELD
[0002] The present invention relates to compounds and methods of use thereof for treating, ameliorating, or promoting recovery from diseases and disorders, such as acute diseases of the liver.
BACKGROUND OF THE INVENTION
[0003] Alcoholic hepatitis (also known as alcohol-associated hepatitis or acute alcohol-associated hepatitis) is an acute form of alcohol-induced liver injury that occurs with the consumption of a large quantity of alcohol over a prolonged period. Alcoholic hepatitis can range in severity from asymptomatic derangement of biochemistries to liver failure and death. Severe alcoholic hepatitis is a severe form of an acute alcoholic liver disease caused by excessive alcohol consumption which may be characterized by rapid onset of jaundice, malaise, tender hepatomegaly, and features of systemic inflammatory response (Shah N.J., Royer A, John S. Alcoholic Hepatitis. Stat Pearls. 2021 Jan; 1-8; hereby incorporated by reference). Severe alcoholic hepatitis (sAH) is a life-threatening medical condition with an average 30-day mortality as high as 17% to 50%, and an average 1-year mortality of about 56% (Mathurin P., et al. Gastroenterology 1996 Jun;l 10(6): 1847-53; Thursz, M.R., et al. N Engl J Med. 2015 Apr 23;372(17): 1619-28; hereby incorporated by reference). Treatment options for patients with sAH are limited to systemic corticosteroids (unless there are contraindications such as sepsis, infection, gastrointestinal bleeding or acute kidney injury) along with supportive care, nutrition, and alcohol abstinence. Corticosteroids do not impart long-term benefit in patients with sAH and their use is limited due to the risk of infection and GI bleeding. Further, liver
transplantation for alcohol-related liver disease is currently at an all-time high (Noureddin, N., et al. Transplant Direct 2020 Oct 8 ;6( 1 l):e612), and the number of patients in the US awaiting and undergoing liver transplantation for acute alcohol-associated hepatitis has increased substantially during the COVID- 19 pandemic (Bitterman, T., et al. JAMA Netw. Open. 2021;4(7):e2118713). Unfortunately, patients with sAH and progressive liver failure who are non-re spenders to corticosteroid therapy and ineligible for liver transplantation are frequently referred for palliative care (Singal, A.K., et al. Am J Gastroenterol. 2018; 113(2): 175— 94; hereby incorporated by reference).
[0004] Another example of an acute liver disease with insufficient treatment options is acute decompensated liver disease, also known as acute-on-chronic liver failure (ACLF). ACLF is a syndrome characterized by acute decompensation of chronic liver disease associated with organ failures and high short-term mortality. Alcoholic hepatitis and chronic viral hepatitis are the most common underlying liver diseases. Up to 40%-50% of the cases of ACLF have no identifiable trigger; in the remaining patients, sepsis, active alcoholism, and relapse of chronic viral hepatitis are the most common reported precipitating factors. An excessive systemic inflammatory response seems to play a crucial role in the development of ACLF.
[0005] Thus, there remains a need for additional therapies for treating acute liver diseases such as sAH and ACLF. The present invention addresses this need and provides other related advantages.
SUMMARY OF THE INVENTION
[0006] In one aspect, the present invention provides a method of treating an acute liver disease comprising administering to a patient in need thereof an effective amount of Compound 1:
Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof.
[0007] In one aspect, the present invention provides a method of treating an acute liver disease comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein the acute liver disease is alcoholic hepatitis (AH).
[0008] In another aspect, the present invention provides a method of treating an acute liver disease comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein the acute liver disease is severe alcoholic hepatitis (sAH).
[0009] In yet another aspect, the present invention provides a method of treating an acute liver disease comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein the acute liver disease is acute-on-chronic liver failure (ACLF).
[0010] In one aspect, the present invention provides a method of treating an acute liver disease (e.g., AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein the patient exhibits a Maddrey discriminant function (MDF) score of >32 prior to treatment with Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof.
[0011] In another aspect, the present invention provides a method of treating an acute liver disease (e.g., AH, sAH or ACLF), comprising administering to a patient in need
thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein the patient exhibits a model for end stage liver disease (MELD or MELD-Na) score of >18, or >20, or >21 prior to treatment with Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof.
[0012] In another aspect, the present invention provides a method of treating an acute liver disease (e.g.. AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein the patient exhibits a MDF score of 32 to 60.
[0013] In another aspect, the present invention provides a method of treating an acute liver disease (e.g., AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein the patient exhibits a MELD score of 18, or 20 or 21 to 25 or 30 or MELD-Na score of 18, or 20, or 21 to 25 or 30.
[0014] In another aspect, the present invention provides a method of treating an acute liver disease (e.g., AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein the patient exhibits a MELD score of 21 to 30 prior to treatment with Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof.
[0015] In one aspect, the present invention provides a method of treating an acute liver disease (e.g., AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein the patient exhibits a Maddrey discriminant function (MDF) score of >32, and a MELD score of 21 to 30 (inclusive) prior to treatment with Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof.
[0016] In another aspect, the present invention provides a method of treating an acute liver disease (e.g., AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein the patient exhibits an AST of > (greater than or equal to) 50 U/L (or IU/L) prior to treatment with Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof.
[0017] In another aspect, the present invention provides a method of treating an acute liver disease (e.g., AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein the patient exhibits an AST I ALT ratio of >1.5 prior to treatment with Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof.
[0018] In another aspect, the present invention provides a method of treating an acute liver disease (e.g., AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein the patient exhibits prior to treatment with Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof one or more of an AST of >50 U/L; an AST / ALT ratio of >1.5; a Maddrey discriminant function (MDF) score of >32; and/or a model for end-stage liver disease (MELD or MELD-Na) score of >18 or >20 or >21, for example from 21-30.
[0019] In another aspect, the present invention provides a method of treating an acute liver disease (e.g., AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein the method reduces the MELD or MELD-Na score of the patient by at least 3 and/or reduces the MDF score of the patient by at least 3 by day 28 of treatment.
[0020] In another aspect, the present invention provides a method of treating an acute liver disease (e.g., AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof is administered daily at a dose of about 1.0 mg to about 300 mg.
[0021] In another aspect, the present invention provides a method of treating an acute liver disease (e.g., AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein Compound 1 or a pharmaceutically acceptable salt or
amino acid conjugate thereof is administered daily at a dose of about 2.5 mg to about 300 mg.
[0022] In another aspect, the present invention provides a method of treating an acute liver disease (e.g., AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein Compound 1 is administered daily at a dose of from about 5 mg to about 120 mg.
[0023] In another aspect, the present invention provides a method of treating an acute liver disease (e.g., AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein Compound 1 is administered daily at a dose of from about 5 mg to about 100 mg.
[0024] In another aspect, the present invention provides a method of treating an acute liver disease (e.g., AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein Compound 1 is administered daily at a dose of from about 5 mg to about 50 mg.
[0025] In another aspect, the present invention provides a method of treating an acute liver disease (e.g., AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein Compound 1 is administered daily at a dose of from about 5 mg to about 25 mg.
[0026] In another aspect, the present invention provides a method of treating an acute liver disease (e.g., AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein Compound 1 is administered daily at a dose of from about 5 mg to about 10 mg.
[0027] In another aspect, the present invention provides a method of treating an acute liver disease (e.g., AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein Compound 1 or a pharmaceutically acceptable salt or
amino acid conjugate thereof is administered daily at a dose of about 5 mg to about 150 mg.
[0028] In another aspect, the present invention provides a method of treating an acute liver disease (e.g., AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof is administered daily at a dose of about 5 mg to about 120 mg.
[0029] In another aspect, the present invention provides a method of treating an acute liver disease (e.g., AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof is administered daily at a dose of about 10 mg to about 100 mg.
[0030] In another aspect, the present invention provides a method of treating an acute liver disease (e.g., AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof is administered daily at a dose of about 50 mg to about 250 mg.
[0031] In another aspect, the present invention provides a method of treating an acute liver disease (e.g., AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein Compound 1 is administered daily at a dose of about 2.5 mg, about 5 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 35 mg, about 45 mg, about 50 mg, about 60 mg, about 75 mg, about 85 mg, about 100 mg, about 115 mg, about 120 mg, about 125 mg, about 140 mg, about 150 mg, about 165 mg, about 175 mg, about 190 mg, or about 200 mg.
[0032] In another aspect, the present invention provides a method of treating an acute liver disease (e.g., AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino
acid conjugate thereof, wherein Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof is administered in single or multiple doses sufficient to achieve a total daily dose of about 1.0 mg to about 300 mg; 1.0 mg to about 300 mg; or about 2.5 mg to about 300 mg; or about 5 mg to about 100 mg; or about 5 mg to about 50 mg; or about 5 mg to about 25 mg; or about 5 mg to about 10 mg; or about 5 mg to about 150 mg; or about 5 mg to about 120 mg; or about 10 mg to about 100 mg; or about 50 mg to about 200 mg; or about 2.5 mg, about 5 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 35 mg, about 45 mg, about 50 mg, about 60 mg, about 75 mg, about 85 mg, about 100 mg, about 115 mg, about 120 mg, 125 mg, about 140 mg, about 150 mg, about 165 mg, about 175 mg, about 190 mg, or about 200 mg.
[0033] In another aspect, the present invention provides a method of treating an acute liver disease (e.g., AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, further comprising monitoring blood levels of a biomarkcr in the patient after administration of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein the biomarker is selected from C4, FGF-19, and endogenous bile acids.
[0034] In another aspect, the present invention provides a method of treating an acute liver disease selected from sAH and ACLF, comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein the patient has a chronic liver disease in addition to sAH or ACLF.
[0035] In another aspect, the present invention provides a method of treating an acute liver disease (e.g., AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein the patient has alcohol-related (or alcohol-associated) liver disease (ALD), previously known as alcoholic liver disease.
[0036] In another aspect, the present invention provides a method of treating an acute liver disease (e.g., AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein the patient exhibits one or more of the following: (1)
ongoing alcohol consumption of more than 40 g of alcohol per day if the patient is a woman and more than 60 g of alcohol per day if the patient is a man for 6 months or more, with less than 60 days of abstinence before the onset of jaundice; (2) the presence of elevated liver enzymes (aspartate aminotransferase [AST] and alanine aminotransferase [ALT] concentrations >50 IU/L but <400 IU/L and an AST/ALT ratio of >1:5); and (3) worsening jaundice, with bilirubin concentrations greater than 3 mg/dL.
[0037] In another aspect, the present invention provides a method of treating an acute liver disease (e.g., AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein the patient exhibits alcohol-associated cirrhosis, liver fibrosis, steatosis, steatohepatitis, alcoholic hepatitis, or intestinal dysbiosis.
[0038] In another aspect, the present invention provides a method of treating an acute liver disease (e.g., AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein the patient has previously been diagnosed with sAH and has suffered at least one relapse of sAH.
[0039] In another aspect, the present invention provides a method of treating an acute liver disease (e.g., AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein the method improves 30-day survival of the patient versus an otherwise similar patient who was not administered Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof.
[0040] In another aspect, the present invention provides a method of treating an acute liver disease (e.g., AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein the method improves 60-day survival of the patient versus an otherwise similar patient who was not administered Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof.
[0041] In another aspect, the present invention provides a method of treating an acute liver disease (e.g., AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino
acid conjugate thereof, wherein the method improves 90-day survival of the patient versus an otherwise similar patient who was not administered Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof.
[0042] In another aspect, the present invention provides a method of treating an acute liver disease (e.g., AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein the method improves 90-day transplant-free survival of the patient versus an otherwise similar patient who was not administered Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof.
[0043] In another aspect, the present invention provides a method of treating an acute liver disease (e.g., AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein the method improves 28-day survival of the patient versus an otherwise similar patient who was not administered Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof.
[0044] In another aspect, the present invention provides a method of treating an acute liver disease (e.g., AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein the method improves the 6-month survival of the patient versus an otherwise similar patient who was not administered Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof.
[0045] In another aspect, the present invention provides a method of treating an acute liver disease (e.g., AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein the method improves the 6-month transplant-free survival of the patient versus an otherwise similar patient who was not administered Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof.
[0046] In another aspect, the present invention provides a method of treating an acute liver disease (e.g., AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein the method improves the patient's MELD and/or Lille
scores at day 28 and/or day 90 after administration of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, versus an otherwise similar patient who was not administered Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof.
[0047] In another aspect, the present invention provides a method of treating an acute liver disease (e.g.. AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein the method improves the patient's occurrence of hospital re-admission for alcohol-associated hepatitis versus an otherwise similar patient who was not administered Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof.
[0048] In another aspect, the present invention provides a method of treating an acute liver disease (e.g., AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein the method improves one or more of: the patient's length of stay in the hospital, the number of days the patient spends in the ICU, the number of major medical procedures performed on the patient, and/or the number of emergency room visits by the patient, versus an otherwise similar patient who was not administered Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof.
[0049] In another aspect, the present invention provides a method of treating an acute liver disease (e.g., AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein the method improves one or more pharmacokinetic and pharmacodynamic biomarkers, including: change from Baseline in one or more serum liver biochemistries selected from ALP, AST, ALT, GGT, and total and direct bilirubin; change from Baseline in IL-6, hs-CRP, CK-18, and TNF-a at Day 28; change from Baseline in Lipoproteins (LDL, HDL, VLDL), total cholesterol, and/or triglycerides at Day 28; and change from Baseline in lipid metabolism (LBP), 16S rDNA and/or stool sample for alpha- 1 -antitrypsin and microbiome/metabolome analysis; versus an otherwise similar patient who was not administered Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof.
[0050] In another aspect, the present invention provides a method of treating an acute liver disease (e.g., AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein the method improves survival by about 10% to about 40% (relative to the standard of care (SOC)).
[0051] In another aspect, the present invention provides a method of treating an acute liver disease (e.g., AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein the method improves survival by about 10% to about 30%. [0052] In another aspect, the present invention provides a method of treating an acute liver disease (e.g., AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein the method improves survival by about 10% to about 20%. [0053] In another aspect, the present invention provides a method of treating an acute liver disease (e.g., AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein the method provides a reduction in health care utilization. [0054] In another aspect, the present invention provides a method of treating an acute liver disease (e.g., AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein the method provides a reduction in liver-related events in patients with sAH.
[0055] In another aspect, the present invention provides a method of treating an acute liver disease (e.g., AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein the method provides a decrease in the patient’s health care utilization by at least 10% for 60 days.
[0056] In another aspect, the present invention provides a method of treating an acute liver disease (e.g., AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein the method reduces one or more of hospital re-admission
within 30-days after discharge, number of hospitalizations, length of stay, emergency room visits, intensive care unit (ICU) days, infectious complications selected from sepsis, pneumonia, urinary tract infection (UTI), cellulitis, spontaneous and bacterial peritonitis (SBP), and major medical procedures.
[0057] In another aspect, the present invention provides a method of treating an acute liver disease (e.g.. AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, further comprises co-administering to the patient an effective amount of anti-inflammatory agent, an antibiotic, a probiotic, a fecal transplant, Zn- supplement or a combination of any of those agents.
[0058] In another aspect, the present invention provides a method of treating an acute liver disease (e.g., AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, further comprises co-administcring to the patient an effective amount of pentoxifylline, Augmentin, bovine colostrum, corticosteroid (e.g., prednisolone or methylprednisolone), an ELAD agent, canakinumab, a TNF inhibitor, IL-22, N- acetylcysteine, metadoxine, IgG anti-LPS, a probiotic, a fecal transplant, Zn- supplement, or a combination of any of those agents.
[0059] In another aspect, the present invention provides a method of treating an acute liver disease (e.g., AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein the patient does not exhibit one or more of: AST or ALT >400 U/L, MDF >60 prior to treatment, MELD score >30 or MELD-Na >25 prior to treatment, other causes of liver disease selected from chronic hepatitis B (hepatitis B surface antigen [HBsAg] positive), chronic hepatitis C (HCV RNA positive), acetaminophen hepatotoxicity, biliary obstruction, and autoimmune liver disease; concomitant of previous history of hepatocellular carcinoma (HCC), a history of liver transplantation, untreated sepsis, known positivity for human immunodeficiency virus infection, uncontrolled gastrointestinal (GI) bleeding or controlled GI bleeding within 7 days of beginning treatment that was associated with shock or required transfusion of more than 3 units of blood, acute kidney injury defined as a serum creatinine >133 pmol/L (>1.5
mg/dL) or the requirement for renal replacement therapy, portal vein thrombosis, acute pancreatitis, or severe associated disease selected from cardiac failure, acute myocardial infarction, severe cardiac arrhythmias, severe pulmonary disease, and neurologic disease . [0060] In another aspect, the present invention provides a method of treating an acute liver disease (e.g., AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein the method provides at least a 15% reduction in mortality at 90 days compared to standard of care (SOC).
[0061] In another aspect, the present invention provides a method of treating an acute liver disease (e.g., AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein the method provides a reduction in hospitalization (length of stay) by at least 15% and/or a reduction in progression to transplant by at least 15%.
[0062] In another aspect, the present invention provides a method of treating an acute liver disease (e.g., AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof is administered to the patient for about 30 to about 90 days.
[0063] In another aspect, the present invention provides a method of treating an acute liver disease (e.g., AH, sAH or ACLF), comprising administering to a patient in need thereof an effective amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof is administered orally.
[0064] In another aspect, the present invention provides a method of determining candidacy of a patient for therapeutic treatment for sAH, comprising determining the patient's MELD-Na score, wherein the patient's MELD-Na score is > 18, for example from 21-30. In some embodiments, the method further comprises determining the patient's MDF score, for example wherein the patient's MDF score is from 32 to 60 inclusive.
[0065] In another aspect, the present invention provides a method for treating sAH comprising selecting a patient having a MELD-Na score > 18, for example from 21-30; and administering a therapeutic treatment for sAH, for example wherein the patient also
has a MDF score > 32, for example from 32 to 60 inclusive. In some embodiments the therapeutic treatment comprises administering a pharmacologic agent to the patient, and/or a liver transplant
BRIEF DESCRIPTION OF THE DRAWINGS
[0066] FIG. 1 and FIG. 2: clinical chemistry results and liver and ileum histology from mouse alcoholic liver disease (ALD) study (Compound 1 is designated as Comp 1 and Compound 2 is designated as Comp 2).
[0067] FIG. 3: Study design for a Phase 2a, Randomized, Double-Blind, Placebo Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of Compound 1 (Comp 1) in Subjects with Severe Alcohol-Associated Hepatitis (sAH).
DETAILED DESCRIPTION OF CERTAIN EMBODIMENTS OF THE INVENTION
1. General Description of Exemplary Embodiments
[0068] The present invention provides a method of treating an acute liver disease comprising administering to a patient in need thereof an effective amount of an FXR agonist. In one aspect, the present invention provides a method of treating alcoholic hepatitis (AH), comprising administering to a patient in need thereof an effective amount of an FXR agonist. In one aspect, the present invention provides a method of treating an acute liver disease selected from severe alcoholic hepatitis (sAH) and acute-on-chronic liver failure (ACLF), comprising administering to a patient in need thereof an effective amount of an FXR agonist.
[0069] In one aspect, the present invention provides a method of treating severe alcoholic hepatitis (sAH) comprising administering to a patient in need thereof an effective amount of an FXR agonist. The present invention provides a method of treating sAH which represent a significant advance over systemic corticosteroid therapy, the standard of care in the treatment of sAH.
[0070] The present invention further provides a method of treating ACLF comprising administering to a patient in need thereof an effective amount of an FXR agonist.
Compound 1 (7a,110-dihydroxy- 6a-ethyl-50-cholan-24-oic acid)
[0072] or a pharmaceutically acceptable salt or amino acid conjugate thereof. In some embodiments, the FXR agonist is a tauro- or gly co-conjugate of Compound 1, or a pharmaceutically acceptable salt thereof. Compound 1 may be prepared using methods known in the art, for example, as described in U.S. Patent Nos. 10,815,267, and 11,319,337, each of which is hereby incorporated by reference in its entirety. These patents also describe various FXR agonists which may be used in accordance with the present invention.
[0073] In one aspect, the present invention provides an FXR agonist for use in treating an acute liver disease. In one aspect, the present invention provides an FXR agonist for use in treating alcoholic hepatitis (AH). In one aspect, the present invention provides an FXR agonist for use in treating an acute liver disease selected from severe alcoholic hepatitis (sAH) and acute-on-chronic liver failure (ACLF).
[0074] In another aspect, the present invention provides Compound 1, or a pharmaceutically acceptable salt or amino acid conjugate thereof, for use in treating an acute liver disease. In some embodiments, the acute liver disease is alcoholic hepatitis (AH). In some embodiments the acute liver disease is severe alcoholic hepatitis (sAH). In some embodiments the acute liver disease is moderate alcoholic hepatitis. In some
embodiments the acute liver disease is mild alcoholic hepatitis. In some embodiments, the acute liver disease is acute-on-chronic liver failure (ACLF).
[0075] In one aspect, the present invention provides Compound 1, or a pharmaceutically acceptable salt or amino acid conjugate thereof, for use in treating alcoholic hepatitis (AH). In one aspect, the present invention provides Compound 1, or a pharmaceutically acceptable salt or amino acid conjugate thereof, for use in treating an acute liver disease selected from severe alcoholic hepatitis (sAH) and acute-on-chronic liver failure (ACLF).
[0076] In some embodiments, the patient has a chronic liver disease in addition to sAH or ACLF. In some embodiments, the chronic liver disease is a cholestatic liver disease. In some embodiments, the chronic liver disease is a non-cholestatic liver disease.
[0077] In some embodiments, the patient exhibits a chronic liver condition in addition to the acute liver disease, such as AH or sAH or ACLF. In some embodiments, the acute liver disease or condition is present in addition to the chronic liver disease or condition which can be selected from, but not limited to, cirrhosis (alcohol-related cirrhosis), liver fibrosis, alcohol-related steatohepatitis (ASH), steatosis, or cholestatic liver disease. In some embodiments, the acute liver disease or condition is present in addition to the chronic liver disease or condition which can be selected from, but not limited to, cirrhosis, liver fibrosis, alcohol-related steatohepatitis, or steatosis. In some embodiments, the patient exhibits cirrhosis. In some embodiments, the patient exhibits liver fibrosis. In some embodiments, the patient exhibits steatosis. In some embodiments, the patient exhibits ASH. In some embodiments, the patient exhibits alcoholic hepatitis.
[0078] In some embodiments, the patient has ALD selected from early ALD (stage 0- 2) or advanced ALD (bridging fibrosis, stage 3; or cirrhosis, stage 4).
[0079] In some embodiments, the patient does not exhibit cirrhosis. In some embodiments, the patient exhibits a Maddrey discriminant function (MDF) score of >32 prior to treatment with the FXR agonist.
[0080] In some embodiments, the patient exhibits a model for end-stage liver disease (MELD or MELD-Na) score of >18 prior to treatment with the FXR agonist.
[0081] In some embodiments, the patient exhibits both an MDF score of >32 and a MELD or MELD-Na score of >18 prior to treatment with the FXR agonist.
[0082] In some embodiments, the patient exhibits an MDF score of 32 to 60.
[0083] In some embodiments, the patient exhibits a MELD score of 18 to 25 or 30 or
MELD-Na score of 18 to 25 or 30.
[0084] In some embodiments, the patient exhibits a MELD score of 21 to 30, or MELD-Na score of 21 to 30.
[0085] In some embodiments, the patient exhibits an MDF score of 20 to 31 optionally in combination with a MELD score of 18 to 25 or 30 or MELD-Na score of 18 to 25 or 30. [0086] In some embodiments, the patient exhibits an MDF score of >32 optionally in combination with a MELD score of 10 to 20 (or MELD-Na <21); or a MELD score of 10 to 17 (or MELD-Na < 18).
[0087] In some embodiments, the patient exhibits an MDF score of >32 in combination with a MELD score of 21-30 (or MELD-Na 21-30).
[0088] In some embodiments, the patient exhibits an MDF score of 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54. 55, 56, 57, 58, 59, or 60.
[0089] In some embodiments, the patient exhibits a MELD or MELD-Na score of 6, 7, 8, 9, or 10. In some embodiments, the patient exhibits a MELD or MELD-Na score of 11, 12, 13, 14, 15, 16, or 17. In some embodiments, the patient exhibits a MELD or MELD- Na score of 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30.
[0090] In some embodiments, the patient exhibits an AST of >50 U/L prior to treatment. [0091] In some embodiments, the patient exhibits an AST / ALT ratio of >1.5 prior to treatment.
[0092] In some embodiments, the patient exhibits one or more of an AST of >50 U/L; an AST / ALT ratio of >1.5; a Maddrey discriminant function (MDF) score of >32; and/or a model for end-stage liver disease (MELD or MELD-Na) score of >18, 20 or 21, for example from 21-30.
[0093] In some embodiments, the method comprises administering to the patient in need thereof the FXR agonist in the amount of about 1 mg to about 500 mg. In some embodiments, the method comprises administering to the patient in need thereof the FXR agonist in the amount of about 1 mg to about 300 mg. In some embodiments, the method comprises administering to the patient in need thereof the FXR agonist in the amount of
about 1 mg to about 200 mg. In some embodiments, the method comprises administering to the patient in need thereof the FXR agonist in the amount of about 1 mg to about 150 mg. In some embodiments, the method comprises administering to the patient in need thereof the FXR agonist in the amount of about 1 mg to about 100 mg. In some embodiments, the method comprises administering to the patient in need thereof the FXR agonist in the amount of about 1 mg to about 50 mg. In some embodiments, the method comprises administering to the patient in need thereof the FXR agonist in the amount of about 1 mg to about 25 mg. In some embodiments, the method comprises administering to the patient in need thereof the FXR agonist in the amount of about 1 mg to about 10 mg. In some embodiments, the method comprises administering to the patient in need thereof the FXR agonist in the amount of about 2.5 mg to about 500 mg. In some embodiments, the method comprises administering to the patient in need thereof the FXR agonist in the amount of about 2.5 mg to about 300 mg. In some embodiments, the method comprises administering to the patient in need thereof the FXR agonist in the amount of about 2.5 mg to about 200 mg. In some embodiments, the method comprises administering to the patient in need thereof the FXR agonist in the amount of about 2.5 mg to about 150 mg. In some embodiments, the method comprises administering to the patient in need thereof the FXR agonist in the amount of about 2.5 mg to about 100 mg. In some embodiments, the method comprises administering to the patient in need thereof the FXR agonist in the amount of about 2.5 mg to about 50 mg. In some embodiments, the method comprises administering to the patient in need thereof the FXR agonist in the amount of about 2.5 to about 25 mg. In some embodiments, the method comprises administering to the patient in need thereof the FXR agonist in the amount of about 2.5 to about 10 mg.
[0094] In some embodiments, the method comprises administering to the patient in need thereof the FXR agonist in the amount of about 2.5 mg, about 5 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 50 mg, about 60 mg, about 75 mg, about 85 mg, about 100 mg, about 120 mg or about 150 mg. In some embodiments, the method comprises administering Compound 1 in the amount of about 2.5 mg, about 5 mg, about 10 mg, about 25 mg, about 50 mg, about 100 mg or about 120 mg. In some embodiments, the method comprises administering Compound 1 in the amount of about 2.5 mg, about 5 mg, about 10 mg, about 25 mg, or about 50 mg. In some embodiments, the method
comprises administering to the patient in need thereof the FXR agonist in the amount of about 5 mg to about 100 mg or 5 mg to about 120 mg. In some embodiments, the method comprises administering to the patient in need thereof the FXR agonist in the amount of about 5 mg to about 50 mg. In some embodiments, the method comprises administering to the patient in need thereof the FXR agonist in the amount of about 5 to about 25 mg. In some embodiments, the method comprises administering to the patient in need thereof the FXR agonist in the amount of about 5 to about 10 mg. In some embodiments, the method comprises administering to the patient in need thereof the FXR agonist in the amount of about 5 mg. In some embodiments, the method comprises administering to the patient in need thereof the FXR agonist in the amount of about 10 mg. In some embodiments, the method comprises administering to the patient in need thereof the FXR agonist in the amount of about 25 mg. In some embodiments, the method comprises administering to the patient in need thereof the FXR agonist in the amount of about 50 mg. In some embodiments, the method comprises administering to the patient in need thereof the FXR agonist in the amount of about 100 mg.
[0095] In some embodiments, the method provides improved 90-day transplant-free survival of the patient versus an otherwise similar patient who was not administered Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof.
[0096] In some embodiments, the method provides a reduction in Lille score at 7 days over standard of care (SOC). In some embodiments, the method reduces Lille score by 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, or 0.9 or greater. In some embodiments, the method reduces Lille score at 7 days by 0.1, 0.2, 0.3, or 0.4. In some embodiments, the method provides a Lille score of 0.4, 0.3, 0.2, 0.1, or less than 0.1.
[0097] In some embodiments, the method provides a clinical outcome of 7-day Lille score of <0.45. In some embodiments, the method provides a clinical outcome of 7-day Lille score of <0.45 and 28-day MELD or MELD-Na score of a decrease to <21, or to <20, or to <18, or a decrease of at least 10-25% (or by least 2 or 3) in combination with one, two, three, four, five, or more endpoints described below:
[0098] In some embodiments, the method provides an improvement in one or more of: liver biochemistry and hepatic synthetic function, inflammation, lipoprotein metabolism, famesoid X receptor (FXR) activation markers, and bacterial translocation (e.g., lipopolysaccharide binding protein [LBP], 16S rDNA, alpha- 1-antitrypsin).
[0099] In some embodiments, the dose of the patient is increased to a maximum of 50 mg per day. In some embodiments, the dose of the patient is increased to a maximum of 100 mg per day. In some embodiments, the dose of the patient is increased to a maximum of 125, 150, 175, 200, 225, 250, 275, or 300 per day.
[00100] In some embodiments, the method reduces the MELD or MELD-Na score of the patient by at least 2, by at least 3, by at least 4, by at least 5, or by at least 6 by day 28 of treatment. In some embodiments, the method reduces the MELD or MELD-Na score of the patient by at least 2 by day 28, or day 90, of treatment. In some embodiments, the method reduces the MELD or MELD-Na score of the patient by at least 3 by day 28, or day 90. of treatment. In some embodiments, the method reduces the MELD or MELD-Na score of the patient by at least 4 by day 28, or day 90, of treatment. In some embodiments, the method reduces the MELD or MELD-Na score of the patient by at least 5 by day 28, or day 90, of treatment. In some embodiments, the method reduces the MELD or MELD- Na score of the patient by at least 6 by day 28, or day 90, of treatment. In some embodiments, the method reduces the MELD or MELD-Na score of the patient by 2 by
day 28, or day 90, of treatment. In some embodiments, the method reduces the MELD or MELD-Na score of the patient by 3 by day 28, or day 90, of treatment. In some embodiments, the method reduces the MELD or MELD-Na score of the patient by 4 by day 28, or day 90, of treatment. In some embodiments, the method reduces the MELD or MELD-Na score of the patient by 5 by day 28, or day 90, of treatment. In some embodiments, the method reduces the MELD or MELD-Na score of the patient by 6 by day 28, or day 90, of treatment.
[00101] In some embodiments, the method reduces the MELD or MELD-Na score by 10-25%. In some embodiments, the method reduces the MELD or MELD-Na score by about 10%, about 15%, about 20%, or about 25%. In some embodiments, the method reduces the MELD or MELD-Na score by about 30%, 35%, 40%, or 50%. In some embodiments, the method reduces the MELD or MELD-Na score by at least 10-25%. In some embodiments, the method reduces the MELD or MELD-Na score by at least 10%, at least 15%, at least 20%, or at least 25% or at least 30%, or at least 35%, or at least 40%.
[00102] In some embodiments, the method reduces the MDF score of the patient by at least 2, by at least 3, by at least 4, by at least 5, or by at least 6 by day 28, or day 90, of treatment. In some embodiments, the method reduces the MDF score of the patient by 5, 6, 7, 8, 9, or 10. In some embodiments, the method reduces the MDF score of the patient by 5 or more. In some embodiments, the method reduces the MDF score by 10-25%. In some embodiments, the method reduces the MDF score by about 10%, about 15%, about 20%, or about 25%. In some embodiments, the method reduces the MDF score by about 30%, 35%, 40%, or 50%. In some embodiments, the method reduces the MDF score by at least 10-25%. In some embodiments, the method reduces the MDF score by at least 10%, at least 15%, at least 20%, or at least 25%.
[00103] In some embodiments, the method reduces the MELD or MELD-Na score of the patient by at least 2-6 and/or reduces the MDF score of the patient by at least 2-6 by day 28, or day 90, of treatment. In some embodiments, the method reduces the MELD or MELD-Na score of the patient by at least 2 and/or reduces the MDF score of the patient by at least 2 by day 28, or day 90, of treatment. In some embodiments, the method reduces the MELD or MELD-Na score of the patient by at least 3 and/or reduces the MDF score of the patient by at least 3 by day 28, or day 90, of treatment. In some embodiments, the method
reduces the MELD or MELD-Na score of the patient by at least 4 and/or reduces the MDF score of the patient by at least 4 by day 28, or day 90, of treatment. In some embodiments, the method reduces the MELD or MELD-Na score of the patient by at least 5 and/or reduces the MDF score of the patient by at least 5 by day 28, or day 90, of treatment. In some embodiments, the method reduces the MELD or MELD-Na score of the patient by at least 6 and/or reduces the MDF score of the patient by at least 6 by day 28, or day 90, of treatment.
[00104] In some embodiments, the method reduces the MELD or MELD-Na score of the patient by at least 5 by day 28, or day 90, of treatment. In some embodiments, the method reduces the MDF score of the patient by at least 5 by day 28, or day 90, of treatment. In some embodiments, the method reduces the MELD or MELD-Na score of the patient by at least 5 and reduces the MDF score of the patient by at least 5 by day 28, or day 90, of treatment. In some embodiments, the method provides a reduction in MELD or MELD-Na score at 28, or 90 days. In some embodiments, the method provides a reduction in MDF score at 28 days or 90 days.
[00105] In some embodiments, the method further comprises monitoring the blood levels of a biomarker in the patient after administration of the FXR agonist of the present disclosure. In some embodiments, the biomarker is selected from C4, FGF-19, and endogenous bile acids.
[00106] In some embodiments, the patient has alcohol-related (or alcohol-associated) liver disease (ALD), also known as alcoholic liver disease. In some embodiments, the patient exhibits jaundice.
[00107] In some embodiments, the patient exhibits one or more of the following: (1) ongoing alcohol consumption of more than 40 g of alcohol per day in women and more than 60 g of alcohol per day in men for 6 months or more, with less than 60 days of abstinence before the onset of jaundice; (2) the presence of elevated liver enzymes (aspartate aminotransferase [AST] and/or alanine aminotransferase [ALT] concentrations >50 IU/L but <400 IU/L and an AST/ALT ratio of >1:5); and (3) worsening jaundice, with bilirubin concentrations greater than 3 mg/dL. In some embodiments, the patient is diagnosed with sAH after a liver biopsy in addition to one, two, three, or all of the preceding signs.
[00108] In some embodiments, the patient exhibits ongoing alcohol consumption of more than 40 g of alcohol per day in women and more than 60 g of alcohol per day in men for 6 months or more, with less than 60 days of abstinence before the onset of jaundice. In some embodiments, the patient exhibits the presence of elevated liver enzymes (aspartate aminotransferase [AST] and/or alanine aminotransferase [ALT] concentrations >50 IU/L but <400 IU/L and an AST/ALT ratio of >1:5). In some embodiments, the patient exhibits worsening jaundice, with bilirubin concentrations greater than 3 mg/dL. In some embodiments, the patient exhibits the absence of any other causes of liver disease.
[00109] In some embodiments, the patient is considered ineligible for a liver transplant per generally-accepted criteria known in the art.
[00110] In some embodiments, the patient has alcoholic use disorder (AUD). AUD can be defined based on consumption of alcohol, e.g., as consuming 3 or more alcoholic drinks per day (men) or 2 or more alcoholic drinks per day (women).
[00111] In some embodiments, the patient has been treated previously for sAH with a corticosteroid. In some embodiments, the patient did not respond to the corticosteroid. In some embodiments, the patient exhibited a Lille score of more than 0.45 after 7 days or more of treatment with the corticosteroid.
[00112] In some embodiments, the patient is currently hospitalized, i.e., hospitalized prior to beginning treatment with the FXR agonist. In some embodiments, the patient is currently hospitalized and exhibits an MDF score of at least 32 and a MELD score of 18, or 20, or 21 to 30 or MELD-Na score of 18, or 20, or 21 to 25 or 30.
[00113] In some embodiments, the patient has suffered at least one relapse of sAH, i.e., has been diagnosed and/or treated at least once before for sAH.
[00114] In some embodiments, the patient exhibits one or more of the following in addition to sAH: obesity, metabolic syndrome, hepatitis C infection, or a genetic polymorphism such as patatin-like phospholipase domain protein 3, membrane bound O- acyltransferase, and transmembrane 6 superfamily member 2 genes.
[00115] In some embodiments, the patient exhibits intestinal dysbiosis.
[00116] In some embodiments, the method improves one or measures of sAH, such as intestinal dysbiosis.
[00117] In some embodiments, the method improves 30-day survival of the patient having sAH or ACLF versus an otherwise similar patient having sAH or ACLF who was not administered the FXR agonist. In some embodiments, the method improves 60-day survival of the patient versus an otherwise similar patient who was not administered the FXR agonist. In some embodiments, the method improves 90-day survival of the patient versus an otherwise similar patient who was not administered the FXR agonist. In some embodiments, the method improves the 120-day, 180-day, or 1-year survival of the patient versus an otherwise similar patient who was not administered the FXR agonist.
[00118] In some embodiments, the method improves 30-day mortality of the patient versus an otherwise similar patient who was not administered the FXR agonist. In some embodiments, the method improves 60-day mortality of the patient versus an otherwise similar patient who was not administered the FXR agonist. In some embodiments, the method improves 90-day mortality of the patient versus an otherwise similar patient who was not administered the FXR agonist. In some embodiments, the method improves the 120-day, 180-day, or 1-year mortality of the patient versus an otherwise similar patient who was not administered the FXR agonist.
[00119] In some embodiments, the improvement in survival or mortality of the patient includes an increase in survival, or a decrease in mortality, of about 10% to about 70%. Such improvements may be measured over, for example, 30 days, 60 days, 90 days, 120 days, 180 days, 1 year, or greater than 1 year. In some embodiments, the improvement in survival or mortality of the patient includes an increase in survival, or a decrease in mortality, of about 10% to about 60%, about 10% to about 50%, about 10% to about 40%, about 10% to about 30%, or about 10% to about 20%.
[00120] In some embodiments, the method provides at least a 15% reduction in mortality at 90 days compared to standard of care (SOC). In some embodiments, the method provides a 15-20% reduction in mortality at 30 days compared to SOC. In some embodiments, the method provides a 10% reduction in mortality at 6 months. In some embodiments, the method provides a 5-10% absolute reduction in mortality at 1 year.
[00121] In some embodiments, the method provides a reduction in risk of mortality for the patient. In some embodiments, the method provides a reduction in risk of mortality and health care utilization for liver-related events in patients with sAH. In some
embodiments, such reductions are compared with the current standard of care, e.g., treatment with a corticosteroid such as prednisolone. In some embodiments, the FXR agonist, such as Compound 1 or a pharmaceutically acceptable salt thereof or an amino acid conjugate thereof, is indicated for first-line therapy.
[00122] In some embodiments, the method provides a decrease in the patient’s health care utilization by at least 10% for 30 days, 60 days, 90 days, 120 days, 180 days, or for 1 year, or for greater than 1 year. As used herein, the term “heath care utilization” includes one or more of hospital re-admission within 30-days after discharge, number of hospitalizations, length of stay, emergency room visits, intensive care unit (ICU) days, and infectious complications (e.g., sepsis, pneumonia, urinary tract infection [UTI], cellulitis, spontaneous bacterial peritonitis [SBP]), and major medical procedures such as liver transplant. In some embodiments, the method provides a decrease in the patient’s health care utilization by at least 20% for 30 days, 60 days, 90 days, 120 days, 180 days, or for 1 year, or for greater than 1 year. In some embodiments, the method provides a decrease in the patient’s health care utilization by at least 30% for 30 days, 60 days, 90 days, 120 days, 180 days, or for 1 year, or for greater than 1 year. In some embodiments, the method provides a decrease in the patient’s health care utilization by about 10% to about 40% for 30 days, 60 days, 90 days, 120 days, 180 days, or for 1 year, or for greater than 1 year.
[00123] In some embodiments, the method improves 90-day survival of the patient and decreases the patient’s re -hospitalizations by at least 10%, or at least 20%, or between 10% and 30%.
[00124] In some embodiments, the method provides an improvement in liver-related events (such as decompensation), or hospitalization/re-hospitalization.
[00125] In some embodiments, the method provides a reduction in hospitalization by at least 15%.
[00126] In some embodiments, the method provides a reduction in progression to transplant by at least 15%.
[00127] Compound 1, is a semi-synthetic bile acid derived from CDCA, the natural ligand for the FXR.
[00128] As a targeted therapy with anti-inflammatory, anti-fibrotic, and potentially anti- apoptotic effects, FXR agonist Compound 1 could represent a significant advance over
systemic corticosteroid therapy, the standard of care in the treatment of patients with sAH. Compound 1 likely also decreases intestinal permeability and could provide a considerable advance over corticosteroids with respect to bacterial translocation and infectious complications seen in patients with sAH.
[00129] The targeted mechanism of action of FXR agonists such as Compound 1 represents a novel therapeutic option over the nonspecific action of corticosteroids, the current standard of care for sAH. As described in further detail herein, in one aspect, the present invention provides methods of treating alcoholic hepatitis or severe alcoholic hepatitis or ACLF, comprising administering to a patient in need thereof an effective amount of an FXR agonist described herein.
[00130] As a targeted therapy with anti-inflammatory, anti-fibrotic, and anti-apoptotic effects, FXR agonists described herein meet a long-felt need in the art for efficacious therapies for acute liver diseases such as severe alcoholic hepatitis (sAH) and acute-on- chronic liver failure (ACLF). Dysfunction of the gut-liver axis, including increased intestinal permeability, is an important driver of alcohol-induced liver damage (Sehrawat, T.S., et al. The knowns and unknowns of treatment for alcoholic hepatitis. Lancet Gastroenterol Hepatol. 2020;5(5)494-506). Recent murine models suggest that extrahepatic FXR deficiency is critical for the development of alcohol induced fatty liver and specifically intestinal FXR may protect against steatohepatitis by maintaining gut integrity (Huang, M., et al. Enhanced alcoholic liver disease in mice with intestine-specific famesoid X receptor deficiency. Lab Invest. 2O2O;lOO(9):1158-68).
Exemplary Diseases and Patient Populations - sAH
[00131] Severe alcoholic hepatitis (sAH) is an acute liver disease distinct from other alcoholic liver diseases, many of which are chronic in nature. Furthermore, sAH has distinctive histopathologic and pathophysiologic features and may be present in a patient along with underlying, chronic liver diseases such as alcoholic liver disease (ALD) (Shah N.J., Royer A, John S. Alcoholic Hepatitis. Stat Pearls. 2021 Jan; 1-8; hereby incorporated by reference). During sAH, endotoxin or lipopolysaccharide (LPS), collectively referred to as pathogen-associated molecular patterns (PAMPs), cross into the portal circulation and initiate the inflammatory cascade. Increased endotoxin levels in alcoholic hepatitis are caused by alcohol-induced qualitative and quantitative changes in the gut microbiota and
increases in intestinal permeability. LPS activates Kupffer cells and hepatic stellate cells via toll-like receptor 4 (TLR4) and produce reactive oxygen species (ROS), proinflammatory cytokines and chemokines that together with alcohol contribute to hepatocyte damage. Other factors contributing to hepatocyte damage include alcohol- induced activation of various immune cells (i.e., neutrophils, T cells, and other leukocytes); in addition, alcohol’s direct effect on adipose tissue results in the production of damage- associated molecular- patterns (DAMPs).
[00132] In the majority of AH cases liver biopsy is not required. However, liver biopsy may be needed to confirm the diagnosis of AH. Findings that confirm the diagnosis of AH on liver biopsy include hepatocyte ballooning, neutrophil infiltrate and Mallory-Denk bodies, on a background of variable degrees of steatosis and fibrosis (Singal, A.K., et al. Journal of Hepatology 2019, vol.70, 305-313). The method of the present disclosure improves one or more histologic measures of sAH, such as macrovesicular steatosis with at least one of the following: neutrophil infiltration, hepatocyte injury (ballooning), and Mallory-Denk bodies. The method of the present disclosure improves macrovesicular steatosis. The method of the present disclosure improves neutrophil infiltration. The method of the present disclosure improves hepatocyte injury (ballooning). The method of the present disclosure improves Mallory-Denk bodies.
[00133] Excessive alcohol consumption is one of the leading causes of liver disease and the seventh leading cause of premature death worldwide. Alcohol-induced liver injury can range from steatosis to alcohol-induced steatohepatitis with fibrosis to cirrhosis and hepatocellular carcinoma. Unfortunately, many alcohol-related liver disease (ALD) patients are diagnosed at more advanced stages of disease and thus data on the prevalence of early-stage disease are limited (Singal, A.K., et al. “ACG clinical guideline: Alcoholic liver disease,” Am J Gastroenterol. 2018;l 13(2): 175- 94; hereby incorporated by reference). The best estimated combined prevalence of non-cirrhotic and cirrhotic ALD is approximately 2% of the general population in the US. Worldwide, deaths due to alcohol-induced cirrhosis account for approximately 10% of all alcohol- attributable deaths and nearly half of deaths due to chronic liver disease.
[00134] Alcoholic hepatitis (AH) (or alcohol-associated hepatitis), also referred to as symptomatic alcoholic steatohepatitis, is a clinical syndrome of acute hepatitis due to heavy
alcohol consumption with distinct histopathologic findings including steatohepatitis, neutrophilic infiltration, and fibrosis (Crabb, D.W., el al., “Standard definitions and common data elements for clinical trials in patients with alcoholic hepatitis: Recommendation from the NIAAA Alcoholic Hepatitis Consortia,” Gastroenterology 2016 Apr;150(4):785-90; hereby incorporated by reference). Most often, a clinical diagnosis of AH is made in a patient with the rapid development of jaundice and liver- related complications in association with documentation of persistent heavy alcohol use within 8 weeks of the onset of symptoms and exclusion of other liver diseases (Singal, A.K., el al. Am J Gastroenterol. 2018; 113(2) : 175- 94). In AH, abnormalities that could contribute to liver injury include production of oxidative stress as a by-product of the metabolism of ethanol and the “leakage” of endotoxin through the intestinal wall and into the portal circulation. Endotoxin binds to receptors on Kupffer cells and activates an inflammatory response. The inflammatory response in the liver leads to hepatocyte dysfunction and death. Among the most important inflammatory cytokines is tumor necrosis factor (TNF)-alfa, elevated levels of which correlate with severity of liver disease. Morgan, T. R. Gastroenterol. Hepatol. (N Y). 2007 Feb; 3(2): 97-99.
[00135] Direct hepatocyte injury is due to the cytotoxic effect of ethanol and its metabolites (e.g., acetaldehyde). The ethanol-induced injury incites an inflammatory response and is associated with high morbidity and mortality, especially in patients with severe disease. Ethanol metabolism also changes the redox state of hepatocytes and interferes with carbohydrate and lipid metabolism, thus contributing to hepatic steatosis. Alcohol increases the susceptibility of hepatocytes to free radical damage by activating the CYP2E1 enzyme inducing mitochondrial dysfunction, depleting antioxidant stores, and recruiting inflammatory cells. Chronic alcohol abuse, particularly when combined with malnutrition, often compounds the effect of oxidative injury by further lowering cellular resilience to oxidative stress and depleting antioxidant stores. Proteasome dysfunction also serves a role in exacerbating oxidative stress and cellular injury. Secondary damage of hepatocytes, mediated by inflammatory cells, also plays a central role in the pathophysiology of alcoholic hepatitis. Chronic alcohol exposure can lead to increased gut permeability and elevated circulating pathogenic products (e.g., lipopolysaccharide), also known as pathogen-associated molecular patterns (PAMPs). Hepatocytes damaged by
ethanol release aseptic inflammatory mediators known as damage-associated molecular patterns (DAMPs). DAMPs and PAMPs bind to pattern recognition receptors and potently stimulate the innate immune response. Activation of the innate immune response by cytokine-mediated and chemokine-mediated attraction of circulating neutrophils and monocytes. This leads to dense neutrophil infiltration of the liver, which is a hallmark of alcoholic hepatitis. Adaptive immune responses, mediated by B cells, T cells, and natural killer cells, also contribute to the hepatic inflammatory storm. Alcoholic hepatitis (or alcohol-associated hepatitis) is thus a distinct disease (Sehrawat, T.S., et al. “The knowns and unknowns of treatment for alcoholic hepatitis,” Lancet Gastroenterol Hepatol. 2020;5(5)494-506; hereby incorporated by reference). Patients with sAH are defined by MDF >32 and/or MELD. The short-term mortality for patients with sAH has been reported to be as high as 46% in prior interventional studies (Akriviadis, E., et al. “Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo- controlled trial,” Gastroenterology 2000 Dec; 119(6): 1637-48; hereby incorporated by reference). A more recent study reported a longer term 1-year mortality (or liver transplantation) rate of 56% to 57% in patients with sAH (Thursz, M.R., et al. “Prednisolone or pentoxifylline for alcoholic hepatitis,” N Engl J Med. 2015 Apr 23;372(17): 1619-28; hereby incorporated by reference). In support of this, intermediate mortality from AH was found to be as high as 44% at 180 days after hospital admission in a meta-analysis evaluating published mortality rates between 1971 and 2016 (Hughes, E., et al. “Survival from alcoholic hepatitis has not improved over time,” PLoS One 2018;13(2):e0192393; hereby incorporated by reference).
[00136] Patients with acute alcoholic hepatitis will have an elevated total bilirubin and transaminases typically at least 2-6 times the upper limit or normal. Severe alcoholic hepatitis may be marked by bilirubin levels over 10-15 mg/dL; levels of aspartate aminotransferase (AST) are usually between 100 and 200 U/L (or IU/L) and are almost always less than 400 U/L (or IU/L); alanine aminotransferase (ALT) is usually approximately 25-50% the value of AST, somewhere in the range of 50-150 U/L (or IU/L); and other typical findings include fever, leukocytosis (white blood cell >10,000/pL), ascites, and tender hepatomegaly (Morgan, T. R. Gastroenterol. Hepatol. (N Y). 2007 Feb; 3(2): 97-99).
[00137] Current guidelines recommend alcohol abstinence in all patients with AH, as well as ALD. In addition, most patients with AH will benefit from nutritional support including total caloric and protein supplementation. However, for patients with sAH (as defined by MDF >32 and/or MELD score >20) the treatment options are limited to the addition of systemic corticosteroids along with supportive care and alcohol abstinence.
[00138] The clinical utility of systemic corticosteroid therapy is largely limited due to the heightened risk of infection and concern for GI bleeding. Thus, all current guidelines recommend clinicians use the Lille score after 7 days of corticosteroid therapy to identify non-responders in order to avoid the risk of unnecessary systemic steroid exposure (European Association for the Study of the Liver (EASL). EASL Clinical Practice Guidelines: Management of alcohol-related liver disease. J Hepatol. 2018; 69:154-81; and Crabb, D.W., et al. “Diagnosis and treatment of alcohol-associated liver diseases: 2019 Practice guidance from the American Association for the Study of Liver Diseases,” Hepatology. 2020;70(l): 306-33; hereby incorporated by reference).
[00139] The Lille Model is a medical modeling tool for predicting mortality in patients with alcoholic hepatitis who are not responding to steroid therapy. The model risk stratifies patients who have been receiving steroid treatment for seven days to predict who will improve and who should be considered for alternative treatment options including early referral for transplant (Mathurin, P., et al., Early change in bilirubin levels is an important prognostic factor in severe alcoholic hepatitis treated with prednisolone. Hepatology, 2003, 38 (6): 1363-9). The model is based on: Age; Albumin; Bilirubin (initial); Bilirubin (day 7); Creatinine; and Prothrombin time (PT). Recent cohort studies demonstrate that those with a Lille score above 0.45 are likely non-responders to steroid therapy (Louvet, A., et al., The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids, Hepatology 2007, 45 (6): 1348-54).
[00140] The Lille model can be used to predict mortality at 6 months. Lower scores indicated more improvement (in response to corticosteroids). Typically, scores >0.45 predict a 6-month survival of 25%. Scores <0.45 predict a 6-month survival of 85%. Lille scores at day 7 can range from less than 0.1 and greater than 0.9. Lille score at day 7 for Responder is <0.45 and Lille score at day 7 for non-Responder is >0.45.
[00141] Several scores such as Maddrey’s discriminant function (MDF), MELD or MELD-Na, ABIC, and GAHS are used for a 28-day mortality prognosis. MDF is defined as 4.6 x (patient - control PT) + serum bilirubin, with severe disease being a score of 32 or higher. An MDF score less than 32 means mild to moderate alcoholic hepatitis. An MDF score equal to or greater than 32 means one is likely to have severe alcoholic hepatitis and is a candidate for corticosteroid therapy or pentoxifylline treatment under current standard of care. MDF less than 32 (mild to moderate AH) does not benefit from steroid therapy. There is some mortality associated with mild to moderate AH, so it is beneficial to have a therapy for this group (given that steroids are not indicated because they do not impart mortality benefit).
[00142] Model for End-Stage Liver Disease (MELD) score is a prognostic scoring system, based on laboratory parameters, used to predict 3-month mortality due to liver disease. The MELD score ranges from 6 to 40 and is based on results from several lab tests. MELD scores for mild AH ranges from 6 to 10. MELD scores for moderate AH ranges from 11 to 20. MELD for sAH ranges from 21 to 30. MELD is defined as 9.57 loge (S creatinine) + 3.78 logc (serum bilirubin) + 11.2 logc (INR) + 6.43. A severe disease is MELD score of 21 or higher. Singal, A.K., et al., “Diagnosis and Treatment of Alcohol- Associated Liver Disease,” JAMA. 2021;326(2): 165-176, hereby incorporated by reference.
[00143] A new version of MELD (MELD 3.0) was recently developed, which added female gender and albumin in the score, demonstrating a slightly more accurate mortality prediction than MELD-Na in cirrhotic patients. See Kim W.R., et al. MELD 3.0: The Model for End-stage Liver Disease Updated for the Modern Era. Gastroenterology 2021 (available on line at https://doi.Org/10.1053/j.gastro.2021.08.050), incorporated herein by reference. Each of the embodiments described herein that list MELD or MELD-Na ranges and/or values are intended to also include the corresponding MELD 3.0 ranges and/or values.
[00144] Severe AH is generally accepted to be defined by a Maddrey discriminant function (MDF) score >32 or a MELD score >=21, with ranges typically seen from 21-30. The MELD-Na score is a modification of the MELD score that adjusts for serum sodium. The MELD-Na score is currently an accepted criterion for determining candidacy for liver
transplants. The study described herein includes patients that have MELD-Na scores of 18-25 (inclusive) and a MDF of >32.
[00145] Low serum sodium is an independent predictor of mortality in patients with cirrhosis. MELD-Na score includes serum Na; this score improves slightly the predictive accuracy of the MELD score in predicting mortality (Kim, W.R., et al. N Engl J Med 2008; 359:1018-1026). The MELD-Na is a validated scoring system used to assess the severity of chronic liver disease. The MELD-Na score is useful in assessing subjects with significant decompensation and is now used by the Organ Procurement and Transplantation Network (OPTN) in the US and the Eurotransplant (ET) regions of the EU to manage the organ allocation for liver transplantation. An increasing MELD-Na score is associated with increased severity of hepatic dysfunction and increased 3-month mortality risk. The MELD-Na score is derived from the subject’s serum total bilirubin, serum creatinine, and INR (International normalized ratio), as appropriate, to predict survival and is calculated according to the following formula MELD-Na Score = 10 x [(0.957 x In(Crcatininc)) + (0.378 x In(Bilirubin)) + (1.12 x In(INR))] + 6.43; MELD-Na = MELD - Na - [0.025 x MELD x (140 - Na)] + 140.
[00146] Patients with sAH and progressive liver failure who are non-responders to corticosteroid therapy and ineligible for liver transplantation are frequently referred for palliative care (Singal, A.K., et al. Am J Gastroenterol. 2018;l 13(2): 175-94). Given the limited treatment options, the side effects and lack of long-term benefit of corticosteroid therapy, there remains a significant unmet medical need for patients with sAH.
[00147] In some embodiments, the patient is of at least 18 years of age. In some embodiments, the patient is of at least 30 years of age. In some embodiments, the patient is of at least 35 years of age. In some embodiments, the patient is of at least 40 years of age. In some embodiments, the patient is of at least 60 years of age. In some embodiments, the patient is 18 to 65 years of age. In some embodiments, the patient is of at least 42, 45, 48, 50, 52, 55, 58, 62, 65, 68, 70, 72, 75, 78, or 80 years of age. In some embodiments, the patient is 40-60 years of age. In some embodiments, the patient is 60-85 year s of age. In some embodiments, the patient is 40-50 year's of age. In some embodiments, the patient is 70-80 years of age.
[00148] In some embodiments, the patient is male. In some embodiments, the patient is female.
[00149] In some embodiments of the present disclosure, the patient is stratified according to disease severity. Short-term mortality can be predicted using the Maddrey discriminant function (MDF), Model for End-Stage Liver Disease (MELD or MELD-Na) score, Age-Bilirubin-Intemational Normalized Ratio -Creatinine score, and Glasgow Alcoholic Hepatitis Scores. Patients with severe AH (sAH) defined by a Maddrey discriminant function of 32 or greater have a 1-month morality rate as high as 20%-50%, so in prior clinical studies, the 30-day survival was the endpoint for most trials. The maximum MDF score is typically less than 60, as patients with MDF score of more than 60 likely need liver transplant. In some embodiments, a MELD or MELD-Na score of >20 or >21 is used as a criterion for selecting a patient. In some embodiments, a MELD or MELD-Na score of >18 is used as a criterion for selecting a patient. For example, a MELD score of 21 or greater predicts a 90-day mortality of 20% . The maximum MELD score is typically less than 30, as patients with MELD score of more than 30 likely need liver transplant. Failure of improvement in serum bilirubin (the Lille score) predicts patients with severe AH who are unlikely to benefit from continued corticosteroid therapy.
[00150] In some embodiments, the patient has mild alcoholic hepatitis. In some embodiments, the patient has moderate alcoholic hepatitis. In some embodiments, the patient has a Maddrey’s discriminant function score of about 32, and/or a MELD or MELD-Na score of 18, 19, 20, 21, 22, 23, 24, or 25.
[00151] In some embodiments, the patient has a Maddrey’s discriminant function score of > 32, and/or a MELD or MELD-Na score of 21-30.
[00152] In some embodiments, the patient has underlying alcohol-related liver disease (ALD) associated with sAH.
[00153] In some embodiments, the patient exhibits jaundice.
[00154] In some embodiments, the patient exhibits one or more of the following: (1) ongoing alcohol consumption of more than 40 g of alcohol per day in women and more than 60 g of alcohol per day in men for 6 months or more, with less than 60 days of abstinence before the onset of jaundice; (2) the presence of elevated liver enzymes (aspartate aminotransferase [AST] and alanine aminotransferase [ALT] concentrations >50
IU/L but <400 IU/L and an AST/ALT ratio of >1:5); and (3) worsening jaundice, with bilirubin concentrations greater than 3 mg/dL. In some embodiments, the patient is diagnosed with sAH after a liver biopsy in addition to one, two, three, or all of the preceding signs of the disease.
[00155] In some embodiments, the patient is considered ineligible for a liver transplant per generally accepted criteria known in the art.
[00156] In some embodiments, the patient has alcoholic use disorder (AUD), defined as consuming 3 or more alcoholic drinks per day (men) or 2 or more alcoholic drinks per day (women).
[00157] In some embodiments, the patient has been treated previously for sAH with a corticosteroid. In some embodiments, the patient did not respond to the corticosteroid. In some embodiments, the patient exhibited a Lille score of more than 0.45 after 7 days or more of treatment with the corticosteroid.
[00158] In some embodiments, the patient has an MDF score of 32 or higher, and/or a MELD or MELD-Na score of 18, or 20, or 21 or higher, for example 21-30.
[00159] In some embodiments, the patient has asymptomatic sAH, or “walking AH.” In some embodiments, the patient has asymptomatic sAH that includes cirrhosis.
[00160] In some embodiments, in addition to sAH, the patient is diagnosed using Child- Turcotte-Pugh criteria. In some embodiments, the patient has a Child-Turcotte-Pugh score of 7 or greater, e.g., 7-15, 8-15. 9-15, 10-15, or 8-12.
[00161] In some embodiments, the patient exhibits alcohol-associated cirrhosis.
[00162] In some embodiments, the patient exhibits alcohol-associated liver fibrosis.
[00163] In some embodiments, the patient exhibits alcohol-associated steatosis.
[00164] In some embodiments, the patient exhibits alcohol-associated steatohepatitis.
[00165] In some embodiments, the patient exhibits alcoholic hepatitis.
[00166] In some embodiments, the patient has ALD in addition to sAH, wherein the ALD is selected from early ALD (stage 0-2) or advanced ALD (bridging fibrosis, stage 3; or cirrhosis, stage 4).
[00167] In some embodiments, the patient does not exhibit cirrhosis.
[00168] In some embodiments, the patient is currently hospitalized, i.e., hospitalized prior to beginning treatment with the FXR agonist. In some embodiments, the patient is
currently hospitalized and exhibits an MDF score of at least 32 and a MELD score of 18, or 20, or 21 to 25 or 30, or 21-30, or MELD-Na score of 18, 20 or 21 to 25 or 30.
[00169] In some embodiments, the patient has suffered at least one relapse of sAH.
[00170] In some embodiments, the patient exhibits one or more of the following in addition to sAH: obesity, metabolic syndrome, hepatitis C infection, or a genetic polymorphism such as patatin-like phospholipase domain protein 3, membrane bound O- acyltransferase, and transmembrane 6 superfamily member 2 genes.
[00171] In some embodiments, the patient exhibits intestinal dysbiosis.
[00172] In some embodiments, the method improves one or measures of sAH, such as intestinal dysbiosis.
[00173] In some embodiments, the present disclosure provides a method of determining candidacy of a patient for therapeutic treatment for sAH, comprising determining the patient's MELD-Na score, wherein the patient's MELD-Na score is > 18. In some embodiments, the method further comprises determining the patient's MDF score, for example wherein the patient's MDF score is from 32 to 60 inclusive.
[00174] In some embodiments, the present disclosure provides a method of determining candidacy of a patient for therapeutic treatment for sAH, comprising determining the patient's MELD score, wherein the patient's MELD score is > 21, for example from 21 to 30. In some embodiments, the method further comprises determining the patient's MDF score, for example wherein the patient's MDF score is > 32, for example from 32 to 60 inclusive.
[00175] In some embodiments, the present disclosure provides a method for treating sAH comprising selecting a patient having a MELD-Na score > 18; and administering a therapeutic treatment for sAH, for example wherein the patient also has a MDF score from 32 to 60 inclusive. In some embodiments the therapeutic treatment comprises administering a pharmacologic agent to the patient, and/or a liver transplant.
[00176] In some embodiments, the present disclosure provides a method for treating sAH comprising selecting a patient having a MELD score > 21, for example from 21 to 30; and administering a therapeutic treatment for sAH, for example wherein the patient also has a MDF score > 32, for example from 32 to 60 inclusive. In some embodiments the
therapeutic treatment comprises administering a pharmacologic agent to the patient, and/or a liver transplant.
[00177] In some embodiments, the method provides improvements in one or more measures of patient health outcomes. In the following embodiments of the invention, references to “a patient” or “the patient” may refer to an individual patient or to a group of patients. For example, a decrease in the patient’s health care utilization may refer to an individual patient or to a group of patients.
[00178] In some embodiments, the method improves 30-day survival of the patient versus an otherwise similar patient who was not administered the FXR agonist. In some embodiments, the method improves 60-day survival of the patient versus an otherwise similar patient who was not administered the FXR agonist. In some embodiments, the method improves 90-day survival of the patient versus an otherwise similar patient who was not administered the FXR agonist. In some embodiments, the method improves the 120-day, 180-day, or 1-ycar survival of the patient versus an otherwise similar patient who was not administered the FXR agonist.
[00179] In some embodiments, the method improves 30-day mortality of the patient versus an otherwise similar patient who was not administered the FXR agonist. In some embodiments, the method improves 60-day mortality of the patient versus an otherwise similar patient who was not administered the FXR agonist. In some embodiments, the method improves 90-day mortality of the patient versus an otherwise similar' patient who was not administered the FXR agonist. In some embodiments, the method improves the 120-day, 180-day, or 1-year mortality of the patient versus an otherwise similar patient who was not administered the FXR agonist.
[00180] In some embodiments, the improvement in survival or mortality of the patient includes an increase in survival, or a decrease in mortality, of about 10% to about 70%. Such improvements may be measured over, for example, 30 days, 60 days, 90 days, 120 days, 180 days, 1 year, or greater than 1 year. In some embodiments, the improvement in survival or mortality of the patient includes an increase in survival, or a decrease in mortality, of about 10% to about 60%, about 10% to about 50%, about 10% to about 40%, about 10% to about 30%, or about 10% to about 20%. In some embodiments, the improvement in survival or mortality of the patient includes an increase in survival, or a
decrease in mortality, of about 20% to about 70%, about 20% to 60%, about 20% to about 50%, about 20% to about 40%, about 20% to about 30%, about 30% to about 70%, about 30% to about 60%, about 30% to about 50%, about 30% to about 40%, about 40% to about 70%, about 40% to about 60%, about 40% to about 50%, about 50% to about 70%, about 50% to about 60%, or about 60% to about 70%. In some embodiments, the improvement in survival or mortality of the patient includes an increase in survival, or a decrease in mortality, of about 10%, 15%, 20%. 25%, 30%, 35%, 40%. 45%, 50%, 55%, 60%. 65%, 70%, 75%, 80%, 85%, 90%, or 95%.
[00181] In some embodiments, the method provides a reduction in risk of mortality for the patient. In some embodiments, the method provides a reduction in risk of mortality and health care utilization for liver-related events in patients with sAH. In some embodiments, such reductions are compared with the current standard of care, e.g., treatment with a corticosteroid such as prednisolone. In some embodiments, the FXR agonist, such as Compound 1 or a pharmaceutically acceptable salt thereof or an amino acid conjugate thereof, is indicated for first-line therapy.
[00182] In some embodiments, the method provides a decrease in the patient’s health care utilization by at least 10% for 30 days, 60 days, 90 days, 120 days, 180 days, or for 1 year, or for greater than 1 year. As used herein, the term “heath care utilization” includes one or more of hospital re-admission within 30-days after discharge, number of hospitalizations, length of stay, emergency room visits, intensive care unit (ICU) days, and infectious complications (e.g., sepsis, pneumonia, urinary tract infection [UTI], cellulitis, spontaneous bacterial peritonitis [SBP]), and major medical procedures such as liver transplant. In some embodiments, the method provides a decrease in the patient’s health care utilization by at least 20% for 30 days, 60 days, 90 days, 120 days, 180 days, or for 1 year, or for greater than 1 year. In some embodiments, the method provides a decrease in the patient’s health care utilization by at least 30% for 30 days, 60 days, 90 days, 120 days, 180 days, or for 1 year, or for greater than 1 year. In some embodiments, the method provides a decrease in the patient’s health care utilization by about 10% to about 40% for 30 days, 60 days, 90 days, 120 days, 180 days, or for 1 year, or for greater than 1 year.
[00183] In some embodiments, the method provides a decrease in the patient’s health care utilization by about 10% to about 40% for 30 days, 60 days, 90 days. 120 days, 180
days, or for 1 year, or for greater than 1 year. In some embodiments, the method provides a decrease in the patient’s health care utilization by about 20% to about 30% for 30 days, 60 days, 90 days, 120 days, 180 days, or for 1 year, or for greater than 1 year. In some embodiments, the method provides a decrease in the patient’s health care utilization by about 10% to about 20% for 30 days, 60 days, 90 days, 120 days, 180 days, or for 1 year, or for greater than 1 year.
[00184] In some embodiments, the method decreases the patient’s re-hospitalizations by at least 10%. In some embodiments, the method decreases the patient’s re-hospitalizations by 10-80%.
[00185] In some embodiments, the method improves 90-day survival of the patient and decreases the patient’s re -hospitalizations by at least 10%.
[00186] In some embodiments, the method further comprises administering the FXR agonist in combination with another therapeutic agent. In some embodiments, the method further comprises co-administcring to the patient an effective amount of anti-inflammatory agent, an antibiotic, a probiotic, a fecal transplant. Zinc- supplement or a combination of any of those agents. In some embodiments, another therapeutic agent can be an antiinflammatory agent, an antibiotic (e.g., Augmentin), an antioxidant, a probiotic, a fecal transplant, Zn-supplement or a combination of any of those agents. In some embodiments, the method comprises administering the FXR agonist and an anti-inflammatory agent. In some embodiments, the anti-inflammatory agent is a corticosteroid. For example, the corticosteroid may be selected from prednisolone (e.g., about 40 mg/d) or methylprednisolone (e.g., about 32 mg/d). In some embodiments, the additional therapeutic agent for co-administration is pentoxifylline. In some embodiments, the FXR agonist is administered in combination with corticosteroid or pentoxifylline. In some embodiments, the method further comprises co-administering to the patient an effective amount of pentoxifylline, Augmentin, bovine colostrum, corticosteroid (e.g., prednisolone or methylprednisolone), an ELAD agent, canakinumab, a TNF inhibitor, IL-22, N- acetylcysteine, metadoxine, IgG anti-LPS, a probiotic, a fecal transplant, Zn-supplement, or a combination of any of those agents.
[00187] In some embodiments, the further treatment comprises alcohol cessation and/or counseling.
Exemplary Diseases and Patient Populations - ACLF
[00188] Acute-on-chronic liver failure (ACLF) is a syndrome characterized by acute decompensation of chronic liver disease associated with organ failures and high short-term mortality. Alcohol and chronic viral hepatitis are the most common underlying liver diseases. Up to 40%-50% of the cases of ACLF have no identifiable trigger; in the remaining patients, sepsis, active alcoholism and relapse of chronic viral hepatitis are the most common reported precipitating factors. An excessive systemic inflammatory response seems to play a crucial role in the development of ACLF. Using a liver-adapted sequential organ assessment failure score, it is possible to triage and prognosticate the outcome of patients with ACLF. The course of ACLF is dynamic and changes over the course of hospital admission. Most of the patients will have a clear prognosis between day 3 and 7 of hospital admission and clinical decisions such as evaluation for liver transplant or discussion over goals of care could be tailored using clinical scores. Bioartificial liver support systems, granulocytc-colony stimulating factors or stem-cell transplant arc under investigation for medical care of this patient population; however, data are too premature to implement them as standard of care.
[00189] In some embodiments, the patient is of at least 18 years of age. In some embodiments, the patient is of at least 30 years of age. In some embodiments, the patient is of at least 35 years of age. In some embodiments, the patient is of at least 40 years of age. In some embodiments, the patient is of at least 60 years of age. In some embodiments, the patient is 18-65 years of age. In some embodiments, the patient is of at least 42, 45, 48, 50, 52, 55, 58, 62, 65, 68, 70, 72, 75, 78, or 80 years of age. In some embodiments, the patient is 40-65 years of age. In some embodiments, the patient is 65-85 years of age. In some embodiments, the patient is 40-50 years of age. In some embodiments, the patient is 70-80 years of age.
[00190] In some embodiments, the patient is male. In some embodiments, the patient is female.
[00191] In some embodiments, the patient has alcoholic use disorder (AUD), defined as consuming 3 or more alcoholic drinks per day (men) or 2 or more alcoholic drinks per day (women).
[00192] In some embodiments, the patient has ALD-related ACLF.
[00193] In some embodiments, the patient has ALD selected from early ALD (stage 0- 2) or advanced ALD (bridging fibrosis, stage 3; or cirrhosis, stage 4).
[00194] In some embodiments, the patient has a Maddrey’s discriminant function (MSF) score of 32 or higher, and/or a MELD or MELD-Na score of 18, 20, or 21 or higher, for example from 21-30.
[00195] In some embodiments, the patient has been diagnosed with ACLF using the Sequential [Sepsis-related] Organ Failure Assessment, APACHE (Acute Physiology and Chronic Health Evaluation), or acute-on-chronic liver failure score.
[00196] In some embodiments, the patient exhibits cirrhosis.
[00197] In some embodiments, the patient exhibits liver fibrosis.
[00198] In some embodiments, the patient exhibits steatosis.
[00199] In some embodiments, the patient exhibits alcoholic hepatitis.
[00200] In some embodiments, the patient does not exhibit cirrhosis.
[00201] In some embodiments, the patient exhibits intestinal dysbiosis.
[00202] In some embodiments, the patient exhibits one or more of the following in addition to ACLF: obesity, metabolic syndrome, hepatitis C infection, or a genetic polymorphism such as patatin-like phospholipase domain protein 3, membrane bound O- acyltransferase, and transmembrane 6 superfamily member 2 genes.
[00203] When ACLF is precipitated by sAH, same therapeutics as for sAH are used for treatment. There is an overlap in treatment options with other forms of ACLF including antibiotics, supplements, antioxidants and steroids. Antioxidants, such as N-acetylcysteine, are used in ACLF.
[00204] In some embodiments, the method of the present disclosure includes a coadministered treatment. In some embodiments, the method comprises administering the FXR agonist in combination with another therapeutic agent. In some embodiments, another therapeutic agent can be an anti-inflammatory agent, an antibiotic (e.g.. Augmentin), an antioxidant, a probiotic, a fecal transplant, Zn-supplement or a combination of any of those agents. In some embodiments, the method comprises administering the FXR agonist and an anti-inflammatory agent. In some embodiments, the anti-inflammatory agent is a corticosteroid. For example, the corticosteroid may be selected from prednisolone (e.g., about 40 mg/d) or methylprednisolone (e.g., about 32 mg/d). In some embodiments, the
additional therapeutic agent for co-administration is pentoxifylline. In some embodiments, the FXR agonist is administered in combination with corticosteroid or pentoxifylline. In some embodiments, the FXR agonist is administered in combination with N-acetylcysteine. In some embodiments, the further treatment comprises alcohol cessation and/or counseling.
2. Uses, Formulation and Administration
Pharmaceutically Acceptable Compositions
[00205] According to another embodiment, the invention provides a composition comprising a disclosed compound and a pharmaceutically acceptable carrier, adjuvant, or vehicle. In certain embodiments, a composition of this invention is formulated for administration to a patient in need of such composition. In some embodiments, a composition of this invention is formulated for oral administration to a patient.
[00206] The term “subject” or “patient,” as used herein, means a human.
[00207] The term “pharmaceutically acceptable carrier, adjuvant, or vehicle” refers to a non-toxic carrier, adjuvant, or vehicle that docs not destroy the pharmacological activity of the compound with which it is formulated. Pharmaceutically acceptable carriers, adjuvants or vehicles that may be used in the compositions of this invention include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances (e.g., hydroxypropyl methylcellulose), polyethylene glycol, sodium carboxymethylcellulose, poly acrylates, waxes, polyethylene- polyoxypropylene-block polymers, polyethylene glycol and wool fat.
[00208] A “pharmaceutically acceptable derivative” means any non-toxic salt, ester, salt of an ester or other derivative of a compound of this invention that, upon administration to a recipient, is capable of providing, either directly or indirectly, a compound of this invention or an active metabolite or amino acid conjugate thereof.
[00209] As used herein, the term “amino acid conjugate” refers to a conjugate of a compound of the invention with any suitable amino acid. Taurine ( NHjCFb SChH), glycine (-NHCH2CO2H), and sarcosine (-N/CHsjCFhCChH) are examples of amino acid
conjugates. Suitable amino acid conjugates of the compounds have the added advantage of enhanced integrity in bile or intestinal fluids. Suitable amino acids are not limited to taurine, glycine, and sarcosine.
[00210] As defined herein, the term “metabolite” refers to glucuronidated and sulfated derivatives of the compounds described herein, wherein one or more glucuronic acid or sulfate moieties are linked to the compound of the invention. Glucuronic acid moieties may be linked to the compounds through glycosidic bonds with the hydroxyl groups of the compounds (e.g., 3-hydroxyl, 7-hydroxyl, 11-hydroxyl). Sulfated derivatives of the compounds may be formed through sulfation of the hydroxyl groups (e.g., 3-hydroxyl, 7- hydroxyl, 11-hydroxyl). Examples of metabolites include, but are not limited to, 3-0- glucuronide, 7-O-glucuronide, 11-O-glucuronide, 3-O-7-O-diglucuronide, 3-0-11-0- triglucuronide, 7-0-11-O-triglucuronide, and 3-O-7-O-ll-O-triglucuronide, of the compounds described herein, and 3-sulfate, 7-sulfate, 11-sulfate, 3,7-bisulfate, 3,11- bisulfatc, 7, 11 -bisulf ate, and 3,7,11-trisulfatc, of the compounds described herein.
[00211] As used herein, “pharmaceutically acceptable salt” refers to a conventional nontoxic salt of a compound of the invention wherein the parent compound is modified by forming acid or base salts thereof. Suitable pharmaceutically acceptable salts according to the present disclosure can be readily determined and prepared by one skilled in the art and will include, for example, basic salts such as aluminum, calcium, lithium, magnesium, potassium, sodium, and zinc salts of Compound 1 or organic salts, such as quaternary ammonium salts of Compound 1.
[00212] The amount of a disclosed compound (i.e., active agent) that should be present in a composition for use a disclosed method or a disclosed pharmaceutical composition will generally be a therapeutically effective amount. A “therapeutically effective amount” or dose (or “effective amount”) refers to that amount of the active agent sufficient to result in a desired therapeutic result.
[00213] In certain embodiments, the effective amount refers to a titrated dosage administered during a titration period. In other embodiments, the effective amount refers to an adjusted or re-adjusted dosage administered after a titration period.
[00214] A “starting dose” as used herein refers to an initial dose provided to a patient to provide a clinical effect while minimizing onset or occurrence of an adverse effect. A
starting dose can, in certain instances, be less than an amount typically administered to a patient. A starting dose is provided in an amount that is titrated or gradually increased over the course of a titration period or during the course of treatment with the FXR agonist described herein. A starting dose can, in certain instances, be more than an amount typically administered to a patient. A starting dose is provided in an amount that is titrated or gradually increased or reduced over the course of a titration period or during the course of treatment with the FXR agonist described herein to achieve the desired therapeutic result. [00215] A “titration period” refers to a length of time for which a starting dose is administered to a patient. A titration period continues for a specified length of time, where the patient is often monitored for liver function and/or liver biochemistry as described herein.
[00216] An “adjusted dose” as used herein refers to a dose of the FXR agonist of the present disclosure or a composition thereof administered after the termination of a titration period. An adjusted dose can be increased or decreased compared to a starting dose but, as provided herein, patient tolerance and other factors described herein determine the dosage amount of an adjusted dose. A “re-adjusted dose” as used herein refers to any changed dosage amount or dose frequency of an adjusted dose in a patient.
[00217] The amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof as provided above can refer to a starting dose administered during a titration period.
[00218] In certain embodiments, a starting daily dose of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof administered to a patient described herein can be 2.5 mg. In certain embodiments, a starting daily dose of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof administered to a patient described herein can be 5 mg. In certain embodiments, a starting daily dose of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof administered to a patient described herein can be 7.5 mg. In certain embodiments, a starting daily dose of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof administered to a patient described herein can be 10 mg. In certain embodiments, a starting daily dose of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof administered to a patient described herein can be 12.5 mg. In certain
embodiments, a starting daily dose of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof administered to a patient described herein can be 15 mg. In certain embodiments, a starting daily dose of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof administered to a patient described herein can be 20 mg. In certain embodiments, a starting daily dose of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof administered to a patient described herein can be 25 mg. In certain embodiments, a starting daily dose of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof administered to a patient described herein can be 50 mg. In certain embodiments, a starting daily dose of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof administered to a patient described herein can be 100 mg. In certain embodiments, a starting daily dose of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof administered to a patient described herein can be 120 mg.
[00219] In some embodiments, the adjusted dose of the patient can be increased to 5 mg, 10 mg, 25 mg, 50 mg, 100 mg or 120 mg. In some embodiments, an adjusted daily dose of the patient can be increased to 5 mg. In some embodiments, an adjusted daily dose of the patient can be increased to 10 mg. In some embodiments, an adjusted daily dose of the patient can be increased to 25 mg. In some embodiments, an adjusted daily dose of the patient can be increased to 50 mg. In some embodiments, an adjusted daily dose of the patient can be increased to 100 mg. In some embodiments, an adjusted daily dose of the patient can be increased to 120 mg. In some embodiments, the adjusted dose of the patient can be increased to 125 mg, 150 mg, 175 mg, 200 mg, 225 mg, 250 mg, 275 mg, 300 mg, 325 mg, 350 mg, 375 mg, 400 mg, 425 mg, 450 mg, 475 mg, or 500 mg.
[00220] In certain embodiments, a starting daily dose of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof administered to a patient described herein can be 120 mg, 100 mg, 50 mg, 25, mg, 20 mg, 15 mg, 12.5 mg, 10 mg, 7.5 mg, or 5 mg.
[00221] In some embodiments, an adjusted daily dose of the patient can be decreased to 100 mg. In some embodiments, an adjusted daily dose of the patient can be decreased to 50 mg. In some embodiments, an adjusted daily dose of the patient can be decreased to 25 mg. In some embodiments, the adjusted dose of the patient is decreased to 20 mg. In some
embodiments, an adjusted daily dose of the patient can be decreased to 10 mg. In some embodiments, an adjusted daily dose of the patient can be decreased to 5 mg. In some embodiments, an adjusted daily dose of the patient can be decreased to 2.5 mg. In some embodiments, the adjusted dose of the patient is decreased to 15 mg, 12.5 mg, 10 mg, 7.5 mg, 5 mg, or 2.5 mg.
[00222] The amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof can refer to an adjusted dose administered after a titration period as described herein. In certain embodiments, an adjusted dose of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof administered to a patient described herein can be 2.5 mg. In certain embodiments, an adjusted dose of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof administered to a patient described herein can be 5 mg. In certain embodiments, an adjusted dose of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof administered to a patient described herein can be 7.5 mg. In another embodiment, an adjusted dose of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof administered to a patient described herein can be 10 mg. In certain embodiments, an adjusted dose of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof administered to a patient described herein can be 12.5 mg. In certain embodiments, an adjusted dose of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof administered to a patient described herein can be 15 mg. In certain embodiments, an adjusted dose of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof administered to a patient described herein can be 20 mg. In still another embodiment, an adjusted dose of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof administered to a patient described herein can be 25 mg. In yet another embodiment, an adjusted dose of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof administered to a patient described herein can be 50 mg. In yet another embodiment, an adjusted dose of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof administered to a patient described herein can be 100 mg. In yet another embodiment, an adjusted dose of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof administered to a patient described herein can be 120 mg. In yet another
embodiment, an adjusted dose of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof administered to a patient described herein can be 150 mg. In yet another embodiment, an adjusted dose of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof administered to a patient described herein can be 200 mg. In yet another embodiment, an adjusted dose of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof administered to a patient described herein can be 250 mg. In yet another embodiment, an adjusted dose of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof administered to a patient described herein can be 300 mg.
[00223] The amount of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof as provided above can refer to a re-adjusted dose administered after a titration period as described herein. In certain embodiments, a re-adjusted dose of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof administered to a patient described herein can be 2.5 mg. In certain embodiments, a readjusted dose of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof administered to a patient described herein can be 5 mg. In certain embodiments, a re-adjusted dose of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof administered to a patient described herein can be 7.5 mg. In another embodiment, a re-adjusted dose of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof administered to a patient described herein can be 10 mg. In still another embodiment, a re-adjusted dose of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof administered to a patient described herein can be 25 mg. In yet another embodiment, a re-adjusted dose of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof administered to a patient described herein can be 50 mg. In yet another embodiment, a re-adjusted dose of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof administered to a patient described herein can be 100 mg. In yet another embodiment, a re-adjusted dose of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof administered to a patient described herein can be 120 mg. In yet another embodiment, a re-adjusted dose of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof administered to a patient described herein can be 150 mg. In
yet another embodiment, a re-adjusted dose of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof administered to a patient described herein can be 200 mg. In yet another embodiment, a re-adjusted dose of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof administered to a patient described herein can be 250 mg. In yet another embodiment, a re-adjusted dose of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof administered to a patient described herein can be 300 mg.
[00224] A titration period can be a period of time of about 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 15 days, 16 days, 17 days, 18 days, 19 days, 20 days, 21 days, 22 days, 23 days, 24 days, 25 days, 26 days, 27 days, 28 days, 29, days, 30 days, or 31 day. In certain embodiments, a titration period includes a time of about 1 week, 2 weeks, 3 weeks, 4 weeks, or 5 weeks. In another embodiment, the titration period includes a time of about 1 month, 2 months, 3 months, 4 months, 5 months, or 6 months. In another embodiment, the titration period can be longer than 6 months. In another embodiment, the titration period includes a time of about 3 days, 5 days, 7 days, 10 days, 14 days, 21 days or 28 days. For example, a titration period can be about 1 week. In another example a titration period can be about 2 weeks. In another example a titration period can be about 3 days. In still another example a titration period can be about 5 days. In yet another example a titration period can be about 5 days.
[00225] Compositions of the present invention may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir. The term “parenteral” as used herein includes subcutaneous, intravenous, intramuscular-, intra-articular, intra-synovial, intracistemal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques. In some embodiments, the compositions are administered orally, intraperitoneally or intravenously. Sterile injectable forms of the compositions of this invention may be aqueous or oleaginous suspension. These suspensions may be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, for example as a solution in 1,3 -butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer’s
solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium.
[00226] For this purpose, any bland fixed oil may be employed including synthetic mono- or di-glycerides. Fatty acids, such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions. These oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant, such as carboxymethyl cellulose or similar dispersing agents that are commonly used in the formulation of pharmaceutically acceptable dosage forms including emulsions and suspensions. Other commonly used surfactants, such as Tweens, Spans and other emulsifying agents or bioavailability enhancers which are commonly used in the manufacture of pharmaceutically acceptable solid, liquid, or other dosage forms may also be used for the purposes of formulation.
[00227] Pharmaceutically acceptable compositions of this invention may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, aqueous suspensions or solutions. In the case of tablets for oral use, carriers commonly used include lactose and corn starch. Lubricating agents, such as magnesium stearate, are also typically added. For oral administration in a capsule form, useful diluents include lactose and dried cornstarch. When aqueous suspensions are required for oral use, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening, flavoring or coloring agents may also be added.
[00228] Alternatively, pharmaceutically acceptable compositions of this invention may be administered in the form of suppositories for rectal administration. These can be prepared by mixing the agent with a suitable non-irritating excipient that is solid at room temperature but liquid at rectal temperature and therefore will melt in the rectum to release the drug. Such materials include cocoa butter, beeswax and polyethylene glycols.
[00229] Pharmaceutically acceptable compositions of this invention may also be administered topically, especially when the target of treatment includes areas or organs readily accessible by topical application, including diseases of the eye, the skin, or the lower intestinal tract. Suitable topical formulations are readily prepared for each of these areas or organs.
[00230] Topical application for the lower intestinal tract can be affected in a rectal suppository formulation (see above) or in a suitable enema formulation. Topical and transdermal patches may also be used.
[00231] For topical applications, provided pharmaceutically acceptable compositions may be formulated in a suitable ointment containing the active component suspended or dissolved in one or more carriers. Carriers for topical administration of compounds of this invention include, but arc not limited to, mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compound, emulsifying wax and water. Alternatively, provided pharmaceutically acceptable compositions can be formulated in a suitable lotion or cream containing the active components suspended or dissolved in one or more pharmaceutically acceptable carriers. Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.
[00232] Pharmaceutically acceptable compositions of this invention may also be administered by nasal aerosol or inhalation. Such compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other conventional solubilizing or dispersing agents.
[00233] In some embodiments, pharmaceutically acceptable compositions of this disclosure are formulated for oral administration. Such formulations may be administered with or without food. In some embodiments, pharmaceutically acceptable compositions of this disclosure are administered without food. In other embodiments, pharmaceutically acceptable compositions of this invention are administered with food.
[00234] In other embodiments, pharmaceutically acceptable compositions of this disclosure are formulated for intravenous (IV) administration.
[00235] The amount of compound(s) of the present invention that may be combined with the carrier materials to produce a composition in a single dosage form will vary depending upon the host treated, the particular mode of administration. Compositions should be formulated so that a dosage of between 0.01 - 100 mg/kg body weigh t/day of the compound can be administered to a patient receiving these compositions.
[00236] It should also be understood that a specific dosage and treatment regimen for any particular patient will depend upon a variety of factors, including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, rate of excretion, drug combination, and the judgment of the treating physician and the severity of the particular disease being treated. The amount of a compound of the present invention in the composition will also depend upon the particular compound in the composition.
Treatment, Duration and Dosing
[00237] As used herein, the term “treating” includes any effect, e.g.. lessening, reducing, modulating, or eliminating, that results in the improvement of the condition, disease, disorder, etc. “Treating” or “treatment” of a disease state includes inhibiting the existing disease state, i.e., arresting the development of the disease state or its clinical symptoms, or relieving the disease state, i. e. , causing temporary or permanent regression of the disease state or its clinical symptoms.
[00238] “Preventing” a disease state includes causing the clinical symptoms of the disease state not to develop in a subject that may be exposed to or predisposed to the disease state but does not yet experience or display symptoms of the disease state.
[00239] The term “inhibiting” or “inhibition” as used herein refers to any detectable positive effect on the progression of a disease or condition. Such a positive effect may include the delay in progression of at least one symptom or sign of the disease or condition, alleviation or reversal of the symptom(s) or sign(s) and slowing of the further worsening of the symptom(s) or sign(s).
[00240] Disclosed methods of treatment encompass administration of the FXR agonist of the present disclosure, or a composition thereof as needed to obtain the desired therapeutic effect. The compound or composition can be administered as long as necessary to maintain the desired therapeutic effect.
[00241] In some embodiments, the FXR agonist of the present disclosure is administered for a period (duration of treatment) between about one week and about 12 months. In some embodiments, the FXR agonist is administered for a period between about one week and about six months. In some embodiments, the FXR agonist is administered for a period between about one week and about three months. In some
embodiments, the FXR agonist is administered for a period between about one week and about ten weeks. In some embodiments, the FXR agonist is administered for a period between about one week and about six weeks. In some embodiments, the FXR agonist is administered for a period between about one week and about four weeks. In some embodiments, the FXR agonist is administered for a period between about one week and about three weeks. In some embodiments, the FXR agonist is administered for a period between about one week and about two weeks. In some embodiments, the FXR agonist is administered for a period of about one week.
[00242] In some embodiments, the FXR agonist is administered to the patient for about
30 days. In some embodiments, the FXR agonist is administered to the patient for about
60 days. In some embodiments, the FXR agonist is administered to the patient for about
90 days. In some embodiments, the FXR agonist is administered to the patient for about
30 to about 90 days. In some embodiments, the FXR agonist is administered to the patient for about 30 to about 180 days. In some embodiments, the FXR agonist is administered to the patient for about 60 to about 120 days. In some embodiments, the FXR agonist is administered to the patient for about 90 to about 120 days. In some embodiments, the FXR agonist is administered to the patient for about 90 to about 180 days.
[00243] In some embodiments, the FXR agonist is administered to the patient from about 3 days to about 365 days. In some embodiments, the FXR agonist is administered to the patient for about 3 days, about 5 days, about 7 days, about 10 days, about 14 days, about 21 days, about 28 days, about 30 days, about 35 days, about 40 days, about 50 days, about 60 days, about 70 days, about 80 days, about 90 days, about 100 days, about 110 days, about 120 days, about 130 days, about 140 days, about 150 days, about 160 days, about 170 days or about 180 days.
[00244] In some embodiments, the FXR agonist is administered for about one month, about two months, about three months, about four months, about five months, about six months, about seven months, about eight months, about nine months, about ten months, about eleven months, about twelve months or as needed to bring about the desired therapeutic effect.
[00245] In some embodiments, the FXR agonist such as Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof is administered daily at a
dose of about 1 mg to about 300 mg. In some embodiments, the FXR agonist such as Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof is administered daily at a dose of about 1.0 mg, about 1.5 mg, about 2.0 mg, about 2.5 mg, about 5 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 40 mg, about 50 mg, about 60 mg, about 75 mg, about 85 mg, about 100 mg, about 120 mg, about 125 mg, about 140 mg, about 150 mg, about 165 mg, about 175 mg, about 200 mg, about 225 mg, about 250 mg, or about 300 mg. In some embodiments. Compound 1 is administered daily at a dose of about 2.5 mg, about 5 mg, about 10 mg, about 25 mg, about 30 mg, about 35 mg, about 50 mg, about 75 mg, or about 100 mg.
[00246] In some embodiments, the FXR agonist such as Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof is administered in single or multiple doses sufficient to achieve a total daily dose of about 1 mg to about 150 mg.
[00247] In some embodiments, the FXR agonist such as Compound 1 or a pharmaceutically acceptable salt thereof or amino acid conjugate thereof is administered three times a day, twice a day, once a day, once every two days, once every three days, once every four days, once every five days, twice per week, once a week, or once every two weeks.
[00248] In some embodiments, the FXR agonist such as Compound 1 or a pharmaceutically acceptable salt thereof or amino acid conjugate thereof is administered at a dose of about 1 am to about 500 mg. In some embodiments, the FXR agonist such as Compound 1 or a pharmaceutically acceptable salt thereof or amino acid conjugate thereof is administered at a dose of about 2.5 mg to about 300 mg. In some embodiments, the FXR agonist such as Compound 1 or a pharmaceutically acceptable salt thereof or amino acid conjugate thereof is administered at a dose of about 2.5 mg to about 120 mg, or about 2.5 mg to about 100 mg. In some embodiments, the FXR agonist of the present disclosure is administered at a dose of about 0.1 mg to about 25 mg. In some embodiments, the FXR agonist of the present disclosure is administered at a dose of about 2.5 mg to about 50 mg. In some embodiments, the FXR agonist of the present disclosure is administered at a dose of about 2.5 mg to about 10 mg. In some embodiments, the FXR agonist of the present disclosure is administered at a dose of about 2.5 mg to about 5 mg. In some embodiments, the FXR agonist of the present disclosure is administered at a dose of about 0.5 mg to about
5 mg. In some embodiments, the FXR agonist of the present disclosure is administered at a dose of about 0.5 mg to about 2.5 mg.
[00249] In some embodiments, the FXR agonist such as Compound 1 or a pharmaceutically acceptable salt thereof or amino acid conjugate thereof is administered at a dose of about 2.5 mg to about 120 mg, 2.5 mg to about 100 mg, about 5.0 mg to about 100 mg, about 10 mg to about 100 mg, or about 50 mg to about 100 mg. In some embodiments, the FXR agonist of the present disclosure is administered at a dose of about 2.5 mg to about 50 mg, about 10 mg to about 50 mg, or about 25 mg to about 50 mg. In some embodiments, the FXR agonist such as Compound 1 or a pharmaceutically acceptable salt thereof or amino acid conjugate thereof is administered at a dose of about 2.5 mg to about 120 mg, about 2.5 mg to about 100 mg, about 10 mg to about 100 mg, about 25 mg to about 100 mg, or about 50 mg to about 100 mg.
[00250] In some embodiments, the FXR agonist such as Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof is administered in single or multiple doses sufficient to achieve a total daily dose of about 2.5 mg, about 5 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 50 mg, about 70 mg, about 80 mg, about 90 mg, about 100 mg, about 110 mg, about 120 mg, about 130 mg, or about 150 mg. In some embodiments, the FXR agonist of the present disclosure is administered in single or multiple doses sufficient to achieve a total daily dose about 2.5 mg, about 5 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 50 mg, about 100 mg, about 120 mg, about 150 mg, about 200 mg, about 250 mg, or about 300 mg.
[00251] In some embodiments, the FXR agonist of the present disclosure is administered to the patient in a fasted state. In some embodiments, the FXR agonist is administered to the patient in a fed state.
[00252] The contents of each document cited in the specification are herein incorporated by reference in their entireties.
EXEMPLIFICATION
Example 1: Treatment Effects of Three Test Articles on the Development of Alcoholic Steatohepatitis in C57BL/6J Female Mice
OBJECTIVE
[00253] The objective of this study was to assess efficacy of the test articles obeticholic acid (OCA), Compound 1 and Compound 2 on liver and intestinal pathology in a mouse model of alcoholic steatohepatitis.
Compound 2
[00254] Compound 2, also known as TC-100, is a semi- synthetic bile acid derived from CDCA, the natural ligand for the FXR. Compound 1 is the first reported example of an 1 ip-OH bile acid and the only known FXR specific bile acid derivative that has no activity on the bile acid G-protein coupled receptor, TGR5. The l ip-OH imparts not only FXR agonist specificity but also makes Compound 1 highly water soluble (16-fold higher than obeticholic acid or OCA), with a high critical micellular concentration like ursodeoxycholic acid, giving Compound 1 a very low liability for detergency and thus low toxicity. The compound showed a very low hepatic residence time being promptly secreted in the bile mostly as such and, therefore, localized along the entire intestinal tract. Pellicciari, R„ et al. J. Med. Chem. 2016, 59, 9201-9214.
FORMULATIONS AND ADMINISTRATION OF TEST ARTICLES
[00255] Vehicles for the diets used in this study are described in the table below.
Preparation of Formulations
[00256] Dose formulations was divided into aliquots where required to allow them to be dispensed on each dosing occasion.
Preparation of Vehicle
[00257] The vehicle, 0.5% CMC (medium viscosity) in deionized water was prepared prior to Day 1 and stored in a refrigerator set to maintain 4°C and used for dosing appropriate groups. The vehicle was stirred at room temperature for at least 30 mins prior to dosing.
Test Articles Preparation
[00258] Test articles for Groups 3-5 was prepared weekly, stored at 2-8°C until ready for use and stirred at room temperature for 30 mins prior to dosing. Dose formulations was sonicated as necessary and stirred during dosing.
[00259] Test articles for Groups 6-7 was prepared every 3 days, stored at controlled room temperature until ready for use and stirred at room temperature for 30 mins prior to dosing. Dose formulations was stirred during dosing. The dosing solutions were homogenous suspensions. Any observations regarding phase separation, color, turbidity were noted.
Preparation of Control Diet
[00260] To make 1 L of the Control Diet, weigh 225.55 gram of dry mix (F1259SP- control diet) into a lidded container. Add 350 mL of RO grade water and shake vigorously for 30 seconds. Make sure that a homogenous suspension is obtained. Add 510 mL of RO water to bring up to IL. A blender may be used to obtain a homogenous suspension. Control diet is administered to all groups on Day -28. The prepared diet may be stored at 4°C and is dispensed within 3 days. The prepared diet should not be kept longer than 48 hours at room temperature to prevent diet deterioration. Additionally, the pre-weighed dry powder can be stored at 4°C for up to one week. Prior to dispensing, the diet is stirred at room temperature for at least 30 minutes.
Preparation of Ethanol Diet
[00261] Please refer to the following Table to prepare 1 L of alcohol diet (F1697SP- ethanol diet). A blender may be used to obtain a homogenous suspension. The prepared diet may be stored at 4°C and is used within 48 hours. Additionally, the pre-weighed dry powder can be stored at 4°C up to one week. Prior to dispensing, the diet was stirred at room temperature for at least 30 minutes.
TEST SYSTEM
[00262] Species: Mouse
Strain: C57BL/6J (JAX # 000664)
Condition: Purpose-bred, naive
Source: Jackson Laboratories
Number of Females: 138 (119 on study + 19 spares)
Target Age at the 10 weeks
Initiation of Study:
Animal Identification
[00263] Method: A subcutaneously implanted electronic identification chip or other approved identification method such as indelible ink where required.
Selection, Assignment, Replacement, and Disposition of Animals
[00264] Upon arrival, all animals were fed 5CR4 chow diet ad libitum. All animals were acclimated to the vivarium for at least 4 days following arrival at the Testing Facility. Animals were weighed on Day -5 and then assigned to treatment groups based on body weight. Replacement: before the initiation of dosing, any assigned animals considered unsuitable for use in the study were replaced by alternate animals. Spare animals were transferred to study Group 1 after Study Day 1. General in-life assessments to include alternate animals until released from study. Disposition: the disposition of all animals was documented in the study records.
Husbandry
[00265] Animals were group housed up to 3 per group per cage in polycarbonate cages including appropriate bedding. Housing set-up was as specified in the USDA Animal
Welfare Act (9 CFR, Pails 1, 2 and 3) and as described in the Guide for the Care and Use of Laboratory Animals.
[00266] Diet: 5CR4 chow until Day -26; Lieber-DeC arli liquid diet Days -28 to Day 15. Upon arrival at the Testing Facility, all animals were placed on PMI Nutrition International Certified Rodent Chow No. 5CR4 ad libitum. During the chow diet phase (until Day -26), the diet in meal form may be provided to individual animals as warranted by clinical signs (e.g., broken/damaged incisors or other health changes).
[00267] On Day -28 and -27, All animals were provided both the Lieber DeCarli liquid control diet (50 mL) and PMI Nutrition International Certified Rodent Chow No. 5CR4.
[00268] On Day -26, all animals received 50 mL ethanol diet (1% v/v ethanol). The percentage of alcohol in the liquid diet was increased by 1 % v/v every day until reaching 5% (v/v) on day -22 and is maintained at 5 %v/v until the end of the study.
[00269] Starting Day 1 of cohort 2, animals that were triple housed received an additional bottle of 50 mL (5% v/v ethanol). Group housed cages containing 3 animals/cagc received a total volume of 100 mL (split between two bottles). The alcohol diet was stirred continuously until administration.
[00270] Fresh diet was prepared every other day from Day -28 to Day 14 and was served in the afternoon.
EXPERIMENTAL DESIGN
N/A = Not Applicable, No. = Number, Cone. = Concentration, QD = once a day a Based on the most recent body weight. b Baseline/start of treatment control (Necropsy for Main Study Cohort 2 on day -3 and Cohort 1-Day 2 and Cohort 2-Day 1; necropsy for PK/BioA Cohort 1 is 24 hours post dose on day 14).
Administration of Test and Control Articles
[00271] Dose Route and timing: Oral Gavage (Group 2-7) Once Daily (Day 1-14). The first day of dosing was designated as Day 1 The dose formulations were stirred continuously during dosing. The doses were given using a syringe with attached gavage cannula.
[00272] Terminal plasma and tissue samples were gathered. Plasma was analyzed for TG. TC, ALT, AST. ALP, FGF15 (LCMS), TBIL, and endotoxin.
Tissue Collection and Preservation
[00273] Representative samples of tissues were collected and preserved as described in the table below. Additional tissue samples were collected as needed to elucidate abnormal findings.
X = Procedure to be conducted; - = Not applicable. aAll liver splits is collected prior to flushing the ileum.
X = Procedure to be conducted; - = Not applicable.
Liver Lipid Analysis
[00274] Frozen liver samples from main study were analyzed in duplicates for the estimation of liver lipids including triglycerides and cholesterol. Liver samples were kept on dry ice until transferred to sample management and stored in a freezer set to maintain - 80°C until analysis.
HISTOLOGY
[00275] The liver and small intestine collected from all animals in Groups 1-7 (Main Study) were fixed in 10% neutral buffered formalin for 24-48 hours and transferred to 70% EtOH, stored under ambient conditions and transferred to the histopathology lab at Testing Facility.
Liver tissue
[00276] Formalin fixed liver tissues were trimmed to slides and stained with H&E and picrosirius red stains. Slides were scored by Charles River board certified veterinarian pathologists.
Small Intestine tissue
[00277] Formalin fixed small intestine tissues were trimmed to slides and stained with H&E and IHC antibodies (PV-1. ZO-1 and Occludin). Slides were scored by board certified veterinarian pathologists.
RESULTS
[00278] As shown in the table below, Compound 2 improved survival better than OCA. Compound 1 (Comp 1 in FIGs. 1 and 2) increased serum ALP but decreased bilirubin. The reduction in serum endotoxin is significant. For steatosis (graded 1-5 by a pathologist), the Compound 2 10 mpk group was close to statistical significance. For fibrosis as analyzed by Pico Sirius Red, the animal model did not have fibrosis at baseline or in the vehicle group. A minimal increase in fibrosis was seen in OCA 30 mpk. Compound 2 30 mpk and Compound 230 mpk. For exploratory endpoints for ileum, all H&E sections IHC stains for tight junctions were normal and the same between groups. See FIGs. 1 and 2 for clinical chemistry results and liver and ileum histology from this study. Without wishing
to be bound by theory, it is believed that these results suggest improved gut function with all compounds, and greatly improved survival for the 10 mg/kg and 30 mg/kg Compound 2 (Comp 2 in FIGs. 1 and 2) groups that was superior to the results with the other two compounds.
*Includes animals for PK
[00279] As shown in FIG. 2, Serum bile acids were markedly increased in vehicle treated ALD mice and were significantly lowered by both doses of Compound 2 (Comp 2) and the high dose of Compound 1 (Comp 1).
Example 2: A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of Compound 1 in Subjects with Severe Alcohol-Associated Hepatitis
[00280] Compound 1 is a modified bile acid with high potency and selectivity for the farnesoid X receptor (FXR). Due to its FXR-mediated effects, Compound 1 is a novel therapy for alcohol-associated hepatitis. We describe below a Phase 2 proof-of-concept study evaluating the safety, tolerability, efficacy, and pharmacokinetics of Compound 1 in patients with severe alcohol-associated hepatitis (sAH).
[00281] This will be a Phase 2a, randomized, double-blind, placebo-controlled, multicenter (approximately 25 sites globally), dose-escalation, proof-of-concept study evaluating the safety, tolerability, efficacy, and PK of Compound 1 in subjects, initially admitted to the hospital, with sAH.
[00282] Compound 1 is administered daily in capsule form at escalating doses starting at 5 mg. and increasing stepwise.
[00283] If there are no clinically significant safety or tolerability concerns, and after review and approval by the Sponsor’s Global Safety Committee (GSC), a decision will be made to escalate to the next dose cohort and the same stepwise process will be followed (e.g., 10, 25, 50, and 100 mg (5 dose cohorts)). The dose levels for the remaining dose additional cohorts, will be defined based on the safety and tolerability data of Compound 1 from the preceding cohorts. Dose escalations will not exceed a 3-fold increase from cohort to cohort and a maximum dose level of 120 mg.
[00284] About 50 subjects aged 18 to 65 years (inclusive) with sAH (defined by a Maddrey discriminant function [MDF] >32 and <60 and a model for end-stage liver disease-sodium [MELD-Na] score of 18 to 25 [inclusive]) are enrolled in the study, including about 50 subjects in the Compound 1 treatment groups. Five dose cohorts are planned with doses ranging from 5 mg to 120 mg Compound 1 (or Comp 1) (FIG. 3). Each dose cohort is comprised of 2 groups containing a total of 10 subjects, with 8 subjects randomized to study treatment (Treatment Group) and 2 subjects to placebo (Control Group). Assuming the responder rates based on the Lille model are 90% in the Compound 1 Response Cohorts and 25% in the Control Cohort, a sample size of 8 subjects per arm provides >80% power to detect treatment differences between the Response Cohorts and the Control Cohort with a 2-sided alpha of 0.05.
[00285] The primary objective of the study is to evaluate the effect of Compound 1 treatment on sAH disease progression, as assessed by the Lille score on Day 7. Secondary objectives include evaluation of the effect of Compound 1 treatment on the MELD-Na score at Day 28, mortality at 56 and 84 days (short-term and intermediate-term mortality) or liver transplantation, and any infectious complications, as well as evaluation of the PK of Compound 1 and its metabolites glyco-Compound 1 and tauro-Compound 1 and evaluation of the safety and tolerability of Compound 1 in the proposed patient population.
Safety and tolerability are assessed by recording adverse events, laboratory assessments, ECGs, vital signs, and physical examinations. Exploratory objectives/measures include (1) occurrence of hospital re-admission for alcohol-associated hepatitis (hospitalization as defined by a stay of >24 hours) during the study period;, (2) hospitalization reason, length of stay, ICU days, major medical procedures, and emergency room visits; (3) change from Baseline in serum liver biochemistries (ALP, AST, ALT, GGT, and total and direct bilirubin); (4) measurement of health-related quality of life (EQ-5D-5L), (5) change from Baseline in IL-6, hs-CRP, CK-18, and TNF-a at Day 28; (6) change from Baseline in Lipoproteins (LDL, HDL, VLDL), total cholesterol, and triglycerides at Day 28; and (8) change from Baseline in lipid metabolism (LBP), 16S rDNA and stool sample for alpha- 1 -antitrypsin and microbiome/metabolome analysis.
[00286] The Control Group (placebo-treated subjects) in the study provides useful information on efficacy and safety outcomes in this patient population with severe alcohol- associated hepatitis treated with standard of care. The placebo-treated subjects within cohorts are meant to blind the study drug administration while the data across dose cohorts will be used for the overall analysis.
[00287] The dose levels for this Phase 2a clinical study are based on the overall safety and tolerability profile of Compound 1 established in the nonclinical program and the dose selection in this study will be based on data from Compound 1 phase 1 dose-escalation study.
[00288] The study is designed to assess increasing doses of Compound 1 in a stepwise fashion (FIG. 3). The decision to progress to the next higher dose cohort is made after a clinical review of safety and tolerability. The study design includes five Compound 1 dose cohorts. Each dose cohort is comprised of 2 groups containing a total of 10 subjects, with 8 subjects randomized to study treatment (Treatment Group) and 2 subjects to placebo (Control Group). Safety and tolerability is evaluated by examining the incidence of unexpected treatment emergent serious adverse events (SAEs), investigational product discontinuations, and the incidence of potential drug induced liver injury (DILI) at each dose. Additional considerations are given to overall treatment-emergent adverse events (TEAEs), clinical laboratory tests, ECGs, and vital signs. An increase in the Lille score to > 0.85 represents potential drug ineffectiveness (rather than liver injury) and is taken into
consideration as part of each dose escalation assessment. Given the acute and progressive nature of sAH, it is important to monitor for potential drug induced liver injury, and/or hepatic decompensation. MELD-Na scores is reviewed at each visit where labs are drawn. [00289] Primary Efficacy Analyses'. The primary efficacy analyses is conducted using the ITT population. The primary efficacy endpoint is the Lille score at day 7. For the analysis of Lille score, all subjects with a Day 7 Lille score will be included. The Lille score is analyzed as a categorical variable. In the primary efficacy analyses, subjects with Lille score <0.45 is counted as responders and those with Lille score >=0.45 is counted as non-responders. The percentage of responders and non-responders at day 7 is summarized by treatment group and compared using Fisher Exact test. An additional descriptive analysis of Lille score as a continuous variable is performed. The efficacy evaluation will start on the highest tolerated dose and go down to lower dose levels using the sequential approach. If the higher dose level is statistically significant on the primary efficacy endpoint, the next lower dose level is evaluated. Otherwise, the efficacy evaluation is stopped on the current dose level. The primary comparison of efficacy evaluation is on the highest tolerated dose.
[00290] Secondary and Exploratory Efficacy Analyses: The secondary and exploratory efficacy analyses is conducted using the ITT population. All continuous and categorical efficacy endpoints is summarized using descriptive statistics at Baseline and at each scheduled post-Baseline visit. For continuous endpoints, the change from Baseline will also be summarized. Analyses of continuous endpoints is carried out using a mixed-effect repeated measures model to evaluate the effect of treatment groups over time based on ITT population. The dependent variable is the change from Baseline. The model will include the terms of treatment group, visit, treatment by visit interaction as factors and Baseline value as covariate. Analyses for categorical endpoints is performed using a Fisher Exact test. Any subject who has an unknown death status at the specified time point will be excluded from the analyses of mortality. In addition, the Lille score at day 7 will also be summarized as a continuous variable by treatment group and compared using an ANOVA model with Lille score as the dependent variable including treatment group as a fixed effect.
Objectives
[00291] Primary Objective:
• To evaluate the efficacy of Compound 1 as assessed by disease progression in severe alcohol-associated hepatitis (sAH)
[00292]
[00293] Secondary Objectives:
• To evaluate the effect of Compound 1 on efficacy as assessed by the Model for End- Stage Liver Disease-Sodium (MELD-Na) score in sAH
• To evaluate the effect of Compound 1 on clinical outcomes as assessed by short-term and intermediate-term mortality and/or liver transplantation in sAH
• To evaluate the effect of Compound 1 on infectious complications in sAH
• To evaluate the pharmacokinetics (PK) of Compound 1 and its metabolites in subjects with sAH
• To evaluate the safety and tolerability of Compound 1 in subjects with sAH
[00294] Exploratory Objectives - To evaluate the effect of Compound 1 on:
• Hospital re-admission due to alcohol-associated hepatitis during the study period
• Measures of health care utilization
• Health-related quality of life
• The following measures:
- Liver biochemistry and hepatic synthetic function, renal function, hematology
- Inflammation
- Lipid metabolism
- Farnesoid X receptor (FXR) activation
- Microbiome/metabolome
- Bacterial translocation
Diagnosis and Main Criteria for Inclusion
[00295] Subject Inclusion Criteria
1. Males or females aged 18 to 65 years (inclusive)
2. Clinical diagnosis of sAH based on all the following: a. History of excess alcohol (>60 g/day [male] or >40 g/day [female]) use for >6 months, with <60 days of abstinence prior to the onset of jaundice b. Serum total bilirubin >3.0 mg/dL
c. AST >50 U/L (or IU/L) d. AST/ALT ratio >1.5 e. MDF >32 and < 60 f. MELD-Na score 18, or 20 or 21 to 25 (inclusive)
3. Onset of jaundice within 8 weeks from the time of admission to the hospital
4. Up to and no more than (NMT) 7 days since admission to the hospital
5. Female subjects must be postmenopausal, surgically sterile, or, if premenopausal (and not surgically sterile), be prepared to use >1 highly effective method of contraception during the study and for 90 days after the last dose of investigational product as follows: Surgical sterilization (bilateral tubal occlusion, etc.); Placement of an intrauterine device (IUD) or intrauterine system (e.g., intrauterine hormone-releasing system [IUS]); Combined (estrogen and progesterone containing) hormonal contraceptive associated with inhibition of ovulation: Oral; Intravaginal; Transdcrmal; Progcstcronc-only hormonal contraception associated with inhibition of ovulation: Oral; Injectable; Implantable; Sexual abstinence, if in line with the preferred and usual lifestyle of the subject (where abstinence is defined as refraining from heterosexual intercourse during the entire period of risk associated with study treatments).
6. Male subjects who are sexually active with female partners of childbearing potential must agree to use a condom with spermicide and to use one other approved method of highly effective contraception from the time of investigational product administration for at least 90 days after the dose of investigational product as listed in Inclusion Criteria 5.
7. Male subjects must refrain from sperm donation from Screening through at least 90 days following the last dose of investigational product
8. Must provide written informed consent and agree to comply with the study protocol. In subjects with hepatic encephalopathy which may impair decisionmaking, consent is obtained per hospital procedures (e.g., by Legally Authorized Representative).
Subjects must agree to participate in an alcohol use disorder (AUD) program during the study period, as recommended by the local institution's addiction medicine specialists, including post-hospitalization.
[00296] Subject Exclusion Criteria
1. Subjects taking systemic corticosteroids or products containing obeticholic acid (OCA) in the 30 days prior to screening, up to and including randomization.
2. Pregnancy, planned pregnancy, potential for pregnancy (i.e., unwillingness to use effective birth control during the study), or current or planned breast feeding
3. Cessation of alcohol consumption for >2 months before Day 1
4. AST or ALT > 400 U/L
5. MDF < 32 or >60 at Screening
6. MELD-Na score < (less than) 18 or >25 at Screening (confirmed by repeat labs within 48 hours)
7. Other causes of liver disease including chronic hepatitis B (hepatitis B surface antigen [HBsAg] positive), chronic hepatitis C (HCV) RNA positive, acetaminophen hepatotoxicity, biliary obstruction, and autoimmune liver disease
8. Current or previous history of hepatocellular carcinoma (HCC)
9. History of liver transplantation or currently listed for liver transplant
10. Untreated sepsis (e.g., has not initiated appropriate medical treatment for infection and/or septic shock)
11. Known positivity for human immunodeficiency virus infection
12. Uncontrolled gastrointestinal (GI) bleeding or controlled GI bleeding within
7 days of Screening that was associated with shock or required transfusion of more than 3 units of blood
13. Kidney injury defined as a serum creatinine >133 pmol/L (>1.5 mg/dL) confirmed by repeat testing within 48 hours or the requirement for renal replacement therapy
14. Portal vein thrombosis
15. Acute pancreatitis or acute gallbladder disease (e.g., cholecystitis)
16. Severe associated disease (e.g., cardiac failure, acute myocardial infarction, severe cardiac arrhythmias, severe pulmonary disease, neurologic disease)
17. Malignancy within the 2 years prior to Screening, with the exception of specific cancers that have been cured by surgical resection (e.g., basal cell skin cancer). Subjects under evaluation for possible malignancy are not eligible
18. Positive Urine Drug Screen (amphetamines, barbiturates, benzodiazepines, cocaine and opiates) except tetrahydrocannabinol (THC) or in the setting of documented prescription medications (e.g., opiates, benzodiazepines, amphetamines, barbiturates, including medications prescribed as part of in-patient management. Subjects being treated for alcohol withdrawal may be exempt, verify with Medical Monitor)
19. Participated in a clinical research study and received any active investigational product being evaluated for the treatment of sAH 3 months before Day 1
20. Participation in a study of another investigational medicine or device within 30 days before Screening
21. Any other condition or clinical laboratory result that, in the opinion of the Investigator, might confound the results, or would impede compliance or hinder completion of the study
22. Received a positive SARS Coronavirus 2 (SARS-CoV-2) test within 4 weeks of Screening or a SARS-CoV-2 vaccination within 2 weeks of Screening
Investigational Product, Dosage and Mode of Administration
[00297] The investigational product, Compound 1, capsule(s) and matching placebo capsule(s) for oral administration once daily. The investigational product, Compound 1, is supplied in multiple capsule strengths ranging from 5 mg to 120 mg. Multiple Compound 1 capsules may be taken to achieve the appropriate Compound 1 dose levels (e.g., 10 mg, 25 mg, 50 mg, 100 mg or 120 mg). Matching placebo capsule(s) will also be provided for blinding purposes. This study is conducted in a double-blind (subjects and site staff) manner, randomized in a 4:1 fashion for each dose cohort.
Reference Therapy, Dosage and Mode of Administration
[00298] All eligible subjects will receive the appropriate supportive measures, including nutritional support, per the local standard of care. Corticosteroid use will not be allowed 30 days prior to screening and up to and including randomization, as it is intended for a
subject to complete the study without the use of corticosteroids, if possible (ophthalmic steroids and low-dose topical or low-dose intranasal steroids are allowable).
[00299] If systemic corticosteroids are initiated during the screening period, the subject will not be considered eligible for randomization. If systemic corticosteroids are initiated within the first 7 days post-randomization, the subject will be discontinued and replaced in that study cohort. The use of systemic corticosteroids post-randomization can be considered on a case-by-case basis if clinically warranted (e.g., Lille score >0.56 with rising total bilirubin at Day 7 or MELD-Na score increases >3 points, not due to acute kidney injury).
Duration of Treatment
[00300] Subjects will receive investigational product for 28 days.
Criteria for Evaluation
[00301] The endpoints supporting the primary, secondary, and exploratory objectives of the study arc as follows:
C4 = 7a-hydroxy-4-cholesten-3-one; CK-18 = cytokeratin 18; hs-CRP = high sensitive c-reactive protein; rDNA = ribosomal deoxyribonucleic acid; ECG = electrocardiogram; FGF-19 = fibroblast growth factor 19; GGT = gamma glutamyl transferase; HDL = high density lipoprotein; ICU = intensive care unit; IL-6 = interleukin 6; IL-18 = interleukin 18; KIM-1 = kidney injury molecule- 1; L-FABP = liver-type fattyacid-binding protein; INR = international normalized ratio; LBP = lipopolysaccharide-binding protein; LDL =low density lipoprotein; MELD-Na = model of end-stage liver disease-sodium; NGAL = neutrophil gelatinase-associated lipocalin; PK = pharmacokinetics; SAE = severe adverse event; SBP = spontaneous bacterial peritonitis; TEAE = treatment-emergent adverse event; TNF-a = tumor necrosis factor-alpha; VLDL = very low- density lipoprotein.
Example 3: A Phase 2b/3, Randomized, Double-Blind, Placebo- Controlled, Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of Compound 1 in Subjects with Severe Alcohol- Associated Hepatitis
[00302] We describe below a Phase 2b/3 study evaluating the safety, tolerability, efficacy, and pharmacokinetics of Compound 1 in patients with severe alcohol-associated hepatitis (sAH).
[00303] This is a Phase 2b/3, randomized, double-blind, placebo-controlled, multicenter (approximately 25 sites globally), dose-escalation, proof-of-concept study evaluating the safety, tolerability, efficacy, and PK of Compound 1 in subjects, initially admitted to the hospital, with sAH.
[00304] About 50 subjects aged 18 to 65 years (inclusive) with sAH (defined by a Maddrey discriminant function [MDF] >32 and a model for end-stage liver disease [MELD] score of 21-30 [inclusive]) are enrolled in the study, including about 50 subjects in the Compound 1 treatment groups. Dose cohorts (2, 3, 4 or 5 cohorts) are planned with doses ranging from 5 mg to 120 mg Compound 1 (or Comp 1). Each dose cohort is comprised of 2 groups containing a total of 10 subjects, with 8 subjects randomized to study treatment (Treatment Group) and 2 subjects to placebo (Control Group). Assuming the responder rates based on the Lille model are 90% in the Compound 1 Response Cohorts and 25% in the Control Cohort, a sample size of 8 subjects per arm provides >80% power to detect treatment differences between the Response Cohorts and the Control Cohort with a 2-sided alpha of 0.05.
[00305] The study is generally carried out in accordance with the objectives, procedures, inclusion and exclusion criteria, efficacy analyses, criterial for evaluation, dosing amounts and regimens described above in Example 2, modified as follows: The primary objective of the study is to evaluate the effect of Compound 1 treatment on 90-day transplant-free survival of patients with sAH. Secondary objectives include evaluation of the effect of Compound 1 treatment on mortality at 28 days (short-term mortality), the MELD and Lille scores at Days 28 and 90, and evaluation of the safety and tolerability of Compound 1 in the proposed patient population at Days 28 and 90, and at 6 months. Safety and tolerability are assessed by recording adverse events, laboratory assessments, ECGs, vital signs, and
physical examinations. Exploratory objectives/measures include (1) mortality at 6-months; 2) healthcare utilization including: occurrence of hospital re-admission for alcohol- associated hepatitis (hospitalization as defined by a stay of >24 hours) during the study period; hospitalization reason, length of stay, ICU days, major medical procedures, and emergency room visits; (3) evaluation of pharmacokinetic and pharmacodynamic biomarkers, including: change from Baseline in serum liver biochemistries (ALP, AST, ALT, GGT, and total and direct bilirubin); change from Baseline in IL-6, hs-CRP. CK-18, and TNF-a at Day 28; change from Baseline in Lipoproteins (LDL, HDL, VLDL), total cholesterol, and triglycerides at Day 28; and change from Baseline in lipid metabolism (LBP), 16S rDNA and stool sample for alpha- 1 -antitrypsin and microbiome/metabolome analysis; and (4) measurement of health-related quality of life (EQ-5D-5L).
Claims
1. A method of treating an acute liver disease comprising administering to a patient in need thereof an effective amount of Compound 1 :
Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof.
2. The method of claim 1, wherein the liver disease is alcoholic hepatitis (AH).
3. The method of claim 1 , wherein the liver disease is severe alcoholic hepatitis (sAH) .
4. The method of claim 1, wherein the liver disease is acute-on-chronic liver failure (ACLF).
5. The method of any one of claims 1-4, wherein the patient exhibits a Maddrey discriminant function (MDF) score of >32 prior to treatment with Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof.
6. The method of any one of claims 1-4, wherein the patient exhibits a model for end-stage liver disease (MELD or MELD-Na) score of >18, or greater than 21, or from 21-
30 prior to treatment with Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof.
7. The method of claim 6, wherein the patient exhibits a MDF score of 32 to 60.
8. The method of claim 5, wherein the patient exhibits a MELD score of 18 to 30, or 21-30, or MELD-Na score of 18 to 25 or 21-30.
9. The method of any one of claims 5-8, wherein the method reduces the MELD or MELD-Na score of the patient by at least 3 and/or reduces the MDF score of the patient by at least 3 by day 28 or day 90 of treatment.
10. The method of any one of claims 1-9, wherein Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof is administered daily at a dose of about 1.0 mg to about 300 mg.
11. The method of any one of claims 1-10, wherein Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof is administered daily at a dose of about 2.5 mg to about 300 mg.
12. The method of any one of claims 1-11, wherein Compound 1 is administered daily at a dose of from about 5 mg to about 100 mg; or from about 5 mg to about 120 mg.
13. The method of any one of claims 1-12, wherein Compound 1 is administered daily at a dose of from about 5 mg to about 50 mg.
14. The method of any one of claims 1-13, wherein Compound 1 is administered daily at a dose of from about 5 mg to about 25 mg.
15. The method of any one of claims 1-14, wherein Compound 1 is administered daily at a dose of from about 5 mg to about 10 mg.
16. The method of any one of claims 1-10, wherein Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof is administered daily at a dose of about 5 mg to about 150 mg.
17. The method of any one of claims 1-10, wherein Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof is administered daily at a dose of about 10 mg to about 100 mg; or from about 5 mg to about 120 mg.
18. The method of any one of claims 1-10, wherein Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof is administered daily at a dose of about 50 mg to about 200 mg.
19. The method of any one of claims 1-10, wherein Compound 1 is administered daily at a dose of about 2.5 mg, about 5 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 35 mg, about 45 mg, about 50 mg, about 60 mg, about 75 mg, about 85 mg, about 100 mg, about 115 mg, about 120 mg, about 125 mg, about 140 mg, about 150 mg, about 165 mg, about 175 mg, about 190 mg, or about 200 mg.
20. The method of any one of claims 1-9, wherein Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof is administered in single or multiple doses sufficient to achieve a total daily dose of about 1.0 mg to about 300 mg.
21. The method of any one of claims 1-20, further comprising monitoring blood levels of a biomarker in the patient after administration of Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, wherein the biomarker is selected from C4, FGF-19, and endogenous bile acids.
22. The method of any one of claims 1-21, wherein the patient has a chronic liver disease in addition to sAH or ACLF.
23. The method of claim 22, wherein the patient has alcoholic liver disease (ALD).
24. The method of any one of claims 1-23, wherein the patient exhibits one or more of the following symptoms: (1) ongoing alcohol consumption of more than 40 g of alcohol per day if the patient is a woman and more than 60 g of alcohol per day if the patient is a man for 6 months or more, with less than 60 days of abstinence before the onset of jaundice; (2) the presence of elevated liver enzymes (aspartate aminotransferase [AST] and alanine aminotransferase [ALT] concentrations >50 IU/L (or U/L) but <400 IU/L (or U/L) and an AST/ALT ratio of >1:5); and (3) worsening jaundice, with bilirubin concentrations greater than 3 mg/dL.
25. The method of any one of claims 1-24, wherein the patient exhibits alcohol- associated cirrhosis, liver fibrosis, steatosis, steatohepatitis, alcoholic hepatitis, or intestinal dysbiosis.
26. The method of any one of claims 1-25, wherein the patient has previously been diagnosed with sAH and has suffered at least one relapse of sAH.
27. The method of any one of claims 1-26, wherein the method improves 30-day survival of the patient versus an otherwise similar patient who was not administered Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof.
28. The method of any one of claims 1-27, wherein the method improves 60-day survival of the patient versus an otherwise similar patient who was not administered Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof.
29. The method of any one of claims 1-28, wherein the method improves 90-day survival of the patient versus an otherwise similar patient who was not administered Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof.
30. The method of any one of claims 27-29, wherein the method improves survival by about 10% to about 40%.
31. The method of any one of claims 27-29, wherein the method improves survival by about 10% to about 30%.
32. The method of any one of claims 27-29, wherein the method improves survival by about 10% to about 20%.
33. The method of any one of claims 1-32, wherein the method provides a reduction in health care utilization.
34. The method of claim 33, wherein the method provides a reduction in liver-related events in patients with sAH.
35. The method of claim 33 or 34, wherein the method provides a decrease in the patient’s health care utilization by at least 10% for 60 days.
36. The method of any one of claims 33-35, wherein the method reduces one or more of hospital re-admission within 30-days after discharge, number of hospitalizations, length of stay, emergency room visits, intensive care unit (ICU) days, infectious complications selected from sepsis, pneumonia, urinary tract infection (UTI), cellulitis, spontaneous and bacterial peritonitis (SBP), and major medical procedures.
37. The method of any one of claims 1-36, further comprising co-administering to the patient an effective amount of anti-inflammatory agent, an antibiotic, an antioxidant, a probiotic, a fecal transplant, Zn-supplement or a combination of any of those agents.
38. The method of any one of claims 1-36, further comprising co-administering to the patient an effective amount of pentoxifylline, Augmentin, bovine colostrum, corticosteroid (e.g., prednisolone or methylprednisolone), an ELAD agent, canakinumab, a TNF inhibitor,
IL-22, N-acetylcysteine, metadoxine, IgG anti-LPS, a probiotic, a fecal transplant, Zn- supplement, or a combination of any of those agents.
39. The method of any one of claims 1-38, wherein the patient does not exhibit one or more of: AST or ALT >400 U/L, MDF >60 prior to treatment, MELD score >25 or >30 or MELD-Na >25 or >30 prior to treatment, other causes of liver disease selected from chronic hepatitis B (hepatitis B surface antigen [HBsAg] positive), chronic hepatitis C (HCV RNA positive), acetaminophen hepatotoxicity, biliary obstruction, and autoimmune liver disease; concomitant of previous history of hepatocellular carcinoma (HCC), a history of liver transplantation, untreated sepsis, known positivity for human immunodeficiency virus infection, uncontrolled gastrointestinal (GI) bleeding or controlled GI bleeding within 7 days of beginning treatment that was associated with shock or required transfusion of more than 3 units of blood, acute kidney injury defined as a serum creatinine >133 pmol/L (>1.5 mg/dL) or the requirement for renal replacement therapy, portal vein thrombosis, acute pancreatitis, or severe associated disease selected from cardiac failure, acute myocardial infarction, severe cardiac arrhythmias, severe pulmonary disease, and neurologic disease.
40. The method of any one of claims 1-39, wherein the method provides at least a 15% reduction in mortality at 90 days compared to standard of care (SOC).
41. The method of any one of claims 1-40, wherein the method provides a reduction in hospitalization by at least 15% and/or a reduction in progression to transplant by at least 15%.
42. The method of any one of claims 1-41, wherein Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof is administered to the patient for about 30 to about 90 days.
43. The method of any one of claims 1-42, wherein Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof is administered orally.
44. Then method of claim 6, wherein Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof is administered in single or multiple doses sufficient to achieve a total daily dose of about:
1.0 mg to about 300 mg; or about 2.5 mg to about 300 mg; or about 5 mg to about 100 mg; or about 5 mg to about 50 mg; or about 5 mg to about 25 mg; or about 5 mg to about 10 mg; or about 5 mg to about 150 mg; or about 5 mg to about 120 mg; about 10 mg to about 100 mg; or about 50 mg to about 200 mg; or about 2.5 mg, about 5 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 35 mg, about 45 mg, about 50 mg, about 60 mg, about 75 mg, about 85 mg, about 100 mg, about 115 mg, about 120 mg, 125 mg, about 140 mg, about 150 mg, about 165 mg, about 175 mg, about 190 mg, or about 200 mg.
45. The method of any one of claims 1-9 wherein the patient exhibits an AST of >50 U/L prior to treatment with Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof.
46. The method of any one of claims 1-9 wherein the patient exhibits an AST I ALT ratio of >1.5 prior to treatment with Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof.
47. The method of any one of claims 1-9 wherein the patient exhibits prior to treatment with Compound 1 or a pharmaceutically acceptable salt or amino acid conjugate thereof, one or more of: an AST of >50 U/L;
an AST / ALT ratio of >1.5; a Maddrey discriminant function (MDF) score of >32; and a model for end-stage liver disease (MELD or MELD-Na) score of >18, or >20, or >21, for example from 21-30.
48. A method of determining candidacy of a patient for therapeutic treatment for sAH, comprising determining the patient's MELD-Na score.
49. The method of claim 48, further comprising determining the patient's MDF score.
50. The method of claim 49, wherein the patient's MELD-Na score is > 18.
51. The method of claim 48, wherein the patient's MELD-Na score is > 18.
52. The method of claim 49, wherein the patient's MDF score is > 32, for example from 32 to 60 inclusive.
53. A method for treating sAH comprising: selecting a patient having a MELD-Na score > 18; or a MELD score of 21-30; and administering a therapeutic treatment for sAH.
54. The method of claim 53, wherein the patient also has a MDF score from 32 to 60 inclusive.
55. The method of claim 53 or 54, wherein the therapeutic treatment comprises administering a pharmacologic agent to the patient, and/or a liver transplant.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202263381754P | 2022-10-31 | 2022-10-31 | |
US63/381,754 | 2022-10-31 | ||
US202363497602P | 2023-04-21 | 2023-04-21 | |
US63/497,602 | 2023-04-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024097247A1 true WO2024097247A1 (en) | 2024-05-10 |
Family
ID=90931391
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2023/036520 WO2024097247A1 (en) | 2022-10-31 | 2023-10-31 | Uses of farnesoid x receptor agonists |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024097247A1 (en) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017156024A1 (en) * | 2016-03-11 | 2017-09-14 | Intercept Pharmaceuticals, Inc. | 3-desoxy derivative and pharmaceutical compositions thereof |
US20190352328A1 (en) * | 2014-05-29 | 2019-11-21 | Bar Pharmaceuticals S.R.L. | Cholane derivatives for use in the treatment and/or prevention of fxr and tgr5/gpbar1 mediated diseases |
US20210046091A1 (en) * | 2013-12-24 | 2021-02-18 | Virginia Commonwealth University | Uses of oxygenated cholesterol sulfates (ocs) |
WO2021067297A1 (en) * | 2019-09-30 | 2021-04-08 | Durect Corporation | Treatment of alcoholic hepatitis |
WO2023205447A2 (en) * | 2022-04-21 | 2023-10-26 | Intercept Pharmaceuticals, Inc. | Uses of farnesoid x receptor agonists |
-
2023
- 2023-10-31 WO PCT/US2023/036520 patent/WO2024097247A1/en unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20210046091A1 (en) * | 2013-12-24 | 2021-02-18 | Virginia Commonwealth University | Uses of oxygenated cholesterol sulfates (ocs) |
US20190352328A1 (en) * | 2014-05-29 | 2019-11-21 | Bar Pharmaceuticals S.R.L. | Cholane derivatives for use in the treatment and/or prevention of fxr and tgr5/gpbar1 mediated diseases |
WO2017156024A1 (en) * | 2016-03-11 | 2017-09-14 | Intercept Pharmaceuticals, Inc. | 3-desoxy derivative and pharmaceutical compositions thereof |
US20210101927A1 (en) * | 2016-03-11 | 2021-04-08 | Intercept Pharmaceuticals, Inc. | 3-desoxy derivative and pharmaceutical compositions thereof |
WO2021067297A1 (en) * | 2019-09-30 | 2021-04-08 | Durect Corporation | Treatment of alcoholic hepatitis |
WO2023205447A2 (en) * | 2022-04-21 | 2023-10-26 | Intercept Pharmaceuticals, Inc. | Uses of farnesoid x receptor agonists |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Rautiainen et al. | Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three‐year randomized trial | |
Arioglu et al. | Clinical course of the syndrome of autoantibodies to the insulin receptor (type B insulin resistance): a 28-year perspective | |
Lobo et al. | The importance of diagnosing the polycystic ovary syndrome | |
Healy et al. | Metabolic syndrome, central obesity and insulin resistance are associated with adverse pathological features in postmenopausal breast cancer | |
Krones et al. | NorUrsodeoxycholic acid ameliorates cholemic nephropathy in bile duct ligated mice | |
Kakabadze et al. | Decellularized human placenta supports hepatic tissue and allows rescue in acute liver failure | |
JP2020147585A (en) | Combination agent comprising omega-3 fatty acid composition and sglt-2 inhibitor for treating liver disease | |
Li et al. | Bile acid G protein-coupled membrane receptor TGR5 modulates aquaporin 2–mediated water homeostasis | |
JP2018507914A (en) | Method for the treatment of non-alcoholic fatty liver disease and / or lipodystrophy | |
Tauchmanovà et al. | Andrenocortical carcinomas: twelve-year prospective experience | |
Talwalkar et al. | Mycophenolate mofetil for the treatment of primary sclerosing cholangitis | |
Wang et al. | Alteration in placental expression of bile acids transporters OATP1A2, OATP1B1, OATP1B3 in intrahepatic cholestasis of pregnancy | |
Nobili et al. | Laparoscopic sleeve gastrectomy improves nonalcoholic fatty liver disease–related liver damage in adolescents by reshaping cellular interactions and hepatic adipocytokine production | |
US20220143003A1 (en) | Compositions and methods to treat non-alcoholic fatty liver diseases (nafld) | |
Takeda et al. | Successful management of a leiomyomatosis peritonealis disseminata with an aromatase inhibitor | |
WO2023205447A2 (en) | Uses of farnesoid x receptor agonists | |
Barreiros et al. | Extended regimens of the combined contraceptive vaginal ring containing etonogestrel and ethinyl estradiol: effects on lipid metabolism | |
Trauner et al. | Safety and sustained efficacy of the farnesoid X receptor (FXR) agonist cilofexor over a 96-week open-label extension in patients with PSC | |
Kotsopoulos et al. | Breastfeeding and the risk of epithelial ovarian cancer among women with a BRCA1 or BRCA2 mutation | |
Granato et al. | Epicardial fat: the role of testosterone and lipid metabolism in a cohort of patients with Klinefelter syndrome | |
Guazzelli et al. | Extended regimens of the contraceptive vaginal ring versus hormonal oral contraceptives: effects on lipid metabolism | |
Sobh et al. | Coadministration of ketoconazole and cyclosporine for kidney transplant recipients: Long-term follow-up and study of metabolic consequences | |
Fedorova et al. | Interaction of Digibind with endogenous cardiotonic steroids from preeclamptic placentae | |
WO2024097247A1 (en) | Uses of farnesoid x receptor agonists | |
Wong et al. | Xanthomatous hypophysitis presenting in an adolescent girl: a long-term follow-up of a rare case and review of the literature |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23886653 Country of ref document: EP Kind code of ref document: A1 |